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Abstract 
 
 
Early arterial changes that precede the late stages of atherosclerosis often appear decades 
before the onset of clinically evident cardiovascular disease (CVD). Arterial endothelial 
dysfunction, in particular, is a key early event that occurs in the presence of risk factors for 
CVD. Impaired nitric oxide synthesis (a key mediator of arterial endothelial cell function) 
signals early vascular damage. As arterial wall damage progresses, structural changes occur in 
the artery wall, particularly intima-media thickening, suggesting a more advanced level of 
arterial injury.  
 
Non-invasive methods, using high-resolution, B-mode ultrasound have been established for 
the study of early changes in arterial function and structure. Brachial artery flow-mediated 
dilatation (FMD), is a non-invasive method used for the assessment of arterial endothelial 
vasodilator function, and is impaired in the presence of early arterial endothelial damage. 
Carotid artery intima-media thickness (IMT) is a non-invasive method used for the assessment 
of arterial wall thickness; a surrogate measure of subclinical vascular disease, which occurs 
later on in the sequence of atherosclerosis-related disease progression.  In this thesis, we use 
these methods to assess CVD risk, and associations with traditional CVD risk factors, in a 
number of populations considered ‘at risk’.  
 
We conducted a study of measurement agreement for carotid IMT measurements, comparing 
a clinic-based, mainframe ultrasound machine (i.e. the Philips ATL 5000) with a portable, 
laptop-based ultrasound machine (i.e. the Teratek Terason 3000 – a machine with many 
features similar to the traditional clinic-based machines, but more portable and affordable). 
This latter machine is suitable for studying rural and remote populations of interest. Inter- and 
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intra-observer variability for each machine type was assessed, separately; and both machine 
types were compared directly in an ‘inter-machine’ comparison, by obtaining replicate 
ultrasound scans in the same patients, in a single visit. We reported acceptable agreement for 
IMT measurements when assessing inter- and intra-observer, and inter-machine variability 
(except for maximum IMT, when using the Philips ATL 5000). The portable, laptop-based 
Teratek Terason 3000 was found to be a suitable alternative to the traditional, clinic-based, 
mainframe ultrasound machines (i.e. the ‘gold-standard’), for use in clinical studies assessing 
carotid IMT.  
 
In a cross-sectional survey of two populations of South-Asian Indians: i) a population living in 
rural Andhra Pradesh, India; and ii) a migrant Indian population living in Sydney, Australia; we 
compared carotid IMT and traditional risk factors for CVD to explore the effects of 
“westernisation”, in this ethnic group. Epidemiological studies suggest that South-Asian 
Indians are at an increased risk of CVD, compared with other ethnic groups. The results of this 
study showed no apparent difference in carotid IMT when comparing populations; however, 
there were striking differences in several traditional CVD risk factors, when comparing 
populations: some findings suggested a more adverse risk factor profile in rural Indians, 
whereas others suggested a more adverse risk in migrant Indians. This study highlights a 
potential need for strategies targeting different risk factors in these two populations, and that 
the effects of “westernisation” on CVD and its risk factors in South-Asian Indians, are complex 
and require further study. 
 
In a cross-sectional study of 405 healthy children, aged 8 years, initially enrolled in a study 
exploring two interventions, administered from birth to age 5 years (in a 2 x 2 factorial design): 
i) omega-3 fatty acid supplementation compared with polyunsaturated fatty acids; and ii) dust 
mite avoidance compared with no avoidance, we investigated carotid IMT and associations 
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with traditional risk factors for CVD. The interventions for omega-3 fatty acid supplementation 
and dust mite avoidance did not influence carotid IMT. We found that several risk factors, 
including total cholesterol, high-density lipoprotein, triglycerides, systolic and diastolic blood 
pressure, height, BMI, sex, birth length and asymmetric dimethylarginine (ADMA; an 
endogenous inhibitor of nitric oxide synthesis) levels were independently associated with 
novel markers of arterial structure and function, in healthy children aged 8 years. These results 
suggest an important role for these factors in early structural changes within the arterial wall, 
potentially contributing to the onset of premature atherosclerosis, in adulthood.  
 
This thesis presents the results of two prospectively planned vascular substudies of the large, 
multicentre Fenofibrate Intervention in Type 2 Diabetes (FIELD) study, of 9,795 patients with 
type-2 diabetes mellitus (T2DM), followed for 5 years for major cardiovascular events, after 
randomisation to the lipid-modulating peroxisome proliferator-activated receptor-alpha-
(PPARα) agonist, fenofibrate, or matching placebo. In the FIELD IMT vascular substudy, the 
effects of fenofibrate compared with placebo on carotid IMT, at 2 and 4 years, in 387 
representative subjects are described. In this substudy, fenofibrate had no effect on carotid 
IMT; however, there was a non-significant trend towards improvement in IMT in those with 
dyslipidaemia, at 2 and 4 years, on fenofibrate; consistent with previous reports of greater 
benefits from fibrates in patients with dyslipidaemia. 
 
In the FIELD FMD vascular substudy, we investigated factors associated with impaired arterial 
function in 193 representative subjects from the main FIELD study, at baseline, prior to 
treatment allocation. In this substudy, FMD (i.e. endothelium-dependent arterial function) 
was significantly impaired, compared with normal values in those without diabetes. We found 
that smooth-muscle cell dilator response to GTN (i.e. endothelium-independent function) was 
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significantly impaired in association with cigarette smoking and albuminuria.  Finally, we 
investigated the effects of fenofibrate compared with placebo on arterial endothelial function, 
at 4 months and 2 years, in the 193 representative subjects in the FMD vascular substudy.  We 
found that fenofibrate was associated with a short-term improvement in FMD, at 4 months, 
but this was not sustained after 2 years of treatment. Statistically significant improvements in 
lipids and lipoproteins, at 4 months and 2 years, did not account for observed improvements 
in FMD. These results suggest the long-term benefits of fenofibrate reported in the main FIELD 
study were mediated via mechanisms other than improvement in endothelial function, in 
large arteries. 
 
 
 
 
 
  
 
  
 
 
16 
 
Abbreviations 
ACR   Albumin:creatinine ratio 
ADMA   Asymmetric dimethylarginine 
aIMT   Aortic intima-media thickness 
Ag   Silver 
AgCl   Sliver chloride 
AIx   Augmentation index 
AMI   Acute myocardial infarction 
ANCOVA  Analysis of covariance 
ANOVA   Analysis of variance 
Apo A1   apolipoprotein A1 
Apo B   apolipoprotein B 
β   Beta-coefficient 
BIF   Bifurcation 
BMI   Body mass index 
BP   Blood pressure 
CABG   Coronary artery bypass grafting 
CAD   Coronary artery disease 
CCA   Common carotid artery 
CDC   Centre for Disease Control 
CHD    Coronary heart disease 
cm   Centimetre 
COX-1   Cyclooxygenase-1 
COX-2   Cyclooxygenase-2 
CRP   C-reactive protein 
CV   Coefficient of variation 
CVD   Cardiovascular disease 
dB   Decibel 
DDAH   Dimethylarginine dimethylaminohydrolase 
DBP   Diastolic blood pressure 
ECA   External carotid artery 
ECG   Electrocardiogram   
eGFR   Estimated glomerula filtration rate 
ELISA   Enzyme linked immunosorbent assay   
eNOS   Endogenous nitric oxide synthase 
FMD   Flow-mediated dilatation 
FW   Far wall 
g   gram 
g/L   grams per litre 
GTN   Glyceryl trinitrate 
HbA1c   Glycosylated haemoglobin 
HC   Hypercholesterolaemia 
HDL-C   High-density lipoprotein 
hs-CRP   High-sensitivity C-reactive protein 
Hz   Hertz 
ICAM-1   Intercellular adhesion molecule-1 
ICA   Internal carotid artery 
IFNγ   Interferon-gamma 
IMT   Intima-media thickness 
iNOS   Inducible nitric oxide synthase 
 
 
17 
 
IL-1   Interleukin-1 
IL-6   Interleukin-6 
IQR   Interquartile range 
JV   Jugular vein 
kg   Kilogram 
KHz   Kilo-hertz 
Ln   Natural log 
Lp(a)   Lipoprotein (a) 
LDL-C   Low-density lipoprotein 
LT   Left side (referring to left of midline) 
m   Metre 
mg   Milligram 
mg/L   Milligrams per litre 
MHz   Mega-hertz 
MI   Myocardial infarction 
min   Minutes  
mm   Millimetre 
mmHg   Millimetres of mercury 
mmol/L   Micromoles per litre 
MRI   Magnetic resonance imaging 
Na   Sodium 
NHMRC   National Health and Medical Research Council of Australia 
NO   Nitric oxide 
NOS   Nitric oxide synthase 
NW   Near wall 
PDGF   Platelet derived growth factor 
PGI2   Prostacyclin 
PPAR-α   Peroxisome proliferator-activated receptor-alpha 
PTCA   Percutaneous transluminal coronary angiography 
PVD   Peripheral vascular disease  
ROI   Region of interest 
RT   Right side (referring to right of midline)  
SBP   Systolic blood pressure 
SD   Standard deviation 
SE   Standard error 
SMC   Smooth muscle cell 
T1DM   Type-1 diabetes mellitus 
T2DM   Type-2 diabetes mellitus 
TC   Total cholesterol 
TG   Triglyceride 
TGC   Time-gain compensation 
TGF   Transforming growth factor 
TIA   Transient ischaemic attack 
TNF   Tumor necrosis factor 
tPA   Tissue plasminogen activator 
VCAM-1  Vascular cell adhesion molecule-1 
v/v   Volume per volume 
w/v   Weight per volume 
WHO   World Health Organisation 
WHR   Waist:hip ratio 
°   Degree (of arc) 
 
 
18 
 
µg   Microgram 
µmmol/L  Micromoles per litre 
%   Percent 
2-D   2-Dimensional 
95%CI   95% confidence interval 
 
 
19 
 
Publications Arising 
 
 
Chapter 4:   APRHI and HINDI Studies 
 
1. Greater adverse effects of cholesterol and diabetes on carotid intima-media thickness 
in South Asian Indians: comparison of risk factor-IMT associations in two population-
based surveys. Chow CK, McQuillan B, Raju PK, Iyengar S, Raju R, Harmer JA, Neal BC, 
Celermajer DS. Atherosclerosis. 2008 Jul; 199(1):116-22. 
 
 
Chapter 5:  CardioCAPS Study 
 
2. HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly 
associated with arterial wall thickness in children. Ayer JG, Harmer JA, Nakhla S, Xuan 
W, Ng MKC, Raitakari OT, Marks GB, Celermajer DS. Arterioscler Thromb Vasc Biol 
2009; 29:943-9. 
 
3. Dietary supplementation with n-3 polyunsaturated fatty acids in early childhood: 
effects on blood pressure and arterial structure and function at age 8 y. Ayer JG, 
Harmer JA,  Xuan W, Toelle B, Webb K, Almqvist C, Marks GB, Celermajer DS. Am J Clin 
Nutr 2009; 90:438-46. 
 
Chapters 6, 7 and 8:  FIELD Vascular Substudies 
 
4. Cigarette smoking and albuminuria are associated with impaired arterial smooth 
muscle function in patients with type-2-diabetes mellitus: a FIELD substudy. Harmer 
JA, Keech AC, Veillard A-S, Skilton MR, Griffiths KA, Celermajer DS, for the FIELD 
vascular substudy investigators. Diabetes Res Clin Pract 2014; 106:328-36. 
 
5.  Fenofibrate and short-term improvement in arterial endothelial function in adults 
with type-2-diabetes mellitus: a FIELD substudy. Harmer JA, Keech AC, Veillard A-S, 
Skilton MR, Griffiths KA, Celermajer DS, for the FIELD vascular substudy investigators. 
Atherosclerosis (published online; 20 July 2015). 
  
 
 
20 
 
Authors Contributions (for Publications Arising) 
 
Chapter 4:   APRHI and HINDI Studies 
 
1. Greater adverse effects of cholesterol and diabetes on carotid intima-media thickness 
in South Asian Indians: comparison of risk factor-IMT associations in two population-
based surveys. Chow CK, McQuillan B, Raju PK, Iyengar S, Raju R, Harmer JA, Neal BC, 
Celermajer DS. Atherosclerosis. 2008 Jul; 199(1):116-22. 
 
The authors’ responsibilities were: CKC: study design, collection and analysis of data, and 
writing of the manuscript; BM: study design, collection and analysis of data; PKR: study design 
and collection of data; SI: study design, collection and analysis of data; RR: study design, JAH: 
study design, data analysis and interpretation; BCN: study design and writing of the 
manuscript; DSC: study design and writing of the manuscript. 
Corresponding Author’s signature: 
 
Chapter 5:  CardioCAPS Study 
 
2. HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly 
associated with arterial wall thickness in children. Ayer JG, Harmer JA, Nakhla S, Xuan 
W, Ng MKC, Raitakari OT, Marks GB, Celermajer DS. Arterioscler Thromb Vasc Biol 
2009; 29:943-9. 
 
The authors’ responsibilities were: JGA: study design, collection and analysis of data, and 
writing of the manuscript; JAH: study design, collection and interpretation of data, review of  
the manuscript; SN: laboratory analysis, collection and interpretation of interpretation; WX: 
data analysis; MKCN: interpretation of data and review of the manuscript; OTR: interpretation 
of data and review of the manuscript; GBM: study design and data analysis DSC: study design 
and writing of the manuscript.  
Corresponding Author’s signature: 
 
 
3. Dietary supplementation with n-3 polyunsaturated fatty acids in early childhood: 
effects on blood pressure and arterial structure and function at age 8 y. Ayer JG, 
Harmer JA,  Xuan W, Toelle B, Webb K, Almqvist C, Marks GB, Celermajer DS. Am J Clin 
Nutr 2009; 90:438-46. 
 
The authors’ responsibilities were: JGA: study design, collection and analysis of data, and 
writing of the manuscript; JAH: study design, collection and interpretation of data, review of 
the manuscript; WX: data analysis; BT: study design and collection of data; KW: study design; 
CA: study design; GBM: study design and data analysis DSC: study design and writing of the 
manuscript.  
Corresponding Author’s signature: 
 
 
21 
 
Conference Abstracts 
 
Chapter 4:   APRHI and HINDI Studies 
 
1. Interrelationship between cardiovascular risk factors and subclinical atherosclerosis 
in South Asian Indians in Rural Indian and Urban Australian Settings. Skilton MR, Chow 
CK, Harmer JA, Celermajer DS. Cardiac Society of Australia and New Zealand Annual 
Scientific Meeting, Brisbane, 2012. 
 
2. Differences in cardiovascular risk factors and carotid intima-media thickness in 
Australian Indians and Caucasians with type-2 diabetes mellitus; an ethnic 
predisposition to Atherosclerosis? Harmer JA, Chow CK, McQuillan BM, Celermajer 
DS. Cardiac Society of Australia and New Zealand Annual Scientific Meeting, 
Melbourne, 2015. 
 
Chapter 5:  CardioCAPS Study 
 
3. Blood pressure and HDL-cholesterol are significant determinants of arterial structure 
and function in 8-year old children. Ayer JG, Harmer JA, Ng K, Toelle B, Marks GB, 
Celermajer DS. Cardiac Society of Australia and New Zealand Annual Scientific 
Meeting, Adelaide, 2008. 
 
4. Blood pressure is associated with abnormal arterial structure and function in a 
community-based cohort of 8-year old children. Ayer JG, Harmer JA, Siriragavan S, Ng 
K, Toelle B, Xuan W, Marks GB, Celermajer DS. American Heart Association Scientific 
Sessions, Orlando, Florida, 2007. 
 
Chapters 6, 7 and 8:  FIELD Vascular Substudies 
 
5. Fenofibrate and carotid intima-media thickness in adults with type-2-diabetes 
mellitus: a FIELD substudy. Harmer JA, Veillard A-S, Skilton MR, Griffiths KA, Keech AC, 
Celermajer DS for the FIELD vascular substudy investigators. Cardiac Society of 
Australia and New Zealand Annual Scientific Meeting, Perth, 2011. 
 
6. Cigarette smoking and albuminuria are associated with impaired arterial smooth 
muscle function in patients with type-2-diabetes mellitus: a FIELD substudy. Harmer 
JA, Keech AC, Veillard A-S, Skilton MR, Griffiths KA, Celermajer DS, for the FIELD 
vascular substudy investigators. Cardiac Society of Australia and New Zealand Annual 
Scientific Meeting, Adelaide, 2010. 
 
7. Fenofibrate and short-term improvement in endothelial function in adults with type-
2-diabetes mellitus: a FIELD substudy. Harmer JA, Keech AC, Veillard A-S, Skilton MR, 
Griffiths KA, Celermajer DS, for the FIELD vascular substudy investigators. Cardiac 
Society of Australia and New Zealand Annual Scientific Meeting, Adelaide, 2010. 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1:  
 
Introduction 
 
  
 
 
23 
 
1.1 The burden of cardiovascular disease   
Cardiovascular disease (CVD) is the leading cause of death worldwide. In 2008, the World 
Health Organisation estimated there were 17.3 million deaths from CVD, representing 30% of 
all deaths globally (1). Of these deaths, 7.3 million (42%) were from coronary heart disease 
(CHD) – the major cause of myocardial infarction (MI) and angina, and 6.2 million (36%) were 
due to cerebrovascular disease – the cause of stroke (2).  
 
Globally, rates of CVD mortality have been changing for several decades. In high-income 
countries, mortality from CVD has been steadily declining due to improvements in prevention, 
diagnosis and treatment of CHD and stroke and its major CVD risk factors. Figure 1.1 shows 
the trend in age-standardised death rates from CVD and CHD in Australia from 1907 to 2006 
(3). Similar trends have been described in other high-income countries. 
 
Figure 1.1 – Trends in age-standardised death rates in Australia from CVD and CHD, between 
1907–2006 (3). 
ASR = age-standardised (death) rates.  
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By contrast, in low-to-middle income countries the prevalence of CVD is rising (1), and over 
80% of CVD mortality, globally, occurs in low-to-middle income countries (4). Multiple reasons  
exist for the disproportionately high burden of CVD in these countries (5): including higher 
rates of exposure to risk factors for CVD – e.g. tobacco, a lack of primary prevention programs, 
less effective or difficult to access health care services, inability to afford health care, and 
possible differences in the susceptibility of some populations to traditional CVD risk factor 
levels – e.g. a greater susceptibility to cholesterol and diabetes in South-Asian Indians (6) – 
discussed in chapter 4. Current trends suggest that global CVD mortality will further increase 
and reach ~ 23.3 million deaths annually, by 2030 (4). A 35% increase in CVD mortality from 
2008. 
 
1.2 Traditional cardiovascular risk factors 
The majority of CVDs are preventable as many of the risk factors are preventable. Traditional 
risk factors for CVD include high blood pressure (BP), high cholesterol, diabetes mellitus, 
tobacco smoking, obesity, physical inactivity, poor nutrition (i.e. lack of daily consumption of 
fruit and vegetables). Non-modifiable risk factors for CVD include age, sex and genetic 
inheritance. CVD risk strongly increases with age and men have higher rates of CVD than 
women; after menopause, the sex-discrepancy starts to decline. The INTERHEART study (7), a 
case-control study of the effect of potentially modifiable risk factors associated with acute 
myocardial infarction (AMI) in 52 countries, found the same nine risk factors were associated 
with > 90% of the risk of an AMI, regardless of sex or the country of origin. These risk factors 
included current smoking, diabetes, hypertension, elevated lipid levels, abdominal obesity, 
psychosocial stress, lack of daily consumption of fruits and vegetables, lack of regular physical 
activity, and regular alcohol consumption. Figure 1.2 shows the association of these risk 
factors with AMI in males and females, in the INTERHEART study. 
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Figure 1.2 – Association of risk factors with acute myocardial infarction in in men and women 
in the INTERHEART study# (7). 
#Adjusted for age, sex, and geographic region. 
 
In Australia, the prevalence of traditional risk factors for CVD is very high. In 2004, ~ 90% of 
the Australian adult population had at least one modifiable risk factor for CVD, while 25% has 
three or more (8). As examples, in the adult Australian population, 60% (7.42 million) were 
overweight, 54% (7.27 million) were physically inactive, 51% (6.40 million) had high 
cholesterol, 30% (3.69 million) had hypertension, 20% (3.06 million) smoked cigarettes daily, 
10% (1.54 million) consumed excessive alcohol, and 8% (0.95 million) had diabetes mellitus 
(8). The presence of multiple risk factors considerably increases the risk of developing CVD. 
Figure 1.3 shows the effect of multiple risk factors on AMI in the INTERHEART study. 
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Figure 1.3 – Effect of multiple risk factors on risk of acute myocardial infarction in the 
INTERHEART study (7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Smk=smoking, DM=diabetes mellitus, HTN=hypertension, Obes=abdominal obesity, PS=psychosocial 
stress, RF=risk factors 
 
1.3 The underlying pathology of cardiovascular disease 
The underlying cause of the majority of CVD and clinical events is atherosclerosis. The process 
of atherogenesis begins in early in childhood and is accelerated by the presence of risk factors 
for CVD. Important steps in the development of atherosclerosis include: endothelial cell injury, 
adhesion molecule expression and the recruitment of inflammatory cells, lipid modification 
and foam cell formation, smooth muscle cell (SMC) proliferation and migration, and the 
development of ‘fibrofatty’ plaque. Our modern understanding of the process of 
atherosclerosis is based on the ‘response to injury’ hypothesis, proposed by Ross (9,10). An 
understanding of the normal artery wall is required before the following discussion on the 
pathogenesis of atherosclerosis. 
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1.3.1 The normal artery wall 
The general composition and architecture of arteries throughout the body is similar. The 
normal artery wall consists of 3 layers: the (tunica) intima, media and adventitia (Figure 1.4). 
The intima – the inner-most layer – is composed of a single-cell sheet of flattened endothelial 
cells, an underlying basal lamina and a thin layer of subendothelial connective tissue. The 
endothelial cell layer has a number of important biological functions: these functions are 
described in section 1.3.2 of this chapter.  
 
The media – the middle-most layer – consists of SMCs arranged in a helical manner. These 
SMCs are embedded in a matrix of elastin (which has extensible properties and is responsible 
for distension) and collagen fibres (which prevent over-distension, by providing tension). Two 
sheets of elastin (the internal and external elastic lamina) form the inner and outer media 
boundaries, separating it from the intima and adventitia layers. Intimal endothelial cells send 
processes through the internal elastic lamina to facilitate inter-cellular communication with 
medial SMCs; this mechanism for communication is important for vascular function and cell 
viability.  
 
The adventitia - the outer-most layer – is comprised of connective tissue, mostly collagen and 
elastin, with no distinct outer border. The adventitia also contains sympathetic nerve fibre 
terminals that release noradrenaline to regulate SMC tone and the vaso vasorum (i.e. ‘vessels 
of vessels’) – which are present in larger arteries to provide oxygen and nutrients to the outer-
most part of the media layer (the inner-most part of the media layer receives its nutrients and 
oxygen by diffusion from the vessel lumen). The main function of the adventitia layer is to 
tether the artery to surrounding tissues. 
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Figure 1.4 – Cross-sectional view of the normal artery wall consisting of 3 layers: the intima, 
media and adventitia.  
 
 
 
 
 
 
 
 
Arteries are subdivided into 3 types according to size, functional and structural characteristics: 
i) large (‘elastic’) arteries ii) medium sized (‘muscular’) arteries, and iii) small arteries and 
arterioles. The structure of the artery wall type is adapted to its function. Elastic arteries – e.g. 
the aorta, subclavian, common carotid and iliac arteries, and the pulmonary trunk – are 1-2 
cm in diameter, highly distensible and act as temporary storage vessels for blood expelled 
from the heart. Medium-sized arteries – e.g. the coronary, femoral, cerebral, brachial and 
radial arteries – are 0.1-1.0 cm in diameter, contain more smooth muscle and are thicker 
(relative to the lumen size) than elastic arteries. The primary role of these vessels is to conduct 
the flow of blood from elastic arteries to smaller arteries and arterioles (i.e. ‘resistance 
vessels’).  
 
Smaller arteries, implied by the term resistance vessels, have a great capacity to dilate and 
contract; thus, they play an important role in regulating regional BP and flow – allowing blood 
flow to be diverted to capillary beds in times of need, without compromising vital supply 
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elsewhere. Capillaries – distal to small arteries and arterioles – allow the rapid passage of 
solutes by diffusion – e.g. gaseous exchange (O2 and CO2), the provision of nutrients and 
essential elements (glucose, amino acids, fatty acids, vitamins and minerals), and the removal 
of wastes (creatinine, urea). Atherosclerosis occurs in large and medium-sized arteries.  
 
1.3.2 Endothelial cell injury 
The ‘normal’ endothelium has a major role in vascular homeostasis and maintaining normal 
circulatory function. Endothelial cells secrete a large number factors that regulate various 
functions, and these have been described in a number of published reviews (11-14). In 
summary, endothelial cells: provide a semi-permeable membrane, controlling the transfer of 
small and large molecules across the artery wall; maintain a thromboresistant surface – via 
the production of anticoagulant, antithrombotic and fibrinolytic molecules – e.g. prostacyclin, 
thrombomodulin, plasminogen activator, and heparin-like molecules; regulate prothrombotic 
responses – via the production of Von Willebrand factor, tissue factor and plasminogen 
activator inhibitor; make components of extracellular matrix – e.g. collagen and 
proteoglycans; regulate inflammatory and immune responses – via the production of IL-1, IL-
6, chemokine and adhesion molecule expression; produce cell growth factors and inhibitors; 
and modulate  blood flow and arterial vasodilatory capacity, via the production of vasodilator 
substances – e.g. nitric oxide (NO), prostacyclin, and endothelium-derived relaxing factor 
(EDRF); and vasoconstrictor substances – e.g. endothelin and angiotensin converting enzyme. 
Figure 1.5 show the various factors produced by endothelial cells and their role.   
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Figure 1.5 – Various mediators produced by ‘normal’ endothelial cells and their role (11).  
 
 
 
 
 
 
 
 
 
 
 
 
NO is the main vasodilator substance produced by endothelial cells, and the main hallmark 
feature of endothelial dysfunction is impaired endothelium-dependent vasodilation, which is 
NO mediated (12). NO is synthesised by endothelial cells from its precursor, L-arginine (an 
amino acid), via the enzymatic action of endothelial NO synthase (eNOS), which is also 
produced by endothelial cells. Asymmetric dimethylarginine (ADMA) inhibits eNOS; thereby 
promoting endothelial dysfunction, via decreased NO synthesis. NO has other important 
functions, including inhibition of platelet adherence and aggregation, leukocyte adhesion, 
oxidation of low-density lipoprotein (LDL-C), SMC proliferation and migration. Thus, impaired 
NO synthesis promotes vasoconstriction, platelet aggregation, leukocyte adhesion, oxidative 
stress, and SMC proliferation and migration – effects that promote the development and 
progression of atherosclerosis (12,15).  
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Figure 1.6 – Cascade of proatherogenic effect resulting from exposure to cardiovascular risk 
factors that promote endothelial dysfunction (15).   
 
 
1.3.3 Adhesion molecule expression and the recruitment of inflammatory cells 
An important early event in the development of atherosclerotic lesions is the upregulated 
expression of adhesion molecules - in particular, vascular cell adhesion molecule-1 (VCAM-1), 
intracellular adhesion molecule-1 (ICAM-1), ICAM-2, E-, P- and L-selectin, and various integrins 
-  which allow monocytes and platelets to adhere to the endothelial cell surface and permit 
the entry of monocytes into the intima (9,10). Chemotactic factors – e.g. monocyte 
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chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8), and several colony stimulating 
factors – develop a gradient enticing cells to transmigrate.  
 
1.3.4 Lipid modification and foam cell formation 
LDL-C within the arterial wall undergoes oxidative modification by oxidative products released 
by macrophages, endothelial cells and SMCs, forming oxidised-LDL which is proatherogenic. 
LDL-C uptake is tightly regulated; however, oxidised-LDL is readily taken up by macrophages 
via scavenger receptors on the cell surface. Macrophages eventually become lipid-laden (i.e. 
‘foam cells’). Oxidised-LDL promotes atherosclerosis as it is chemotactic for monocytes, 
upregulates adhesion molecule and cytokine expression and modifies SMC phenotype (16).  
 
1.3.5 Smooth muscle cell proliferation, migration and vascular remodelling 
SMC in the medial layer of the arterial wall respond to cytokines produced by foam cells and 
lymphocytes. This causes them to migrate into the intima, proliferate, and secrete abnormal 
amounts of collagen and other connective tissue proteins. Diffuse intimal thickening occurs 
over time due to the accumulation of SMC and connective tissue matrix. Early vascular lesions 
consist of focal alterations superimposed on the diffusely thickened intima.  
 
1.3.6 Atherosclerotic plaque rupture 
A more advanced stage of atherosclerosis is the fibrous plaque, with a fibrous cap that 
overlays the dense lipid core. Complicated lesions also contain more extensive calcification 
and often have extensive cellular necrosis. If the fibrous cap ruptures due to breakdown or 
fracture, thrombosis can be initiated potentially leading to an acute coronary syndrome. 
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Cytokines and matrix metalloproteinases produced T-lymphocytes inhibit collagen synthesis 
and promote collagen breakdown – resulting in a potentially ‘vulnerable’ (or unstable) plaque. 
Figure 1.7 shows the progression of atherosclerosis from early lesions to advanced, 
complicated plaque. 
Figure 1.7 – Representation of the time line for the progression of atherosclerosis from early 
lesions (‘fatty streaks’) to complicated plaques. 
 
 
 
 
 
 
1.4 Carotid artery intima-media thickness 
Carotid artery intima-media thickness (IMT) is a non-invasive measure of subclinical vascular 
disease that has been used extensively in clinical studies as a surrogate marker for CVD. The 
technique was first described by Pignoli P. et.al. (17) in 1986. Measurement of carotid IMT 
with high-resolution, B-mode ultrasound is a non-invasive, safe and reproducible technique. 
Several studies that have compared histology with ultrasound measurements of IMT have 
indicated that the far wall (FW) carotid IMT reflects the true thickness of the artery wall (17-
19). IMT measured at the near wall (NW) is only an approximation (18,20). Figures 1.8 and 1.9 
show carotid artery ultrasound scans for the assessment of IMT. Carotid IMT protocols differ 
(21): some use only a single optimal B-mode image – e.g. the FW of the common carotid artery 
(CCA), whereas others use multiple optimal B-mode images from a combination of sites – e.g. 
the CCA, internal carotid artery (ICA), and the carotid bifurcation. A few centres routinely 
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performing carotid IMT studies obtain images from various angles of interrogation. Some 
report mean or maximum IMT, or both. As described by Bots M.L. et.al. (21), associations with 
traditional CVD risk factors with carotid IMT are present in most studies, but no formal 
comparison of methods has been conducted. Chapter 2 provides a detailed description of the 
methods used in this thesis for the assessment of carotid IMT. 
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Figure 1.8 – Assessment of carotid IMT: a) ultrasound probe aligned with the carotid artery; 
b) B-mode ultrasound image of a normal carotid artery; c) B-mode image of a carotid artery 
from a patient with diabetes mellitus. 
 
 
 
 
Figure 1.9. Selection of the region of interest for measurement of carotid IMT in the common 
carotid artery. 
 
 
 
 
 
 
 
             Images provided by Dr Michael Skilton, Sydney Medical School; The University of Sydney. 
b) 
c) 
a) 
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1.5 Evidence for carotid intima-media thickness as a surrogate risk marker 
A number of observational studies have provided substantial evidence of a strong relationship 
between increased carotid IMT and risk of CVD events. In the Kuopio Ischaemic Heart Disease 
Risk Factor study (KIHD), 1,228 men with maximum carotid IMT > 1 mm at baseline who were 
followed-up for 2.5 years had a 2.2-fold (95% confidence interval [CI]: 0.7, 6.74) increased risk 
of MI (22). In the Atherosclerosis Risk in Communities (ARIC) study, > 12,000 subjects with a 
mean carotid IMT ≥ 1 mm at baseline who were followed-up for 5.2 years had 1.85-fold 
(95%CI: 1.28, 2.69) increased risk of CHD in men, and a 5.07-fold (95%CI: 3.08, 8.36) increased 
risk in women (23). Furthermore in the ARIC study, a baseline carotid IMT ≥ 1mm had a 3.6-
fold (95% CI: 1.5, 9.2) increased risk of stroke in men, and an 8.5-fold (95%CI: 3.5, 20.7) 
increased risk in women, compared with an IMT < 0.06 mm (24).  
 
 In the Rotterdam study, each increment in maximum IMT of 0.163 mm increased the risk of 
MI by 1.43-fold (95%CI: 1.16, 1.78), and the risk of stroke by 1.41-fold (95%CI: 1.25, 1.82) over 
2.7 years (25). In the Cardiovascular Health Study (CHS), 5,858 older adults without a history 
of CVD had a 3.9-fold increase (95%CI: 2.72, 5.51) in the risk of MI or stroke in individuals with 
the highest quintile for maximum IMT compared with the lowest quintile (26). Other studies 
showed similar associations (27,28). Thus, there is substantial evidence from large-scale 
prospective studies that carotid IMT is significantly associated with risk of MI, stroke and CHD 
deaths. 
 
Numerous studies have shown significant associations between carotid IMT and traditional 
cardiovascular risk factors. Increased carotid IMT has been found in association with ageing 
(29), male sex (29), hypertension (30,31), diabetes (32-34), insulin resistance (35,36), 
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overweight and obesity (29,37), and cigarette smoking (38). These and other novel risk factors 
associated with carotid IMT in adults have been summarised in several review articles (39,40). 
Similarly, a recent review describes associations with carotid (and abdominal aortic) IMT in 
children and adolescents (41).  
 
Interventional studies have shown that ‘active’ cardiovascular therapies when compared with 
placebo can slow the progression of carotid IMT. A meta-analysis of 7 trials of statins that had 
measured both carotid IMT and CVD events showed that a mean change in IMT progression 
of -0.012 mm/year (95%CI: -0.016, -0.007) was associated with an odds ratio of 0.48 (95%CI: 
0.30, 0.78) for a reduction in CVD events (42). A meta-analysis of antihypertensive agents 
compared with placebo or no treatment showed a mean change in carotid IMT progression of 
-0.007 mm/year (95%CI: -0.014, -0.002) (43). The trials in this meta-analysis did not correlate 
IMT measurements with CVD events. Thus, there is a large, comparative body of literature, 
and substantial evidence in support of the usefulness of carotid IMT as a surrogate measure 
of CVD risk. 
 
1.6 Brachial artery flow-mediated dilatation 
Brachial artery flow-mediated dilatation (FMD) is a non-invasive measure of arterial function 
that has been used extensively in clinical studies as a surrogate marker for CVD. The technique 
was first described by Celermajer D.S. et.al. (44) in 1992. Similar to carotid IMT, the 
measurement of FMD with high-resolution, B-mode ultrasound is a non-invasive, safe and 
reproducible technique. Increased blood flow (reactive hyperaemia) resulting from cuff 
inflation and deflation stimulates the release of vasodilator substances from the endothelium, 
such as nitric oxide (NO), which in turn causes arterial dilatation (which is measured as FMD) 
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(45). Sublingual glyceryl trinitrate is an exogenous NO-donor and can be used in addition to 
FMD in order to test SMC-dependent vasodilator capacity. The methods for the assessment 
of FMD are less variable across different study centres. A detailed description of this technique 
is provided in Chapter 2. Figure 1.9 shows brachial artery ultrasound scans for the assessment 
of FMD (i.e. endothelium-dependent vasodilator function) and vasodilator response to GTN 
(i.e. endothelium-independent function).  
 
1.7 Evidence for flow-mediated dilatation as a surrogate risk marker 
Several studies have explored the association between impaired FMD and the clinical extent 
of coronary artery disease (CAD) and events. A study by Neunteufl T. et.al. (46) explored the 
predictive value of FMD > 10% versus < 10%, in 73 patients with angina that were followed-
up for 5 years. In this study, subjects with preserved FMD > 10% had fewer coronary 
angioplasties (7% versus 37%; p=0.009) and fewer coronary artery bypass graft procedures 
(GABG; 0% versus 15%; p=0.009), but had no difference in MI. On stepwise regression analysis, 
the extent of CAD was independently associated with FMD. In a pilot study by Schroeder S. 
et.al. (47), impaired FMD was used as a screening test to identify CAD in patients. Of the 122 
patients in the study, 101 had angiographically detectable disease. FMD was shown to be 
higher in those with CAD compared to those without CAD (7.0 ± 3.5 % versus 3.8 ± 4.1 %; 
p<0.001). A study by Matsushima, Y. et.al. (48), compared the predictive value of FMD and 
IMT for CAD severity. This study had 73 patients with significant CAD and 30 patients with no 
CAD, and found that FMD was impaired (3.7 ± 3.0 % versus 7.5 ± 2.9%) and IMT was higher in 
patients with CAD.   
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In a study by Takase B. et.al. (49), the predictive value of FMD, IMT and exercise stress test for 
CAD prognosis was assessed. Of the 103 patients, 73 had CAD and 30 had no CAD; and 15 
patients had coronary events. On Kaplan-Meier analysis, FMD and exercise stress test but not 
IMT were predictors for coronary events. In a study by Kaku B. et.al. (50), the relationship 
between FMD and the extent and severity of CAD was assessed. FMD was shown to be 
independently associated with coronary stenosis index: a marker for CAD severity. 
Furthermore, FMD was 10.2 ± 4.8% in patients without CAD, 7.7 ± 6.0% in patients with single 
vessel disease, 5.2 ± 5.5% in patients with double vessel disease, and 2.0 ± 3.9% in those with 
triple vessel disease. A study by Corretti, M.C. et.al. (51), however, did not show a relationship 
between FMD and CAD. Observational studies with large numbers of subjects, exploring an 
association between FMD and CVD mortality, are lacking.  
 
FMD has been shown to be associated with traditional CVD risk factors in adults and children. 
In the first published report of FMD by Celermajer D.S. et.al. (44), FMD was shown to be 
impaired in smokers, children with familial hypercholesterolaemia and adults with CAD. Active 
cigarette smoking is associated with impaired FMD (52), as is passive smoking (53). Obesity is 
associated with impaired FMD (54). A study conducted in 500 clinically well, non-hypertensive 
subjects found an association between impaired FMD and male sex, hypercholesterolaemia, 
smoking, hypertension, larger vessel size, and a family history of premature CVD (55).  
 
A number of studies have shown the potential for reversibility in impairment of FMD. Folic 
acid supplementation in hyperhomocystinaemia has been shown to improve FMD (56). In a 
study of obese children, diet and exercise combined, improved FMD after achieving weight 
loss (54).  
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Figure 1.9 – Assessment of brachial artery FMD: a) baseline scan; b) FMD scan taken 45-60 sec 
after cuff release; c) dilator response to sublingual GTN. Vessel diameter measurements are 
taken at each point, in the sequence of scans. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
              Images provided by Dr Michael Skilton, Sydney Medical School; The University of Sydney. 
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Similarly, studies have shown that impaired FMD in those who actively smoke cigarettes, or 
are exposed to passive smoking, show some improvement in FMD after smoking cessation 
(52) or prolonged withdrawal from passive smoking (53). Large intervention studies of lipid-
lowering medications (e.g. statins) and antihypertensive drugs (e.g. angiotensin converting 
enzyme-inhibitors, angiotensin I receptor blockers and calcium channel blocker) have been 
shown to significantly improve FMD (57-59). Potential reversibility in arterial endothelial 
function and its correlation with improvements in clinical endpoints lends weight to use of 
FMD as a useful surrogate for CVD risk. 
 
1.8 Aims of this thesis 
The research described in this thesis explores the use of non-invasive ultrasound for the 
assessment of carotid artery IMT (a measure of subclinical vascular disease) and brachial 
artery FMD (a measure of endothelium-dependent vasodilator function) to assess CVD risk, 
and associations with traditional CVD risk factors, in a number of populations considered ‘at 
risk’.   
The specific aims of this thesis are as follows: 
i. To study measurement agreement for carotid IMT measurements, comparing a 
clinic-based mainframe ultrasound machine and a portable, laptop-based ultrasound 
machine. This study aims to determine whether portable ultrasound machines are 
similar to clinic-based, mainframe ultrasound machines, in their assessment of 
subclinical vascular disease (Chapter 3). 
ii. To investigate the effects of ‘westernisation’ on traditional CVD risk factors and 
carotid IMT (using a portable ultrasound machine) in South-Asian Indians, by 
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comparing rural Indians (in Andhra Pradesh, India) to migrant Australian-Indians to a 
reference population of rural Indians (in Andhra Pradesh) (Chapter 4).  
iii. To investigate the determinants of novel measures of arterial structure and function 
in a cohort of children aged 8-years, including carotid IMT and markers of carotid 
IMT heterogeneity, using a portable ultrasound machine (Chapter 5). 
iv. To explore the effects of fenofibrate, a lipid-modifying agent, on carotid IMT in 
adults with T2DM (Chapter 6). 
v. To study the determinants of arterial function, as assessed by brachial artery FMD, 
in adults with T2DM (Chapter 7). 
vi. To investigate the effects of fenofibrate on arterial endothelial function in adults 
with T2DM (Chapter 8). 
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CHAPTER 2:  
 
Ultrasound Methods for the Assessment of Carotid Artery Intima-Media 
Thickness and Brachial Artery Flow-Mediated Dilatation 
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2.1 Equipment and set-up 
2.1.1 Laboratory setting 
The studies described in this thesis were conducted in a number of different settings, 
depending upon the population under investigation. IMT studies were performed in a 
simulated clinic environment containing an examination bed, dim lighting (to facilitate 
ultrasound imaging), and curtains, if a separate room was not available (to provide privacy for 
patients). Achieving ambient room temperature was not always possible when performing 
IMT studies – e.g. when conducting carotid ultrasound scans in rural India (described in 
Chapter 4). By contrast, all studies involving an assessment of FMD were performed in a clinic 
environment, at ambient room temperature. Studies have shown that room temperature can 
influence reliable testing of FMD; thus, studies involving the assessment of FMD were 
routinely performed at 25 °C. 
 
2.1.2 Medical consumables 
Water-soluble, ultrasound transmission gel was from Medtel, Lane Cove, NSW, Australia 
(http://www.medtel.com.au). Multipurpose rayon cloths (32 x 33 cm) were used to remove 
ultrasound gel from the patients skin and to protect clothing was from Cello Paper Pty. Ltd, 
Fairfield, NSW, Australia (http://www.cello.com.au). 3M Red Dot, radiolucent electrodes with 
foam tape, sticky gel and abrader pad and Ag/AgCl, for recording the 3-lead ECG tracing, were 
from 3M HealthCare, Pymble, NSW, Australia (http://www.3m.com.au). Chlorohexidine 
gluconate 0.5% (w/v) in ethanol 70% (v/v) solution (Pharmacia Perth Pty. Ltd, Bently, WA, 
Australia; http://www.pfizer.com.au) was used as a disinfectant. Sony super-VHS videotapes 
were from FATS Digital, Chatswood, NSW, Australia (http://www.fats.com.au). Digital images 
were saved to Sony 4.7 Gigabyte DVD-R disks, for archiving. 
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2.1.3 Patient preparation and consent 
Studies involving FMD testing were performed in the morning on fasting (> 8 hours) subjects. 
IMT studies were performed on non-fasting subjects, unless fasting blood samples were 
required as a part of the study design, or if conducting FMD studies. All subjects were asked 
to refrain from heavy exercise on the day of the study to minimise the effect of exercise on 
vasodilator function. All ultrasound studies were performed with subjects lying supine on an 
examination bed with the patients head supported by a standard pillow. For FMD studies, the 
patient’s right arm was extended, and its weight was supported by a small mobile table 
attached to the side of the examination bed. Written, informed consent was obtained from 
all subjects (or their legal guardians, for studies involving children). Participation in these 
studies was entirely voluntary, and subjects were able to withdraw from testing at any stage.  
 
2.2 Carotid artery intima-media thickness 
2.2.1 Ultrasound settings 
Several ultrasound settings were standardised to reduce the degree of variability introduced 
by adjustable settings that were known to impact on imaging quality. The following were 
applied to all IMT studies described in this thesis: high-frequency (≥ 7.0 MHz), B-mode 
ultrasound was used; depth was set to 4 cm; a single focal point was positioned at the far wall, 
or two separate focal points were positioned, with one at the near wall and the other at the 
far wall (if available); high frame rate was used (> 15 Hz); persistence was turned ‘off’, or 
adjusted to the lowest possible setting; compound imaging was used (if available); and the 
use of other imaging optimisation tools was avoided. Operator-defined adjustment of time-
gain compensation was encouraged, to reduce the impact of ultrasound artefacts and 
optimise image quality at the far wall (i.e. the region of interest; ROI, for IMT assessment – 
described below).  
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2.2.2 IMT image acquisition 
High-resolution, B-mode ultrasound images were obtained of the left and right common 
carotid arteries (CCA), with subject lying supine. The patients head and shoulders were 
supported by a pillow, which assisted with extension of the neck to expose the proximal 
segment of the CCA and relax the sternocleidomastoid muscle: contraction of neck muscles 
provided difficulty with skin contact, and introduced ultrasound artefact. The left CCA was 
routinely imaged first by rotating the patients head ~ 45° from midline and towards the right. 
The right CCA was then scanned by rotating the patients head in the opposite direction, again 
~ 45° from midline, but this time to the left. A continuous 3-lead ECG tracing was recorded 
throughout IMT studies for later off-line analysis.  
 
First, the neck was scanned in the transverse plane (referred to as the ‘transverse scan’) to 
explore the anatomy of the vessels and identify the presence of any atherosclerotic plaque, 
which may dictate selection of CCA segment used for IMT measurements. The transducer was 
placed midway along the neck in an anterolateral position. The CCA and jugular vein (JV) were 
positioned at the centre of the screen and the transducer was slowly advanced superiorly, 
revealing the carotid bulb (B) and the internal (ICA) and external (ECA) carotid arteries (Figure 
2.1). This scan was recorded as a single digital loop (of 5-10 seconds), or recorded continuously 
to super-VHS video tape. If atherosclerotic plaque was visualised, additional images were 
obtained to characterise the burden of focal atherosclerotic disease. Figure 2.2 demonstrates 
the use of compressive pressure during ultrasound, while scanning in the transverse plane, to 
help distinguish between the CCA and the JV. 
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Figure 2.1 – Transverse ultrasound scan of the left carotid artery, advancing superiorly from 
the aortic arch. Common carotid artery (CCA), jugular vein (JV), thyroid gland (TG), bulb (B), 
internal carotid artery (ICA), external carotid artery (ECA), skeletal muscle (M). 
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Figure 2.2 – Compressive pressure through the transducer during ultrasound imaging is useful 
for distinguishing between the common carotid artery (CCA) and the jugular vein (JV). The 
muscular carotid artery wall is not easily compressible. 
 
 
 
 
 
 
 
 
 
 
 
 
Second, the neck was scanned in the longitudinal plane (i.e. 90° from the transverse position). 
The carotid bulb was positioned to the left of the screen and the transducer was angled so 
that the CCA was parallel to the ultrasound beam. The angle of the transducer was adjusted 
so that the JV was positioned above the CCA to provide an acoustic window. If the JV was 
found to be compressed, then lighter pressure was applied through the transducer to open 
the JV. Figure 2.3 shows a typical longitudinal ultrasound scan of the CCA, suitable for the 
assessment of carotid IMT.   
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Third, optimised CCA images for IMT assessment were obtained in longitudinal plane with the 
transducer positioned immediately below the carotid bulb. Images were magnified using high-
definition zoom – a technique that directs all available transducer channels into the selected 
region – increasing image size and resolution. The pre-specified region of interest (ROI) for the 
assessment of carotid IMT in studies described in this thesis was the FW of CCA, 0-1 cm 
proximal to the carotid bulb (Figure 2.4). If this segment of the CCA contained focal 
atherosclerotic plaque, then the most proximal segment of the CCA free of plaque was used. 
A minimum of 2 distance markers were recorded at the time of scanning, to permit image 
calibration during later off-line analysis. Images were saved as digital cineloops of 15-60 
seconds for each side of the neck (typically 4-6 cineloops per side), or to super-VHS videotape, 
depending upon the study design.  
 
 
Figure 2.3 – Longitudinal ultrasound scan of the left common carotid artery (CCA), with the 
carotid bulb (B) positioned to the left of the screen. Jugular vein (JV); skeletal muscle (M). 
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Figure 2.4 – The pre-specified region of interest (ROI) for carotid IMT measurements of the 
common carotid artery (CCA).  
 
 
 
 
 
 
 
 
 
 
 
2.2.3 IMT analysis 
As described above, optimised carotid IMT images were saved as digital cineloops or to super-
VHS videotape. Prior to analysis, sets of images were reviewed and the most suitable 
recordings where identified for conversion into bitmap files: a requirement of the semi-
automated IMT analysis package used in this thesis. For digital cineloops, proprietary software 
supplied within each ultrasound machine was used to generate single frame bitmap files. For 
images recorded to super-VHS videotape, images were re-digitised using a commercially 
available video capture device (Studio Plus 700 USB, Version 10; Pinnacle Systems Inc., 
Germany). In brief, images were re-played from a standard video cassette recorder into the 
video capture device, using composite (red, green, blue; RBG) video. Component video was 
streamed into the computer via USB connection, and converted into .AVI files using a DivX 
codex with 2:1 compression. After re-digitising, single frame bitmap files were saved from .AVI 
files, using the video editing software with the Studio Plus 700 USB package. Bitmap files were 
generated on R-wave frames, to correspond with end-diastole. A single bitmap file was 
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generated per cardiac cycle, and selected on the basis of overall image quality at the ROI 
(including FW definition, appropriate use of time-gain compensation (TGC), minimal 
reverberation or slice-thickness artefact and angle of the vessel angle on the screen – with a 
preference for more horizontal vessels). Bitmap files were reviewed by a single observer and 
the best quality images were selected for IMT measurements. In a typical analysis, an average 
of 4-5 (with a minimum of 2) bitmap frames were measured for each side of the neck. 
 
A semi-automated IMT analysis package (designed by Dr Brian Bailey, Department of 
Cardiology, Royal Prince Alfred Hospital, Sydney, Australia) was used for IMT measurements 
in studies described in this thesis. This software has been used extensively and previously 
validated (60). In brief, a single bitmap file was opened and calibrated using two distance 
markers (5-10 mm apart), recorded at the time of image acquisition. The pre-specified ROI 
was sampled by tracing a selection box around the desired artery wall segment – vertically, 
this extended from the lumen into the adventitia (Figure 2.5). At its maximum length, the 
selection box included only 200 single point-to-point measures; the full length was often 
selected, unless image quality was affected by artefacts and other factors, leading to poor wall 
definition. The pre-specified minimum number of single point-to-point measures accepted for 
reliable IMT assessment was 40; frames with < 40 single point-to-point measures were 
disregarded. Figure 2.6 shows examples of suitable and unsuitable selection boxes, for 
defining the ROI for IMT assessment. The final step involved selecting two areas within the 
media layer to define threshold levels of grey-scale, used by the semi-automated analysis 
package for assigning boundaries of the intima-media complex, for IMT analysis (Figure 2.7). 
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Figure 2.5 – Selection of an appropriate region of interest (ROI) for carotid IMT measurements, 
0-1 cm from the carotid bulb (B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 – Selection of suitable (a) and unsuitable (b, c, d) ROI selections for carotid IMT 
measurements. 
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Figure 2.7 – Cursor placement for assigning threshold levels of ‘grey’ for semi-automated 
carotid IMT measurement. Selection of appropriate brightness and contrast determines the 
threshold levels for edge detection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 – Assignment of accepted (green-red) and rejected (yellow-blue) points, 
determined by the semi-automated analysis software for carotid IMT measurement. Only 
point-to-point distances calculated from accepted (green-red) points are included in the data 
output for mean and maximum IMT. 
  
 
 
The lumen interface is shown here in green and yellow and the junction between the intima-media complex (I-M 
boundary) and the adventitia is shown in red and blue.  
 
 
  
1st cursor 
point 
selection 
2nd cursor 
point 
selection 
Lumen interface 
Lumen interface 
I-M boundary 
 
 
54 
 
 
Accepted points (shown in green and red) and rejected points (shown in yellow and blue), 
assigned by the semi-automated analysis package, were displayed on the monitor (Figure 2.8); 
any incorrect points could be manually selected (for inclusion) or de-selected (for exclusion) 
by the operator, prior to calculation of the final IMT value. Mean IMT was calculated as the 
average of the accepted single point-to-point IMT measurements, and maximum IMT was 
calculated as the maximum of the accepted single point-to-point measurement. A minimum 
of 2 (but typically 4-5) frames were used to obtain IMT values for each side of the neck. Overall 
IMT was calculated from left and right carotid IMT measurements as follows: overall mean 
IMT = (mean left carotid IMT + mean right carotid IMT)/2; and overall maximum IMT = 
(maximum left carotid IMT + maximum right carotid IMT)/2.  
 
 
 
Table 2.1 – Data output from a single carotid IMT measurement, using the semi-automated 
IMT analysis package. 
 
 
ID =       <#text field>  
Calibration:    __ pixels/mm 
Average diameter:   __ mm 
 Number of points accepted:  __ (no units) 
 Number of points rejected:  __ (no units) 
 Standard deviation:   __ mm 
 Maximum diameter:   __ mm 
 Minimum diameter:   __ mm 
 
Average diameter = mean IMT; maximum diameter = maximum IMT; Minimum diameter = minimum IMT. # text 
field is operator defined and can represent any string of characters – e.g. patient number or name etc. The data 
output shown here could be copied directly into an Excel spreadsheet, which minimises transcribing errors. 
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2.2.4 Problematic vessels for IMT assessment 
Patients were excluded from carotid IMT assessment if they had had carotid artery surgery, 
percutaneous interventions (such as stent placement), or significant anatomical or functional 
constraints that impaired adequate assessment of the carotid artery tree (e.g. extremely deep 
vessels, a high carotid bifurcation obscured by the mandible, tortuous vessels, neck pain or 
chronic deformity from injury or extensive cervical spine surgery). Morbid obesity increased 
the level of difficulty of imaging the carotid artery wall for IMT assessment; however, suitable 
images were obtained in the majority of subjects, with appropriate positioning.  
 
Continuous swallowing interfered with carotid artery imaging, as did exaggerated respiratory 
effort. In studies of 8 year old children (described in Chapter 4), awareness of the effect of 
repetitive swallowing on movement of the carotid wall, accompanied by anxiety, increased 
motion artefact. An effective strategy we adopted to minimise this was to: scan the right 
carotid artery first, so that children faced away from the ultrasound screen while becoming 
accustomed to the technique; the use of distraction techniques – e.g. the use of toys (such as 
finger puppets), talking about school, games and sport; and reassurance from parents or 
guardians, who were present during the examination. Exaggerated respiratory effort was 
often problematic in overweight or obese subjects, and this was overcome by asking subjects 
to hold their breath on inspiration or expiration for brief periods, or by repositioning subjects 
with the use of additional pillows to support the neck.  
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2.3 Brachial artery flow-mediated dilatation (FMD) 
1.3.3 Ultrasound settings 
Similar ultrasounds settings were used for IMT (described in section 2.2.1) and FMD studies, 
including the use of high-frequency (≥ 7.0 MHz), B-mode ultrasound, a depth of 4 cm, high 
frame rate (> 15 Hz), persistence ‘off’ or at the lowest setting, and the use of compound 
imaging (if available). In FMD studies, two focal points were routinely used and positioned at 
or above the near and far wall of the vessel. Operator-defined adjustments of time-gain 
compensation were again used to minimise artefacts, and improve image quality for more 
accurate assessment of vessel diameters.   
  
2.3.2 FMD image acquisition 
High-resolution, B-mode ultrasound images were obtained of the brachial (or radial) artery: 
the radial artery was used if the resting brachial artery diameter was > 5.0 mm. Subjects were 
scanned laying supine with continuous ECG tracing. The right arm was used for FMD studies, 
unless subjects had structurally (or haemodynamically) altered arterial blood flow (described 
in section 2.3.4).  The arm was extended ~ 90° from the body and supported by a side-arm 
table and a single pillow. A rapid inflation cuff was placed around the forearm, below the 
elbow (Figure 2.9) for studies of the brachial artery. The cuff was attached to an automatic 
insufflation device with adjustable pressure settings. A paediatric cuff was placed around the 
forearm proximal to the wrist, for radial artery studies. The transducer was positioned at the 
anterior aspect of the upper arm when imaging the brachial artery (Figure 2.9), and at the 
anterior aspect of the forearm when imaging the radial artery. As the vast majority (> 95%) of 
studies described in this thesis were conducted using the brachial artery, the remainder of 
this chapter describes methods for brachial artery imaging; in general, however, the principles 
for imaging the brachial and radial artery for the assessment of FMD were similar. 
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Figure 2.9 – Position of the right arm, rapid inflation cuff and transducer for FMD studies of 
the brachial artery.  
 
 
 
 
 
 
 
 
 
 
 
Fasting subjects were asked to rest for 5 minutes before commencement of the study. The 
brachial artery was located several centimetres above the elbow. Reproducible, anatomical 
landmark features were identified on the screen to help maintain the same position along the 
length of the artery, for repeated measurements at the same artery segment: landmark 
features commonly used included accompanying veins, small arterial branches, and distinct 
patterns vascular sheath or connective tissue (Figure 2.10). B-mode images were optimized 
by selecting the best focal zones, image size (using high-definition zoom; described in section 
2.2.2), and appropriate use time-gain compensation.  
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Figure 2.10 – High-resolution, B-mode ultrasound image of the brachial artery showing 
anatomical landmark features to help with repeated scanning (and measuring) the same 
artery segment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Four sets of pictures were collected. A resting scan was recorded for 1 minute to obtain a 
baseline vessel diameter. Using the rapid inflation cuff placed distal to the scanning site, 
regional blood flow was interrupted by inflating to 250 mmHg for 4.5 minutes. A second 
ultrasound scan was recorded continuously from 30 seconds prior to cuff release until 90 
seconds afterwards. The vessel diameter measured at 45-60 seconds after cuff deflation was 
used to determine the FMD, expressed as a percentage of the average baseline diameter. A 
third ultrasound scan was recorded after 10 minutes of rest to obtain another baseline vessel 
diameter. Sublingual GTN spray (400 µg; metered dose) was then administered, and a final 
ultrasound scan was performed 3-4 minutes later to determine the dilator response to GTN, 
again expressed as a percentage of the average baseline vessel diameter (Figure 2.11).  
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Small arterial branch 
Brachial artery lumen 
Vascular sheath 
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Figure 2.11 – Brachial artery diameter measurements for the assessment of flow-mediated 
dilatation (FMD) and dilator response to glyceryl trinitrate (GTN), in a typically healthy, young 
subject. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The baseline diameter used in the calculation of FMD and GTN (expressed as a % change from resting diameter) 
was based on an average resting vessel diameter obtained from scan 1: (baseline) and scan 3: (repeat baseline).  
X 
4.5 mm 
X 
Scan 1: Baseline scan 
X 
4.5 mm 
X 
Scan 3: Repeat baseline scan; 
after 10 minutes of rest 
Scan 2: FMD scan = (5.0/4.5) x 100   
= 11% increase 
X    
X 
5.0 mm 
Scan 4: GTN scan = (5.3/4.5) x 100 
= 18% increase 
X 
X 
5.3 mm 
 
 
60 
 
2.3.3 FMD analysis 
All ultrasound studies were recorded to super-VHS videotape for later offline analysis. The 
ECG was recorded continuously to permit vessel diameter measurements on R-wave frames 
(i.e. end-diastole). Images were reviewed prior to analysis to identify the correct time points 
for measurements, for each of the four scans. A hand-drawn sketch of the vessel was made 
to identify reproducible landmark features for the blinded observer to use as a guide for 
selection of the same artery segment for serial measurements.   
 
Images were replayed from videotape and small cineloops (of 5-10 seconds) were re-digitised 
using a video capture card within the ultrasound machine. The image was calibrated, using 
two distance markers recorded along with the image. Vessel diameters were measured with 
callipers for distance measurements, from a minimum of 4 end-diastolic frames for each of 
the four scans (Figure 2.11). All vessel diameter measurements were performed by an 
experienced observer, blinded to the identity of the subjects, study sites at which the scans 
were performed, and the sequence of the images within each patient’s scan.  
 
2.3.4 Problematic vessels for FMD assessment 
FMD studies were routinely performed in the right arm. Subjects who had had an arterio-
venous (or other) fistula, right-sided mastectomy, or trauma, were scanned using the left arm. 
Stenosing atherosclerotic plaque in the brachial (or radial) artery is extremely uncommon, but 
can affect vessel diameter measurements. Thus, if encountered, FMD studies should be 
performed elsewhere. In our studies, we did not observe any atherosclerotic plaque in the 
brachial or radial arteries of any of the subjects scanned.   
 
 
 
 
61 
 
Similar to carotid IMT studies, morbid obesity increased the level of difficulty of conducting 
FMD studies; however, suitable images were again obtained in the majority of subjects. 
Increased vessel depth and excess adipose tissue (with higher acoustic impedance) were the 
main contributing factors. A careful survey of the full length of the brachial artery often 
revealed segments of sufficient quality to perform FMD studies in most cases. Other strategies 
found to be effective included adjusting the angle of insonation to position one of the brachial 
veins above the artery, creating an acoustic window. Variable pressure applied through the 
transducer could also be used to displace artefacts away from the arterial wall, allowing 
accurate measurements. If such techniques could not improve image quality sufficient for 
reliable measurements, then the radial artery was imaged instead.  
 
While not a factor affecting image quality, the current use of vasoactive medications was 
considered an exclusion factor for subjects when conducting FMD studies. Subjects that had 
refrained from using such medications on the day of investigation were included in our 
studies. A report from the International Task Force on Brachial Artery Reactivity (61) 
recommends excluding subjects taking vasoactive medications for at least 4 half-lives. 
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CHAPTER 3:  
 
Comparison of Intima-Media Thickness Measurements Between a 
Mainframe and a Portable Ultrasound Machine: a Validation Study 
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3.1  Introduction 
Carotid IMT assessment has been used extensively as a non-invasive measure of subclinical 
vascular disease, and correlates with the extent and severity of coronary artery disease and is 
predictive of future CVD events (62). Methods for the accurate and reproducible assessment 
of carotid IMT have been described in a number of published reviews (21,63-67). Carotid IMT 
assessment has the advantage of being safe and reproducible, and thus is suitable for serial 
measurement in clinical trials – e.g. in prospective cohort and interventional studies. As 
described in Chapter 1, there is now a large body of comparative literature reporting on IMT.  
 
Until recently, studies incorporating carotid IMT into their design have largely been limited to 
a clinic-type setting, where mainframe ultrasound machines are available. With recent 
advances in medical imaging and technology, a series of smaller, more portable, and less 
costly ultrasound machines have been developed with the potential to overcome several 
limitations associated with the use of mainframe ultrasound machines. As an example, the 
Teratek Terason 3000, is a portable, laptop-based, ultrasound machine with features 
comparable to many clinic-based, mainframe ultrasound machines.  
 
The Teratek Terason 3000 utilises high-resolution (≥ 7 MHz) imaging and has multiple 
adjustable settings and appropriate ranges for depth, frame rate, and time-gain 
compensation: requisites for high-quality ultrasound imaging, suitable for carotid IMT 
assessment (described in Chapter 2). The Teratek Terason 3000 has several additional features 
that make it an attractive alternative to clinic-based mainframe ultrasound machines, 
including a reduced machine size and weight, a rechargeable (lithium ion) battery (with > 50 
hours of battery life), and a substantially lower cost. Prior to their use in clinical studies; 
however, portable ultrasound machines must be validated for agreement against the “gold 
standard” machine type – i.e. clinic-based mainframe ultrasound machines.  
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We conducted a study of measurement agreement for carotid IMT measurements, comparing 
the Philips ATL 5000 (as an example of a clinic-based, mainframe ultrasound machine, used in 
many published IMT studies) with the portable Teratek Terason 3000. There were three parts 
to this validation study. First, inter-observer variability for each machine type was assessed, 
separately, by comparing IMT measurements obtained from two independent observers 
measuring the same images. Second, intra-observer variability for each machine type was 
assessed by comparing repeated IMT measurements performed on the same images, by a 
single observer. Third, inter-machine variability was assessed by comparing IMT 
measurements from duplicate carotid artery scans, obtained from the same patients, in a 
single visit, using both ultrasound machine types.  
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3.2  Methods 
3.2.1 Study Design 
The overall study design for IMT validation studies presented in this chapter is shown in Figure 
3.1. There were three parts to this validation study. First, in section 3.4.1 – ‘Inter-observer 
variability’, the agreement between two independent observers (“observer 1” and “observer 
2”), measuring carotid IMT for each machine type, is presented. The two independent 
observers were well rehearsed in methods for carotid IMT assessment (described in Chapter 
2). The observers did not have knowledge of the clinical condition or the identity of subjects, 
prior to conducting IMT measurements. An overview of the study design for assessing inter-
observer variability for carotid IMT measurements is provided in Figure 3.2.  
 
Second, in section 3.4.2 – ‘Intra-observer variability’ – the agreement between repeated 
carotid IMT measurements by a single observer (observer 1: “1st and “2nd reading”), for each 
machine type, is presented. Measurements were made on two separate occasions (> 1 week 
apart), by a single observer, without reference to the previous results, the clinical condition 
or identity of subjects. An overview of the study design for assessing intra-observer variability 
for carotid IMT measurements is provided in Figure 3.3. 
 
Third, in section 3.4.3 – ‘Inter-machine variability’ – the agreement between measurements 
from duplicate carotid artery scans, obtained from the same patients in a single visit, using 
both ultrasound machine types under investigation (i.e. the Philips ATL 5000: a clinic-based, 
mainframe ultrasound machine; and the Teratek Terason 3000: a portable, laptop-based 
ultrasound machine), is presented. Figure 3.4 provides an overview of the study design for 
inter-machine variability for IMT measurements.  
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Figure 3.1 - Overall study design for carotid IMT validation studies, described in chapter 3. 
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Figure 3.2 - Design for inter-observer variability studies. 
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Figure 3.3 - Design for intra-observer variability studies. 
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Figure 3.4 - Design for inter-machine variability studies. 
 
 
Replicate ultrasound scans were obtained on the same patients in a single visit. Ultrasound machine order was not 
randomised, and scans were routinely performed first with the Philips ATL 5000 and then the Teratek Terason 
3000.  
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3.2.2 Ultrasound Machines 
We conducted a study of measurement agreement for carotid IMT measurements using two 
different ultrasound machine types: the Philips ATL 5000 (Philips Medical Systems, The 
Netherlands), as an example of a clinic-based, mainframe ultrasound machine (shown in 
Figure 3.5); and the Teratek Terason 3000 (Teratek Corporation, USA), as an example of a 
portable, laptop-based ultrasound machine (shown in Figure 3.6). Many of the physical 
characteristics and settings for these two machine types were similar, with a few exceptions: 
including differences in machine size and weight, power requirements, the number of 
transducer elements (for transmitting and receiving signals), and the frame rate. A comparison 
of the physical characteristics for the two ultrasound machine types used in this IMT validation 
study is summarised in Table 3.1.  
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Figure 3.5 – Philips ATL 5000 (mainframe ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(source: http://www.meditool.nl/ultrasound.html) 
 
 
Figure 3.6 – Teratek Terason 3000 (portable ultrasound machine). 
(source:http://www.medgadget.com/2005/12/the_terason_t30.html) 
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Table 3.1 – Physical characteristics of ultrasound machines used in the IMT validation study. 
 
 
Parameter 
Clinic-based, mainframe 
ultrasound machine 
(Philips ATL 5000) 
Portable, laptop-based 
ultrasound machine 
 (Teratek Terason 3000) 
Transducer type 12-5 MHz, linear array 12-5 MHz,  linear array 
Transducer length, mm 38 40 
Transducer elements 512 128 
Transducer frequency, MHz 5-12 5-12 
Frame rate, per second 50 30 
Gain settings Operator defined Operator defined 
Grey scale Operator defined Operator defined 
Machine weight, kg 172.0 2.4 
Size – width, cm 72.0 33.0 
Size – height, cm 157.5  #Open: 31.5; Closed: 4.5 
Size – depth, cm 110.4 27.4 
Power supply A/C – 240V; 50 Hz; 1.45 amps Li+ ion battery; 53.28 hours 
Operating Temperature, °C High: 40; Low: 16 High: 32; Low: 10 
Operating Pressure, atm High: 1.0; Low: 0.7 High: 1.0; Low: 0.6 
Operating Relative Humidity, % High: 95; Low: 15 High: 80; Low: 5 
Storage Temperature, °C High: 65; Low: -35 High: 40; Low: -5 
Storage Relative Humidity, % High: 95; Low: 15 High: 90; Low: 5 
Depth for carotid examination, cm 3.9 4.0 
Range of depth, cm 2.4 – 7.9 2.0 – 8.0 
 #Height of the ultrasound machine open for operation and when closed for transport.  
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3.2.3 Subjects 
3.2.3.1 Inter- and intra-observer variability 
Carotid IMT data from two vascular substudies incorporating IMT assessment into their study 
design were included in this analysis of inter- and intra-observer variability. The Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) study was a multicentre, randomised, 
placebo-controlled trial investigating the effects of fenofibrate on fatal and non-fatal coronary 
events in 9,795 adults with T2DM, aged 50-75 years (a detailed description of this study design 
and the selection of subjects is provided in Chapter 6). A subset of 403 subjects had carotid 
artery ultrasound scans (for the assessment of IMT) obtained at baseline with clinic-based, 
mainframe ultrasound machine (i.e. the Philips ATL 5000). Of these, 397 had satisfactory 
images of the far wall of the CCA for inclusion in the IMT vascular substudy analyses. At 
random, 56 (14%) subjects were selected for inclusion in the IMT validation study; details of 
these subjects are shown in Table 3.2. 
 
Table 3.2 - Characteristics of subjects randomly selected from the FIELD IMT vascular 
substudy, for inclusion in the analysis of inter-and intra-observer variability, for IMT 
assessment. 
 
 
Characteristic 
Subjects 
N = 56 
Age, years 67 ± 7 
Male, % 62 
Age at diagnosis of T2DM, years 56 ± 12 
Current Smoking, % 9 
Prior AMI, % 4 
Weight, kg 86.9 ± 16.8 
Waist:Hip ratio 0.95 ± 0.06 
HbA1c, % 7.2 
Duration of T2DM, years 9 ± 5.4 
SBP, mmHg 135 ± 12 
DBP, mmHg 76 ± 10 
Continuous variables are expressed as mean ± SD 
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The Childhood Asthma Prevention Study (CAPS) was a single-centre, randomised, double-
blind, 2x2 factorial trial of the effectiveness of house-dust mite avoidance and omega-3-fatty 
acid supplementation on the incidence of asthma and allergic disease, in children from birth 
to 5 years of age (a detailed description of this study design and the selection of subjects is 
provided in Chapter 5). At 8 years follow-up, 410 (67%) of the original cohort consented to 
participate in a cardiovascular substudy (‘CardioCAPS’), which included carotid IMT 
assessment; in this substudy, carotid artery ultrasound scans were obtained using a portable, 
laptop-based ultrasound machine (i.e. the Teratek Terason 3000). Of the 410 children, 405 
were included in the final analysis: 2 subjects were excluded due to a diagnosis of type-1 
diabetes mellitus (T1DM), 2 subjects consented but did not complete cardiovascular testing, 
and 1 subject was outside of the pre-specified age range of 8.0 ± 0.5 years. At random, 50 
(12%) of these subjects were selected for inclusion in the IMT validation study; characteristics 
of these subjects are shown in Table 3.3. 
 
Table 3.3 - Characteristics of subjects randomly selected from CardioCAPS, for inclusion in the 
analysis of inter-and intra-observer variability, for IMT assessment. 
 
 
Characteristic 
Subjects 
N = 50 
Age, years 8.0 ± 0.1 
Male, % 58 
Weight, kg 29.4 ± 6.8 
Height, cm 128 ± 0.1 
BMI, kg/m2 17.8 ± 3.2 
Waist circumference, cm 59.9 ± 8.1 
Hip circumference, cm 71.3 ± 7.9 
Waist:Hip ratio 0.8 ± 0.03 
SBP, mmHg 101.4 ± 6.7 
DBP, mmHg 59.9 ± 4.8 
Continuous variables are expressed as mean ± SD 
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 3.2.3.2 Inter-machine variability 
Subjects included in the analysis of inter-machine variability for IMT assessment were healthy, 
volunteer subjects participating in a number of different vascular studies, conducted within a 
research clinic at the Royal Prince Alfred Hospital, Camperdown; this site was chosen for the 
selection and study of subjects as it had access to the two ultrasound machine types under 
investigation (i.e. the ‘Philips ATL 5000’ and the ‘Teratek Terason 3000’). 64 subjects 
participated in this inter-machine validation study. Characteristics of these subjects are shown 
in Table 3.4. 
 
Table 3.4 - Characteristics of subjects participating in inter-machine variability study, for IMT 
assessment. 
 
 
Characteristic 
Subjects 
N = 64 
Male, % 56 
Age, years 39.1 ± 14.9 
Weight, kg 83.6 ± 23.9 
Height, cm 174.7 ± 7.6 
BMI, kg/m2 27.4 ± 7.5 
Waist circumference, cm 90.5 ± 21.7 
Hip circumference, cm 106.1 ± 13.9 
Waist:hip ratio 0.8 ± 0.1 
SBP, mmHg 119.6 ± 11.0 
DBP, mmHg 73.4 ± 8.8 
Continuous variables are expressed as mean ± SD 
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3.2.4 Carotid intima-media thickness assessment 
Methods for the assessment of carotid IMT are described in Chapter 2. Images obtained with 
the Philips ATL 5000 ultrasound machine, for inter- and intra-variability studies, were saved 
by analogue recording (i.e. to super-VHS videotape) and later re-digitised, prior to IMT 
analysis. Images obtained with the Teratek Terason 3000 ultrasound machine were recorded 
digitally. For the inter-machine validation study, all images were saved digitally. The order of 
ultrasound machines used for obtaining duplicate scans was not randomised, and subjects 
were routinely scanned with the Philips ATL 5000 and then the Teratek Terason 3000. 
 
3.2.5 Statistics 
Subject characteristics were expressed as percentages for categorical variables and as mean 
(SD) or median (IQR) for normally distributed and non-normally distributed variables, 
respectively. The estimated mean of means for carotid IMT was calculated as an average of 
measurement 1 and measurement 2. The difference of means was calculated as measurement 
1 minus measurement 2. Percent coefficient of variation (%CV) was calculated as the SD of 
the difference of means divided by the estimated mean of means for IMT. Paired-samples t-
tests were used to compare duplicate measurements by different observers, the same 
observers at different time points, and different ultrasound machine types. A two-tailed P-
value < 0.05 was considered significant. All analyses were performed using SPSS (version 22.0).  
 
Mean and maximum IMT values for left, right and overall left/right carotids (i.e. an average of 
left and right carotid IMT values) are provided in tables in section 3.3 (Results). Scatter plots 
show the linear relationship between measurements, compared with the line of perfect 
agreement (i.e. y=x+0), and report the Pearson’s correlation coefficient (R) and R2. Bland-
Altman plots show the level of agreement between measurements, by displaying the 
estimated mean or mean (or maximum) IMT against the difference in mean (or maximum) 
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IMT, for duplicate measurements. According to Bland and Altman (68,69), if differences 
between repeated measurements are normally distributed, 95% of measurements will be 
within ± 1.96 x SD of the mean (which represents the ‘limits of agreement’; LOA). Potential 
variation in measurements introduced by other factors, such as age, sex and other clinical 
characteristics is eliminated, leaving only the measurement error. Agreement between 
repeated measurements was considered acceptable if the mean difference for carotid IMT 
was within ± 0.10 mm, and the LOA were within ± 0.15 mm of the mean difference. Pre-
specified criteria for the interpretation of %CV for repeated measurements were:  ≤ 5.0 (very 
good), > 5.0 to 10.0 (good), > 10.0 to 15.0 (fair), poor (> 15.0). Agreement was considered 
acceptable if the %CV was ≤ 10.0 %. 
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3.3 Results 
3.3.1 Inter-observer variability 
3.3.1.1 Philips ATL 5000 (mainframe ultrasound machine) 
Mean carotid IMT measurements from two independent observers, measuring images 
obtained with a Philips ATL 5000 mainframe ultrasound machine, are shown in Table 3.5. The 
overall mean IMT for observer 1 and observer 2 was 0.92 ± 0.14 mm and 0.95 ± 0.14 mm, 
respectively. The difference in mean IMT was -0.02 mm (95%CI: -0.04, 0.00; p=0.03). The % 
measurement error, expressed as a percentage of the estimated mean IMT, was 2.1% (Table 
3.15). The %CV for the difference in mean IMT was 5.7%. Figure 3.7 shows the linear 
correlation between mean carotid IMT measurements from independent observers (R=0.876; 
p<0.001). Figure 3.8 shows the Bland-Altman plot of the difference in mean IMT between 
observer 1 and observer 2.  
 
Maximum carotid IMT measurements from two independent observers, measuring images 
obtained from a Philips ATL 5000 ultrasound machine, are shown in Table 3.6. The overall 
maximum IMT for observer 1 and observer 2 was 1.11 ± 0.16 mm and 1.20 ± 0.18 mm, 
respectively. The difference in maximum IMT was -0.09 mm (95%CI: -0.12, -0.06; p<0.001). 
The % error, expressed as a percentage of the estimated maximum IMT was 7.8% (Table 3.15). 
The %CV for the difference in mean IMT values was 10.5%. Figure 3.9 shows the linear 
correlation between maximum carotid IMT measurements from independent observers 
(R=0.781; p<0.001). Figure 3.10 shows the Bland-Altman plot of the difference in maximum 
IMT between observer 1 and observer 2. 
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3.3.1.2 Teratek Terason 3000 (portable ultrasound machine) 
Mean carotid IMT measurements from two independent observers, measuring images 
obtained with a Teratek Terason 3000 portable ultrasound machine, are shown in Table 3.7. 
The overall mean IMT for observer 1 and observer 2 was 0.59 ± 0.06 mm and 0.59 ± 0.06 mm, 
respectively. The difference in mean IMT was 0.00 mm (95%CI: -0.01, 0.00; p=0.46). The % 
measurement error was 0.0% (Table 3.15). The %CV for the difference in mean IMT was 2.4%. 
Figure 3.11 shows the correlation between mean carotid IMT measurements from 
independent observers (R=0.963; p<0.001). Figure 3.12 shows the Bland-Altman plot of the 
difference in mean IMT between observer 1 and observer 2. 
 
Maximum carotid IMT measurements from two independent observers, measuring images 
obtained with a Teratek Terason 3000 ultrasound machine, are shown in Table 3.8. The overall 
maximum IMT for observer 1 and observer 2 was 0.72 ± 0.07 mm and 0.69 ± 0.07 mm, 
respectively. The difference in maximum IMT was 0.02 (95%CI: 0.01, 0.04; p<0.001). The % 
measurement error was 2.8% (Table 3.15). The %CV for the difference in mean IMT values 
was 5.8%. Figure 3.13 shows the linear correlation between maximum carotid IMT 
measurements from independent observers (R=0.836; p<0.001). Figure 3.14 shows the Bland-
Altman plots of the difference in maximum IMT between observer 1 and observer 2. 
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Table 3.5 – Mean carotid IMT from two independent observers measuring images generated 
using a Philips ATL 5000 (mainframe ultrasound machine). 
 
 Observer 1 Observer 2   
Mean IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 0.92 0.15 0.95 0.16 0.94 -0.03 (-0.06, -0.01) 0.012 8.3 
Right carotid 0.93 0.16 0.94 0.18 0.94 -0.01 (-0.04, 0.01) 0.337 6.5 
#Overall Left/Right 0.92 0.14 0.95 0.14 0.94 -0.02 (-0.04, 0.00) 0.029 5.7 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (observer 1 minus observer 2). Values were compared by paired-samples t-test. N = 56 
subjects. 
 
 
Table 3.6 – Maximum carotid IMT from two independent observers measuring images 
generated using a Philips ATL 5000 (mainframe ultrasound machine). 
 
 Observer 1 Observer 2   
Maximum IMT Mean SD Mean SD 
Mean of  
means *Diff  95% CI P-value % CV 
Left carotid 1.12 0.19 1.23 0.23 1.17 -0.11 (-0.16, -0.07) <0.001 11.9 
Right carotid 1.11 0.19 1.18 0.22 1.15 -0.07 (-0.11, -0.03) <0.001 9.3 
#Overall - Left/Right 1.11 0.16 1.20 0.18 1.16 -0.09 (-0.12, -0.06) <0.001 10.5 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (observer 1 minus observer 2). Values were compared by paired-samples t-test. N = 56 
subjects. 
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Figure 3.7 – Correlation between mean carotid IMT measurements for two independent 
observers, using images obtained from a Philips ATL 5000 (mainframe ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 – Bland Altman plot of mean carotid IMT measurements for two independent 
observers, using images obtained from a Philips ATL 5000 (mainframe ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in mean IMT (observer 1 minus observer 2) = -0.02 mm. Limits of agreement 
(mean ± 1.96 x SD) = -0.16, 0.12 mm. N = 56 subjects.  
 
#Mean 
Mean + 1.96 SD 
Mean - 1.96 SD 
(   ) Pearsons correlation 
       R=0.876; p<0.001 
       R2=0.756 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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Figure 3.9 – Correlation between maximum carotid IMT measurements for two independent 
observers, using images obtained from a Philips ATL 5000 (mainframe ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 – Bland Altman plot of maximum carotid IMT measurements for two independent 
observers, using images obtained from a Philips ATL 5000 (mainframe ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in maximum IMT (observer 1 minus observer 2) = -0.09 mm. Limits 
of agreement (mean ± 1.96 x SD) = -0.31, 0.13 mm. N = 56 subjects. 
 
 
 
#Mean 
Mean + 1.96 SD 
Mean - 1.96 SD 
(   ) Pearsons correlation 
       R=0.781; p<0.001 
       R2=0.610 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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Table 3.7 – Mean carotid IMT from two independent observers measuring images generated 
using a Teratek Terason 3000 (portable ultrasound machine). 
 
 Observer 1 Observer 2   
Mean IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 0.60 0.08 0.60 0.08 0.60 0.00 (-0.01, 0.00) 0.260 2.0 
Right carotid 0.58 0.07 0.58 0.07 0.58 0.00 (-0.01, 0.01) 0.955 3.5 
#Overall - Left/Right 0.59 0.06 0.59 0.06 0.59 0.00 (-0.01, 0.00) 0.460 2.4 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (observer 1 minus observer 2). Values were compared by paired-samples t-test. N = 50 
subjects.  
 
 
Table 3.8 – Maximum carotid IMT from two independent observers measuring images 
generated using a Teratek Terason 3000 (portable ultrasound machine). 
 
 Observer 1 Observer 2   
Maximum IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 0.73 0.09 0.70 0.09 0.72 0.02 (0.01, 0.04) 0.005 6.0 
Right carotid 0.71 0.08 0.68 0.08 0.70 0.02 (0.01, 0.04) <0.001 4.6 
#Overall - Left/Right 0.72 0.07 0.69 0.07 0.71 0.02 (0.01, 0.04) <0.001 5.8 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (observer 1 minus observer 2). Values were compared by paired-samples t-test. N = 50 
subjects. 
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Figure 3.11 – Correlation between mean carotid IMT measurements for two independent 
observers, using images obtained from a Teratek Terason 3000 (portable ultrasound 
machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 – Bland Altman plot of mean carotid IMT measurements for two independent 
observers, using images obtained from a Teratek Terason 3000 (portable ultrasound 
machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in mean IMT (observer 1 minus observer 2) = 0.00 mm. Limits of agreement 
(mean ± 1.96 x SD) = -0.03, 0.03 mm. N = 50 subjects. 
Mean + 1.96 SD 
#Mean 
Mean - 1.96 SD 
(   ) Pearsons correlation 
       R=0.963; p<0.001 
       R2=0.927 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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Figure 3.13 – Correlation between maximum carotid IMT measurements for two independent 
observers, using images obtained from a Teratek Terason 3000 (portable ultrasound 
machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 - Bland Altman plot of maximum carotid IMT measurements for two independent 
observers, using images obtained from a Teratek Terason 3000 (portable ultrasound 
machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in maximum IMT (observer 1 minus observer 2) = -0.02 mm. Limits of 
agreement (mean ± 1.96 x SD) = -0.10, 0.05 mm. N = 50 subjects. 
Mean + 1.96 SD 
Mean - 1.96 SD 
#Mean 
(   ) Pearsons correlation 
       R=0.836; p<0.001 
       R2=0.699 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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3.3.2 Intra-observer variability 
3.3.2.1 Philips ATL 5000 (mainframe ultrasound machine) 
Mean carotid IMT measurements from a single observer on two separate occasions, using 
images obtained with a Philips ATL 5000 mainframe ultrasound machine, are shown in Table 
3.9. The overall mean IMT for the 1st and 2nd readings was 0.95 ± 0.14 mm and 0.97 ± 0.14 
mm, respectively. The difference in mean IMT was -0.02 mm (95%CI: -0.03, -0.01; p<0.001). 
The % measurement error was 2.1% (Table 3.15). The %CV for the difference in mean IMT 
values was 2.5%. Figure 3.15 shows the linear correlation for repeated mean carotid IMT 
measurements made by a single observer (R=0.971; p<0.001). Figure 3.16 shows the Bland-
Altman plot of the difference in mean IMT between the 1st and 2nd reading. 
 
Maximum carotid IMT measurements from a single observer on two separate occasions, using 
images obtained with a Philips ATL 5000 mainframe ultrasound machine, are shown in Table 
3.10. The overall maximum IMT for the 1st and 2nd readings was 1.20 ± 0.18 mm and 1.21 ± 
0.18 mm, respectively. The difference in maximum IMT was 0.00 mm (95%CI: -0.02, 0.02; 
p=0.75). The % measurement error was 0.0% (Table 3.15). The %CV for the difference in 
maximum IMT was 6.5%. Figure 3.17 shows the linear correlation for repeated maximum 
carotid IMT measurements made by a single observer (R=0.903; p<0.001). Figure 3.18 shows 
the Bland-Altman plot of the difference in maximum IMT between the 1st and 2nd reading. 
 
3.3.2.2 Teratek Terason 3000 (portable ultrasound machine) 
Mean carotid IMT measurements from a single observer on two separate occasions, using 
images obtained with a Teratek Terason 3000 portable ultrasound machine, are shown in 
Table 3.11. The overall mean IMT for the 1st and 2nd readings was 0.59 ± 0.06 mm and 0.59 ± 
0.06 mm, respectively. The difference in mean IMT was 0.00 (95%CI: 0.00, 0.00; p=0.50). The 
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% measurement error was 0.0% (Table 3.15). The %CV for the difference in mean IMT was 
0.5%. Figure 3.19 shows the linear correlation for repeated mean carotid IMT measurements 
made by a single observer (R=0.995; p<0.001). Figure 3.20 shows the Bland-Altman plot for 
the difference in mean IMT between the 1st and 2nd readings. 
 
Maximum carotid IMT measurements from a single observer on two separate occasions, using 
images obtained with a Terason 3000 portable ultrasound machine, are shown in Table 3.12. 
The overall maximum IMT for the 1st and 2nd readings was 0.69 ± 0.07 mm and 0.70 ± 0.07 
mm, respectively. The difference in maximum IMT was 0.00 (95%CI: -0.01, 0.00; p=0.20). The 
% measurement error was 0.0% (Table 3.15). The %CV for the difference in maximum IMT was 
4.2%. Figure 3.21 shows the linear correlation for repeated maximum carotid IMT 
measurements made by a single observer (R=0.959; p<0.001). Figure 3.22 shows the Bland-
Altman plot of the difference in maximum IMT between the 1st and 2nd reading.  
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Table 3.9 – Mean carotid IMT from a single observer on two separate occasions (> 1 week 
apart), measuring images generated using a Philips ATL 5000 (mainframe ultrasound 
machine). 
 
 
Observer 1 
1st reading 
Observer 1 
2nd reading 
 
 
Mean IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 0.95 0.16 0.97 0.16 0.96 -0.01 (-0.02, 0.00) 0.012 2.5 
Right carotid 0.94 0.18 0.97 0.17 0.95 -0.03 (-0.04, -0.01) 0.001 4.7 
#Overall - Left/Right 0.95 0.14 0.97 0.14 0.96 -0.02 (-0.03, -0.01) <0.001 2.5 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (1st reading minus 2nd reading). Values were compared by paired-samples t-test. N = 56 
subjects. 
 
 
Table 3.10 – Maximum carotid IMT from a single observer on two separate occasions (> 1 
week apart), measuring images generated using a Philips ATL 5000 (mainframe ultrasound 
machine). 
 
 
Observer 1 
1st reading 
Observer 1 
2nd reading 
 
 
Maximum IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 1.23 0.23 1.22 0.20 1.22 0.01 (-0.02, 0.04) 0.475 6.7 
Right carotid 1.18 0.22 1.20 0.22 1.19 -0.02 (-0.05, 0.01) 0.125 6.2 
#Overall - Left/Right 1.20 0.18 1.21 0.18 1.21 0.00 (-0.02, 0.02) 0.746 6.5 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (1st reading minus 2nd reading).  Values were compared by paired-samples t-test.  
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Figure 3.15 – Correlation between mean carotid IMT measurements from a single observer 
on two separate occasions, using images from a Philips ATL 5000 (mainframe ultrasound 
machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 - Bland-Altman plot of mean carotid IMT measurements from a single observer on 
two separate occasions, using images from a Philips ATL 5000 (mainframe ultrasound 
machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in mean IMT (1st reading minus 2nd reading) = -0.02 mm. Limits of agreement 
(mean ± 1.96 x SD) = -0.09, 0.05 mm. N = 56 subjects. 
  
#Mean 
Mean + 1.96 SD 
Mean - 1.96 SD 
(   ) Pearsons correlation 
       R=0.971; p<0.001 
       R2=0.944 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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Figure 3.17 – Correlation between maximum carotid IMT measurements from a single 
observer on two separate occasions, measuring images from a Philips ATL 5000 (mainframe 
ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 - Bland-Altman plot of maximum carotid IMT measurements from a single 
observer on two separate occasions, using images from a Philips ATL 5000 (mainframe 
ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in maximum IMT (1st reading minus 2nd reading) = 0.00 mm. Limits 
of agreement (mean ± 1.96 x SD) = -0.16, 0.15 mm. N = 56 subjects. 
 
 
Mean + 1.96 SD 
Mean - 1.96 SD 
#Mean 
(   ) Pearsons correlation 
       R=0.903; p<0.001 
       R2=0.815 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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Table 3.11 – Mean carotid IMT from a single observer on two separate occasions (> 1 week 
apart), measuring images from a Teratek Terason 3000 (portable ultrasound machine). 
 
 
Observer 1 
1st reading 
Observer 1 
2nd reading 
 
 
Mean IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 0.60 0.08 0.60 0.08 0.60 0.00 (0.00, 0.00) 0.855 0.7 
Right carotid 0.58 0.07 0.58 0.07 0.58 0.00 (0.00, 0.00) 0.595 0.8 
#Overall - Left/Right 0.59 0.06 0.59 0.06 0.59 0.00 (0.00, 0.00) 0.497 0.5 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (1st reading minus 2nd reading). Values were compared by paired-samples t-test. N = 50 
subjects. 
 
 
Table 3.12 – Maximum carotid IMT from a single observer on two separate occasions (> 1 
week apart), measuring images from a Teratek Terason 3000 (portable ultrasound machine). 
 
 
Observer 1 
1st reading 
Observer 1 
2nd reading 
 
 
Maximum IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 0.70 0.09 0.70 0.09 0.70 0.00 (-0.01, 0.01) 0.862 2.2 
Right carotid 0.68 0.08 0.69 0.08 0.69 -0.01 (-0.02, 0.00) 0.235 4.8 
#Overall - Left/Right 0.69 0.07 0.70 0.07 0.70 0.00 (-0.01, 0.00) 0.200 4.2 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (1st reading minus 2nd reading). Values were compared by paired-samples t-test. N = 50 
subjects. 
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Figure 3.19 – Correlation between mean carotid IMT measurements from a single observer 
on two separate occasions, using images from a Teratek Terason 3000 (portable ultrasound 
machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 - Bland-Altman plot of mean carotid IMT measurements from a single observer on 
two separate occasions, using images from a Teratek Terason 3000 (portable ultrasound 
machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in mean IMT (1st reading minus 2nd reading) = 0.00 mm. Limits of agreement 
(mean ± 1.96 x SD) = -0.01, 0.01 mm. N = 50 subjects. 
  
#Mean ± 1.96 SD 
(   ) Pearsons correlation 
       R=0.995; p<0.001 
       R2=0.991 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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Figure 3.21 – Correlation between maximum carotid IMT measurements from a single 
observer on two separate occasions, using images from a Teratek Terason 3000 (portable 
ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 - Bland-Altman plot of maximum carotid IMT measurements from a single 
observer on two separate occasions, using images from a Teratek Terason 3000 (portable 
ultrasound machine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in maximum IMT (1st reading minus second reading) = 0.00 mm. Limits of 
agreement (mean ± 1.96 x SD) = -0.04, 0.04 mm. N = 50 subjects. 
  
Mean + 1.96 SD 
(   ) Pearsons correlation 
       R=0.959; p<0.001 
       R2=0.920 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
 
#Mean 
Mean - 1.96 SD 
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3.3.3 Inter-machine variability 
Mean carotid IMT measurements from replicate scans obtained using the two different 
ultrasound machines types are shown in Table 3.13. The overall mean IMT for images from 
the Philips ATL 5000 and the Teratek Terason 3000 was 0.67 ± 0.15 mm and 0.70 ± 0.13 mm, 
respectively. The difference in mean IMT was -0.03 (95%CI: -0.05, -0.02; p<0.001). The % 
measurement error, expressed as a percentage of the estimated mean IMT was 4.4% (Table 
3.15). The %CV for the difference in mean IMT was 5.7%. Figure 3.23 shows the linear 
correlation between mean carotid IMT measurements from replicate scans obtained from the 
two ultrasound machine types (R=0.901; p<0.001). Figure 3.24 shows the Bland-Altman plot 
of the difference in mean IMT between images from the Philips ATL 5000 and the Teratek 
Terason 3000.  
 
Maximum carotid IMT measurements from replicate scans obtained using the two different 
ultrasound machine types are shown in Table 3.14. The overall mean IMT for images from the 
Philips ATL 5000 and the Teratek Terason 3000 was 0.86 ± 0.17 mm and 0.87 ± 0.16 mm, 
respectively. The difference in maximum IMT was -0.01 (95%CI: -0.03, 0.01; p=0.31). The % 
measurement error was 1.2% (Table 3.15). The %CV for the difference in maximum IMT values 
was 6.6%. Figure 3.25 shows the linear correlation between maximum IMT measurements 
from replicate scans obtained from the two ultrasound machine types (R=0.904; p<0.001). 
Figure 3.26 shows the Bland-Altman plot of the difference in maximum IMT between images 
from the Philips ATL 5000 and the Teratek Terason 3000. 
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Table 3.13 – Mean carotid IMT from replicate scans performed on the same subjects (in a 
single visit), using two different ultrasound machine types: i) the Philips ATL 5000 (mainframe 
ultrasound machine), and ii) the Teratek Terason 3000 (portable ultrasound machine). 
 
 ATL 5000 Terason 3000   
Mean IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 0.68 0.18 0.71 0.16 0.69 -0.03 (-0.05, -0.01) 0.004 7.3 
Right carotid 0.66 0.15 0.70 0.14 0.68 -0.04 (-0.05, -0.02) <0.001 7.1 
#Overall - Left/Right 0.67 0.15 0.70 0.13 0.68 -0.03 (-0.05, -0.02) <0.001 5.7 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (ATL 5000 minus Terason 3000). Values were compared by paired-samples t-test. N = 
64 subjects. 
 
 
 
 
Table 3.14 – Maximum carotid IMT from replicate scans performed on the same subjects (in 
a single visit), using two different ultrasound machine types: i) the Philips ATL 5000 
(mainframe ultrasound machine), and ii) the Teratek Terason 3000 (portable ultrasound 
machine). 
 
 ATL 5000 Terason 3000   
Maximum IMT Mean SD Mean SD 
Mean of  
means *Diff 95% CI P-value % CV 
Left carotid 0.87 0.21 0.87 0.19 0.87 0.00 (-0.03, 0.03) 0.802 8.8 
Right carotid 0.85 0.17 0.87 0.16 0.86 -0.02 (-0.05, 0.00) 0.092 6.8 
#Overall - Left/Right 0.86 0.17 0.87 0.16 0.86 -0.01 (-0.03, 0.01) 0.306 6.6 
 
#Overall – Left/Right = mean of left and right carotid IMT.  
*Diff = difference of means (ATL 5000 minus Terason 3000). Values were compared by paired-samples t-test. N = 
64 subjects. 
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Figure 3.23 – Correlation between mean carotid IMT measurements from replicate scans 
performed on the same subjects, using two different ultrasound machine types: i) the Philips 
ATL 5000, and ii) the Teratek Terason 3000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24 - Bland-Altman plot of mean carotid IMT measurements from replicate scans 
performed on the same subjects, using two different ultrasound machine types: i) the Philips 
ATL 5000, and ii) the Teratek Terason 3000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in mean IMT (ATL 5000 minus Terason 3000) = -0.03 mm. Limits of agreement 
(mean ± 1.96 x SD) = -0.16, 0.09 mm. N = 64 subjects.  
#Mean 
Mean + 1.96 SD 
Mean - 1.96 SD 
(   ) Pearsons correlation 
       R=0.901; p<0.001 
       R2=0.813 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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Figure 3.25 – Correlation between maximum carotid IMT measurements from replicate scans 
performed on the same subjects, using two different ultrasound machine types: i) the Philips 
ATL 5000, and ii) the Teratek Terason 3000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 - Bland-Altman plot of maximum carotid IMT measurements replicate scans 
performed on the same subjects, using two different ultrasound machine types: i) the Philips 
ATL 5000, and ii) the Teratek Terason 3000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#Mean = mean difference in maximum IMT (ATL 5000 minus Terason 3000) = -0.01 mm. Limits of 
agreement (mean ± 1.96 x SD) = -0.16, 0.16 mm. N = 64 subjects. 
  
#Mean 
Mean - 95% CI 
Mean + 95% CI 
(   ) Pearsons correlation 
       R=0.904; p<0.001 
       R2=0.817 
(   ) Line of ‘perfect agreement’ 
       i.e. y=1x + 0 
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Table 3.15 – Summary of mean and maximum carotid IMT measurements from studies of 
measurement agreement, presented in Chapter 3. (i) inter-observer, (ii) intra-observer, and 
(iii) inter-machine variability. 
 
Mean IMT R R2 
Difference 
 (mm) 
Difference 
(95% CI) 
% Difference 
of estimated 
mean % CV 
(i) Inter-observer variability       
Mean IMT       
        Philips ATL 5000 (‘mainframe’) 0.870 0.756 -0.02 (-0.04, 0.00) 2.1 5.7 
        Teratek Terason 3000 (‘portable’) 0.963 0.927 0.00 (-0.01, 0.00) 0.0 2.4 
Maximum IMT        
        Philips ATL 5000 (‘mainframe’) 0.781 0.610 -0.09 (-0.12, -0.06) 7.8 10.5 
        Teratek Terason 3000 (‘portable’) 0.836 0.699 0.02 (0.01, 0.04) 2.8 5.8 
(i) Intra-observer variability       
Mean IMT       
        Philips ATL 5000 (‘mainframe’) 0.971 0.944 -0.02 (-0.03, -0.01) 2.1 2.5 
        Teratek Terason 3000 (‘portable’) 0.995 0.991 0.00 (0.00, 0.00) 0.0 0.5 
Maximum IMT       
        Philips ATL 5000 (‘mainframe’) 0.903 0.815 0.00 (-0.02, 0.02) 0.0 6.5 
        Teratek Terason 3000 (‘portable’) 0.959 0.920 0.00 (-0.01, 0.00) 0.0 4.2 
(i) Inter-machine variability       
Mean IMT       
        ATL 5000 versus Terason 3000 0.901 0.813 -0.03 (-0.05, -0.02) 4.4 5.7 
Maximum IMT       
        ATL 5000 versus Terason 3000 0.904 0.817 -0.01 (-0.03, 0.01) 1.2 6.6 
 
R = Pearson’s correlation coefficient; Difference of means = reading 1 minus reading 2; 95% CI = 95% confidence 
intervals for difference of means; % CV = percent coefficient of variation;  
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3.4 Discussion 
The aim of this study was to assess agreement for repeated carotid IMT measurements, 
comparing two different ultrasound machine types – i) the Philips ATL 5000 (as an example of 
a clinic-based, mainframe ultrasound machine; the “gold standard”), and ii) the Teratek 
Terason 3000 (a portable, laptop-based ultrasound machine).  
 
Inter-observer variability 
Inter-observer variability was assessed by comparing IMT measurements from two 
independent observers, using images obtained from separate vascular substudies (described 
in section 3.2.3.1), using the different ultrasound machine types. Inter-observer variability for 
mean carotid IMT measurements obtained with the Philips ATL 5000 ultrasound machine was 
considered acceptable [mean difference: -0.02 mm; LOA (i.e. mean difference ± 1.96 x SD): -
0.16, 0.12 mm]. The %CV of 5.7% was within the pre-specified range for ‘good’ agreement. 
Similarly, inter-observer variability for mean IMT measurements obtained with the Teratek 
Terason 3000 portable machine was considered acceptable [mean difference: 0.00 mm; LOA: 
-0.03, 0.03 mm]. The %CV of 2.4% was representative of ‘very good’ agreement. 
 
Inter-observer variability for maximum IMT, using images from the Philips ATL 5000 machine, 
was not considered acceptable, according to pre-specified criteria [mean difference: -0.09 
mm; LOA: -0.31, 0.13 mm]. In this case, the LOA were outside of the accepted range of ± 0.2 
mm. Similarly, the %CV of 10.5% was above the pre-specified cut-off value for ‘good’ 
agreement. Inter-observer variability for maximum IMT, using images from the Teratek 
Terason 3000 machine, was considered acceptable [mean difference: -0.02 mm; LOA: -0.10, 
0.05 mm]. The %CV of 5.8% was within the pre-specified range for ‘good’ agreement. 
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Images from the Teratek Terason 3000 showed slightly better agreement for carotid IMT 
measurements, when compared to the Philips ATL 5000 ultrasound machine (i.e. the ‘gold-
standard’). Subjects selected for each study had vastly different clinical characteristics 
(described in section 3.2.3.1): in particular, subjects from the FIELD study (imaged with the 
Philips ATL 5000), were aged 50-75 years, had a diagnosis of T2DM, and a high prevalence of 
traditional cardiovascular risk factors (including hypertension, dyslipidaemia, obesity, 
cigarette smoking history, and prior CVD), compared with subjects from the CardioCAPS study 
(imaged with the Teratek Terason 3000), aged 8 years without a prior history of CVD, and an 
extremely low prevalence of traditional CVD risk factors (e.g. those with a history of T1DM 
were excluded from the study, and no subjects had a diagnosis of T2DM). Difficulty with 
obtaining suitable acoustic windows due to body habitus, as an example, may have influenced 
image quality.  
 
Subjects from the FIELD study had higher IMT values, which is not a surprising finding. Bland-
Altman plots did not reveal a systematic increase in measurement error for higher IMT values; 
however, we cannot exclude the potential for a greater measurement error (systematic or 
random), when assessing carotid IMT images obtained from the FIELD study compared with 
CardioCAPS. Indeed, a potential source of systematic measurement error may have been 
introduced in the FIELD study, through the use of continuous analogue recording for the 
storage of images for later off-line analysis. By contrast, images obtained for IMT assessment 
in CardioCAPS were recorded digitally, in the original file format; thus, reducing the potential 
loss of image quality and resolution.  
 
Inter-observer variability for maximum IMT measurements, using images from the Philips ATL 
5000, was considered not acceptable – according to pre-specified criteria for acceptable 
measurement agreement (described in section 3.2.5). For reasons described above, there was 
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potentially greater measurement error for images obtained with the Philips ATL 5000. 
Furthermore, differences in characteristics of the subjects – i.e. age and the prevalence of risk 
factors for CVD – may have contributed to a more heterogenous arterial wall thickness; thus 
increasing not only the absolute values for maximum IMT, but also the likelihood of selecting 
regions with potentially different artery wall thicknesses, increasing measurement variability. 
Despite having carefully designed methods and robust protocols for IMT assessment, there 
will always be some random measurement error introduced by repeat sampling, and 
systematic measurement error when using two different observers. 
 
A potentially important source of measurement error may result from differences in the 
calculation for mean and maximum IMT. Mean IMT is calculated as an average of multiple 
single ‘point-to-point’ measurements of IMT, from a single frame. The semi-automated IMT 
analysis package used in these studies (section 2.2.3) permits up to 200 single ‘point-to-point’ 
measures, with the selected ROI, for inclusion in the final ‘mean’ IMT value. Thus, the 
influence of a single ‘erroneous’ value, if not detected and manually excluded by the operator, 
is potentially small. By contrast, the maximum IMT is taken as the largest single ‘point-to-point 
measurement, across the possible 200 single ‘point-to-point’ measures. This value can be 
greatly affected by a single ‘erroneous’ value. For this reason, we often see more extreme 
outliers when evaluating measurement agreement for maximum IMT, when compared with 
mean IMT.  
 
Intra-observer variability 
Intra-observer variability was assessed by comparing repeated IMT measurements of the 
same images by a single observer, on two separate occasions (> 1 week apart), using each 
ultrasound machine type, separately. Intra-observer variability for mean carotid IMT 
measurements obtained with the Philips ATL 5000 ultrasound machine was considered 
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acceptable [mean difference: -0.02 mm; LOA: -0.09, 0.05 mm]. The %CV of 2.5% was within 
the pre-specified range for ‘very good’ agreement. Similarly, intra-observer variability for 
mean IMT measurements obtained with the Teratek Terason 3000 portable machine was 
considered acceptable [mean difference: 0.00 mm; LOA: -0.01, 0.01 mm]. The %CV of 0.5% 
was representative of ‘very good’ agreement. 
 
Intra-observer variability for maximum IMT, using images from the Philips ATL 5000 machine, 
was considered acceptable, according to pre-specified criteria [mean difference: -0.00 mm; 
LOA: -0.16, 0.15 mm]. The %CV of 6.5% was within the pre-specified range for ‘good’ 
agreement. Inter-observer variability for maximum IMT, using images from the Teratek 
Terason 3000 machine, was also considered acceptable [mean difference: 0.00 mm; LOA: -
0.04, 0.04 mm]. The %CV of 4.2% was within the pre-specified range for ‘good’ agreement. 
 
The finding of better measurement agreement for intra-observer variability for both machine 
types, compared with inter-observer variability, was not surprising given the increased 
likelihood of systematic measurement error when using different observers. This is again 
reflected by having fewer extreme outliers for intra-observer variability, as a single observer 
would be likely to adopt a systematic approach towards repeated IMT measurements; thus, 
leaving the random measurement error. Again, inter-observer variability was higher for 
maximum IMT, when compared with mean IMT. 
 
Inter-machine variability 
In this validation study, inter-machine variability was assessed by comparing carotid IMT 
measurements from replicate scans, performed on the same patients (in a single visit), using 
the two ultrasound machine types. The difference for mean carotid IMT when comparing the 
two machine types was -0.03 mm; with LOA: -0.16, 0.09 mm; which was within the pre-
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specified criteria for acceptable agreement. The %CV of 5.7% was also within the pre-specified 
range for ‘good’ agreement. The difference in maximum IMT when comparing machine types 
was -0.01 mm; LOA: -0.16, 0.16 mm; again, within pre-specified levels for acceptable 
agreement. Similarly, the %CV of 6.6% was reflective of ‘good’ agreement. Thus, the portable, 
Teratek Terason 3000 ultrasound machine had acceptable agreement with the clinic-based, 
Philips ATL 5000 ultrasound machine (i.e. the ‘gold-standard’); making it suitable for the 
assessment of carotid IMT, in clinical studies. 
 
A potential source of measurement error identified in studies investigating inter- and intra-
observer variability, when comparing both machine types, may have resulted from the use of 
continuous analogue recording of carotid artery scans, for images obtained with the Philips 
ATL 5000. To eliminate this potential source of error from our direct machine comparison, 
images obtained from both machine types were recorded digitally. Thus any difference in 
measurements would be due to machine-dependent factors, and random measurement 
error.  
 
The ultrasound machines used in this direct comparison had many similar features, including 
high-frequency (5-12 MHz) scanning, equivalent transducer lengths (38 mm versus 40 mm), 
and similar ranges for depth (2.4-7.9 cm versus 2.0-8.0 cm). These and other features are 
summarised in Table 3.1. High-frequencies provides better ‘spatial’ resolution (i.e. the ability 
to resolve 2 objects in each of these planes). Similar frequencies for the two machines used in 
this study eliminated any potential difference in ‘spatial’ resolution.  
 
A potentially important difference between ultrasound machines was frame rate – i.e. 50 
frames per second for the Philips ATL 5000, and 30 frames per second for the Teratek Terason 
3000. Higher frame rates improve temporal resolution (i.e. the ability to track moving objects 
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over time). Thus, there was a potential for better temporal resolution with the Philips ATL 
5000, compared with the Teratek Terason 3000. Despite this, the impact of differences in 
frame rates was likely minimised by measuring carotid IMT from still frames captured during 
end-diastole (i.e. on R-wave frames), which represents the least dynamic part of the cardiac 
cycle when imaging the artery wall. Furthermore, the results of this inter-machine comparison 
show good agreement for carotid IMT measurements, when directly comparing ultrasound 
machine types.  
 
Another difference between ultrasound machines used was the number of transducer 
elements sending and receiving acoustic signals – i.e. 512 transducer elements for the Philips 
ATL 5000, and 128 transducer elements for the Teratek Terason 3000. Active transducer 
elements convert electrical energy into ultrasonic energy when transmitting signals (and vice 
versa when receiving signals). The Philips ATL 5000 also had a ‘dual element’ function, 
separating elements used to transmit and receive signals; a function not available with the 
Teratek Terason 3000. Additional transducer elements improves near-surface resolution; 
however, given the average depth of the common carotid artery far wall (the ROI was < 2-3 
cm from the skin surface), near-surface resolution was unlikely to be significantly affected in 
this study.  
 
Magnussen C.G. et.al. (70), conducted a similar inter-machine validation study, comparing IMT 
measurements obtained from a Seimens Acuson Sequoia (a clinic-based, ultrasound machine) 
and a Siemans Acuson Cypress (a portable ultrasound machine). The two machines in this 
study had similar transducer frequencies, persistence settings and operator-defined settings 
for depth and gain, but differences in frame rate, depth settings, and image resolution. Similar 
to our inter-machine comparison, this study reported good agreement when comparing 
carotid IMT from both machine types. A priori levels for good agreement in this study were a 
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mean difference of ± 0.1 mm, and LOA ± 0.1 mm of the mean difference between machines. 
We adopted similar pre-specified levels for good agreement – i.e. a mean difference of 0.1 
mm, however, used LOA of ± 0.20 mm an absolute cutt-off value. %CV are frequently reported 
in the published literature for IMT measurement agreement. We assigned pre-specified 
criteria for acceptable levels of agreement for %CV, with an acceptable level of agreement of 
≤ 10%, which correlated better with absolute LOA of ± 0.20 mm. 
 
Numerous clinical studies have reported values for IMT reproducibility; in the Rotterdam 
study (71), as an example, inter-observer variability for mean IMT was 0.066 mm (SD: 0.07), 
including data from 77 subjects, and inter-sonographer variability (comparing two 
sonographers, using the same patients and ultrasound machine) was 0.005 mm (0.09), for 75 
subjects. The authors conducted an analysis of variance of measurement error and found that 
13% of variability in IMT measurements was attributed to sonographers and observers, with 
most of that error due to differences between observers. Differences in mean IMT, shown for 
inter- and intra-observer and inter-machine variability in our validation study, were less than 
that reported in the Rotterdam study. 
 
A review by Kanters S. et.al. (72) provided a summary of IMT reproducibility data, for studies 
published in MEDLINE between 1991 and 1995. In this review, 23 studies showed a wide range 
of values for inter- and intra-observer variability, for mean IMT and maximum IMT. Typical 
values for the mean difference in mean IMT (measured at the CCA) ranged from 0.02 to 0.13 
mm, for inter-observer variability, and 0.03 to 0.18 mm, for intra-observer variability. This 
review highlighted the impact of a lack of consensus on agreed methods for conducted carotid 
IMT assessment, as reflected by a number of different arterial segments included in analyses 
– e.g. the CCA, ICA or ECA, in various combinations; similarly, inclusion of the near and far 
wall, in some studies. All IMT studies conducted in this thesis were conducted on the CCA only, 
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and used only the far wall (described in chapter 2). Further discussion on a consensus on 
methods for the reproducible and valid assessment of carotid IMT is beyond the scope of this 
chapter, but has been the subject of a number of published reviews (21,63-67).  
 
Studies occasionally report correlation coefficients (R) as a measure of agreement between 
two sets of measurements; this is inappropriate, as correlation coefficients describe only the 
strength of a linear relationship between two variables. A perfect correlation (i.e. R = 1) can 
be obtained if a set of duplicate measurements lie on an exact straight line, even if the 
absolute measurements themselves are not the same. Thus, poor measurement agreement 
can occur with perfect linear correlations, and vice versa.  
 
The coefficient of variation (CV) – often expressed as a ratio or percent (%CV) – is a useful 
measure of variability, and is frequently reported in studies, when assessing agreement 
between sets of measurements.  The vast majority of studies in the published literature, in 
particular, studies reporting inter- and intra-observer variability for carotid IMT 
measurements, use %CVs. This measure of variability is most useful when the SD increases 
proportionally with the value of the measurement.  
 
The Bland-Altman limits of agreement method uses simple calculations to assess the level of 
agreement between two sets of measurements. There are a number of advantages and these 
have been summarised elsewhere (68,69). In brief, because the mean difference is plotted 
against the estimated mean (the average of the two different measurements), a relationship 
between the magnitude of the measurements and the level of disagreement can be easily 
seen. If a systematic bias is noted, an adjustment can be made to permit a direct comparison 
of datasets. The variable does not have to be normally distributed, and Bland-Altman analysis 
removes the variation between subjects, leaving behind the true measurement error 
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(described in section 3.2.5). While this method of measurement agreement is robust and 
simple, it is not used widely for assessing reproducibility in IMT measurements, in the medical 
literature. 
 
Limitations 
There were a number of limitations to this study. First, images used for the assessment of 
inter- and intra-observer variability, for each ultrasound machine type, were from different 
vascular substudies: subjects from the FIELD study (imaged with the Philips ATL 5000), were 
aged 50-75 years, had a diagnosis of T2DM, and a high prevalence of traditional cardiovascular 
risk factors (previously described), and subjects from the CardioCAPS study (imaged with the 
Teratek Terason 3000), were aged 8 years without a prior history of CVD, and an extremely 
low prevalence of traditional CVD risk factors. These important clinical differences may have 
influenced image quality, as younger and leaner subjects have less adipose tissue, better 
acoustic windows, and are unlikely to have had atherosclerotic plaque at the ROI. 
 
 Second, different recording media - i.e. digital (for images from the Teratek Terason 3000) 
and analogue (for images from the Philips ATL 5000) – were used in the two different vascular 
substudies, for the assessment of inter- and intra-observer variability. This may have led to a 
difference in image resolution, and consequently accuracy of IMT measurements. While the 
Philips ATL 5000 ultrasound machine can record digitally, the hard-drive storage space and 
data transfer rate, is very limited; thus, making digital recording less practical for studies with 
larger numbers of subjects. The Teratek Terason 3000 had a large disk storage space (> 80 
gigabytes), and a 6-pin firewire port permitting rapid data transfer to an external hard-drive, 
which made it suitable for digital recording.  
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Third, the order of the ultrasound machines used in obtaining replicate ultrasound scans in 
the inter-machine variability study was not randomised. While a ‘machine-order-effect’ may 
have been possible, it is unlikely to have significantly influenced the study findings. Identical 
carotid artery ultrasound scans were performed, according to a standardised protocol (see 
chapter 2), and conducted by a single operator who was experienced in the methods. 
Furthermore, scans were performed on the same subjects, in a single visit, under similar 
conditions. The inter- and intra-observer variability studies described above reported 
acceptable agreement, suggesting the methods adopted were indeed reproducible. Fourth, 
inter- and intra-observer variability was not assessed for inter-machine variability. This 
analysis might be useful in exploring the effect that eliminating analogue recording has on the 
reproducibility of carotid IMT measurements; however, directly comparing images recorded 
simultaneously to analogue and digital media (using the Philips ATL 5000) would be a better 
approach.  
 
3.5 Conclusion 
In this series of validation studies for IMT assessment, inter- and intra-observer variability 
from images obtained using both the Philips ATL 5000 (clinic-based, mainframe) and the 
Teratek Terason 3000 (portable, laptop-based) ultrasound machine, reported acceptable 
agreement; with the exception of maximum IMT, for the Philips ATL 5000. Overall, the level 
of agreement was slightly better for images from the Teratek Terason 3000; however, this was 
likely due to differences in subject characteristics and the use of analogue versus digital 
recording, rather than technical differences between machine types. The inter-machine 
variability study showed acceptable agreement for carotid IMT measurements, when 
comparing the two ultrasound machine types. Thus, the portable, laptop-based ultrasound 
machine (i.e. Teratek Terason 3000) investigated in this study, can be used as a suitable 
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alternative to the traditional, clinic-based, mainframe ultrasound machines (i.e. the ‘gold-
standard’), for use in clinical studies assessing carotid IMT.  
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Preface 
In the following two chapters, the results of clinical studies conducted in populations remote 
from a tertiary referral centre, exploring traditional cardiovascular risk factors and their 
association with the burden of subclinical vascular disease, using carotid IMT as a surrogate 
measure of structural changes in the arterial vasculature, are presented. In these studies, 
carotid artery ultrasound images for the assessment of IMT were obtained using a portable, 
laptop-based, ultrasound machine (the Teratek Terason 3000), described in the previous 
chapter. The overall success of these studies was dependent upon the ability of the portable 
ultrasound machine to accurately and reproducibly measure carotid IMT compared with high-
end, clinic-based (‘mainframe’) ultrasound machines, which was addressed in chapter 3.  
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CHAPTER 4:  
 
Association Between Carotid Intima-Media Thickness and Traditional 
Cardiovascular Risk Factors in Migrant Australian Indians Compared 
with Rural Indians. 
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4.1  Introduction 
Several studies in countries with large migrant populations – e.g.  Canada, Singapore and The 
United Kingdom– have provided evidence that South Asian-Indians may have an increased risk 
of CVD when compared with other ethnic groups (73-76). The Study of Health Assessment and 
Risk in Ethnic groups (SHARE) study, a population-based study of 3 ethnic groups in Canada, 
showed that South-Asian Indians had a higher prevalence of CVD, when compared to Chinese 
and Europeans (73). Similarly, the Singapore Cardiovascular Cohort Study, reported a higher 
mortality from ischaemic heart disease, when compared with other ethnic groups (74).  
 
In the INTERHEART study (7), a case-control study of risk factors associated with a first AMI in 
52 countries, there was a lower median age of onset of clinically-evident CVD in South-Asian 
Indians, by ~ 5-10 years, compared with other ethnic groups. The earlier age of onset of CVD 
events in the INTERHEART study was explained by the higher levels of traditional CVD risk 
factors, in particular the prevalence of tobacco smoking and diabetes mellitus (7), and at a 
younger age than in other ethnic groups (77).  Similarly, in the SHARE study, there was a higher 
prevalence of TC, LDL-C, triglycerides, glucose intolerance, as well as lower HDL-C, compared 
with other ethnic groups (73). Not all studies have reported a higher prevalence of traditional 
CVD risk factors that can explain the higher rates of CVD mortality in South-Asian Indian 
migrants (78).   
 
Another possible explanation for the higher risk of CVD in South-Asian Indians is a difference 
in susceptibility to certain traditional CVD risk factors. We have previously shown there to be 
a stronger association between carotid IMT, a surrogate measure of subclinical vascular 
disease, and cholesterol and diabetes mellitus in South-Asian Indians in rural Andhra Pradesh, 
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compared with Caucasians in Australia (6). Furthermore, a study by Whincup PH et.al. found 
a stronger association between adiposity and insulin concentration and resistance in South-
Asian Indian children compared to those of European descent (79).  
 
The effects of “westernisation” and associated diet and other lifestyle changes has previously 
been shown to have a detrimental effect on traditional CVD risk factor levels and carotid IMT, 
in Chinese migrants (80). The effects of “westernisation” in South-Asian Indians, in particular, 
in Australia has not been previously studied. We hypothesised that diet and other lifestyle 
changes associated with “westernisation” would have adverse effects on CVD risk factors 
levels and carotid IMT, in South-Asian Indians. Therefore, we studied traditional CVD risk 
factors and carotid IMT in migrant Australian Indians living in Sydney, Australia, and compared 
this to our previously published reference population of rural Indians, living in Andhra 
Pradesh, India (6).  
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4.2 Methods 
4.2.1  Study participants 
This cross-sectional study recruited migrant South-Asian Indians (aged ≥ 20 years) living in 
Sydney (or surrounding districts), Australia, for ≥ 10 years, or Australian-born migrants of such 
descendants. Non-probability sampling using a stratified convenience sampling method was 
used to select subjects. Advertisements published in community newspapers, posters 
displayed in public areas – including shopping centres, general practitioners clinics, and 
community centres, attendance at cultural festivals and events, and in the latter part of the 
study advertisements on free-to-air talk back radio targeting the Indian community, were used 
to recruit subjects. 
 
Consecutively eligible participants were stratified by age group (20-34, 35-44, 45-54, 55-64, 
65+ years) and sex. Active recruitment continued until at least 10 male and 10 female 
participants were allocated to each strata. A total of 341 subjects completed the study and 
had carotid artery ultrasound scans for IMT assessment. All study data was collected in a study 
single visit. Methods used for the assessment of carotid IMT, medical histories, physical 
examination and blood sampling were similar for the two cross-sectional studies described in 
this chapter. This study was approved by ethics committee at The University of Sydney, 
Australia. All participants provided written, informed consent.  
 
In this study, data obtained from migrant Australian Indians was compared to a reference 
population of rural Indians living in two villages in the Godavari district of rural Andhra 
Pradesh, India. Methods used for population sampling in rural India have been previously 
described (6,81,82). A total of 303 rural Indian subjects had carotid artery ultrasound scans 
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and data available for traditional CVD risk factors, and were used in this study for comparison 
to migrant Australian Indians.   
 
4.2.2 Anthropometry, blood pressure, medical history and definitions 
Height was measured to the nearest 0.5 cm and weight to the nearest 0.1 kg using a portable 
stadiometer and calibrated electronic scales. BMI was calculated as weight (kg)/height (m)2. 
Waist circumference (cm) was measured at end-expiration, at the midpoint between the 
costal margin and the iliac crest. Hip circumference (cm) was measured at the level of the 
anterior superior iliac spine. Waist:hip ratio was calculated as waist circumference (cm)/hip 
circumference (cm). BP was recorded from the left brachial artery after sitting at rest for 10 
minutes, using an Omron M2 manual inflation blood pressure monitor. The average of two BP 
readings was used in these analyses. Pulse pressure (PP) was the difference between SBP and 
DBP (i.e. SBP – DBP) in mmHg.  
 
Detailed medical histories were obtained from participants using a self-administered 
questionnaire, designed by Dr Clara Chow (PhD – USYD, 2007). The questionnaire was 
administered in English. The questionnaire obtained information on traditional cardiovascular 
risk factors, the current use of prescription and non-prescription medications and non-
traditional therapies, socio-economic and educational status, and level of knowledge of 
cardiovascular disease. Questionnaires were checked for completeness by trained staff, and 
participants were given an opportunity to discuss responses, if participants had difficulty with 
understanding questions or providing answers required. Participants with language difficulties 
(mostly elderly subjects) were assisted by family members. 
 
 
 
116 
 
A prior history of CVD was documented as a history of MI, stroke or PVD. Hypertension was 
defined as SBP > 140 mmHg or DBP > 90 mmHg, or a previous medical diagnosis requiring 
treatment with anti-hypertensive agents. Diabetes mellitus was defined as a fasting plasma 
glucose ≥ 7.0 mmol/L, or a previous diagnosis of diabetes. A history of tobacco smoking was 
defined as smoking for ≥ 5 days per week, and including smoking tobacco in the form of 
cigarettes, beedi or cigars. Chewing tobacco was not included in a history of smoking. Tobacco 
smoking status was recorded as present (for current smoker), past (for ex-smoker) or as never-
smoker (for those who did not meet any of the above criteria). 
 
4.2.3  Blood sampling and biochemical analysis 
Venous blood samples were obtained from fasting (≥ 8 hours) subjects and stored 
immediately on ice after collection and transferred to a laboratory within 6 hours for 
processing. Blood samples were analysed using a Hitachi Boeringer Mannheim 902 Automatic 
analyser and Elecys 1010. Quality control and standardisation of samples collected in the two 
cross-sectional studies was achieved using quality assurance materials provided by the Royal 
College of Pathologists Australia quality control program, and were run concurrently with 
study samples. LDL:HDL ratio was calculated as LDL-C (mmol/L)/HDL-C (mmol/L).  
 
4.2.4 Carotid intima-media thickness assessment 
Methods used for the assessment of carotid IMT have been described in chapter 2.  Carotid 
artery ultrasound scans were obtained using the Teratek Terason 3000 (if performed in 
centres remote from the vascular laboratory, at the Royal Prince Alfred Hospital), or with a 
clinic-based, mainframe ultrasound machine (i.e. Philips ATL 5000). 
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4.2.5 Statistics 
Subject characteristics were expressed as mean (SD) or median (IQR) for continuous variables, 
or count (and percentages) for continuous variables, respectively. Several variables were non-
normally distributed, including glucose, TG, and mean and maximum IMT, and were log 
transformed (Ln) prior to analysis. Data obtained from migrant Australian Indians and a 
reference population of rural Indians living in Andhra Pradesh, India (6), were compared by 
independent samples t-tests for continuous variables and χ2 tests for categorical variables. 
Multivariable analysis was performed using backward linear regression. A two-tailed p-value 
< 0.05 was considered significant. All analyses were performed using SPSS version 22.0 (IBM, 
Chicago, IL, USA).   
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4.3 Results 
4.3.1 Participant characteristics 
The mean age of subjects was 50.3 years (SD; 14.8 years) and 50.3% were male. Fasting blood 
glucose was 4.8 ± 0.9 mmol/L (median ± IQR), TC was 5.0 ± 1.0 mmol/L (mean ± SD), LDL-C 
was 3.0 ± 0.8 mmol/L, HDL-C was 1.35 ± 0.34 mmol/L, LDL:HDL ratio was 2.3 ± 0.8, TG was 
1.30 ± 0.80 mmol/L (median ± IQR), and creatinine was 73.8 ± 16.5 µmol/L (mean ± SD). SBP 
was 129 ± 19 mmHg (mean ± SD), DBP was 76 ± 11 mmHg and PP was 53 ± 11 mmHg. 5.3 % 
had a prior history of CVD, 15.2% had diabetes mellitus and 24.9% had a history of 
hypertension. 3.8% were current smokers, 8.5% were past smokers and 87.7% had never 
smoked (Table 4.1). 
 
Migrant Australian Indian participants were compared to a reference population of rural 
Indians in Andhra Pradesh, India (6). Compared with rural Indians, migrant Australian Indians 
had a similar age (p=0.944), but significantly higher height (p<0.001), weight (p<0.001), BMI 
(p<0.001), waist circumference (p<0.001), waist:hip ratio (p<0.001), SBP (p<0.001), DBP 
(p=0.040), PP (p<0.001), HDL-C (p<0.001), TG (p=0.014), fasting glucose (p<0.001), plasma 
creatinine (p<0.001), and a higher proportion of participants with diabetes mellitus (p<0.001) 
and hypertension (p=0.042). By contrast, migrant Australian Indians had a lower LDL-C 
(p<0.001), LDL:HDL ratio (p<0.001) and lower rates of current tobacco smoking (p<0.001). 
There was no difference in TC (p=0.165) and the proportion with prior CVD (p=0.915); 
however, there was a higher proportion of males in the migrant Indian population (p=0.041). 
Participant characteristics for rural Indians are listed in the discussion section; p-values for this 
comparison are shown in Table 4.1.  
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4.3.2 Participant characteristics by sex 
When comparing migrant Australian Indians by sex, males had a higher height (p<0.001), 
weight (p<0.001), waist circumference (p<0.001), waist:hip ratio (p<0.001), SBP (p=0.049), 
DBP (p=0.006), fasting glucose (p=0.004), TG (p=0.003), LDL:HDL ratio (p<0.001), plasma 
creatinine (p<0.001), and higher rates of current (p=0.002) and past tobacco smoking 
(p<0.001); and females had a higher BMI (p=0.015), hip circumference (p=0.001) and HDL-C 
(p<0.001). There was no difference in age, PP, TC, LDL-C, HbA1c, or rates of prior CVD, diabetes 
mellitus or hypertension, when comparing male and female migrant Australian Indians (Table 
4.2). 
 
Compared with male rural Indians, male migrant Australian Indians had a higher height, 
weight, BMI, waist circumference, waist:hip ratio, SBP, DBP, PP, TC, HDL-C, TG, fasting glucose, 
creatinine, rates of diabetes mellitus and hypertension. By contrast, male migrant Indians had 
a lower LDL:HDL ratio and rates of current tobacco smoking. There was no difference in age 
between the two populations. When comparing male participants by population, LDL-C was 
no longer significantly higher in migrant Indians. Similarly, past smoking was no longer higher 
in rural Indian males, compared with migrant Australian Indians. TC, which was similar when 
comparing migrant Australian Indians to rural Indians overall, was significantly higher in 
migrant Australian males (Table 4.3). 
 
Comparing females, migrant Australian Indians had a higher height, weight, BMI, waist and 
hip circumference, SBP, PP, HDL-C, fasting glucose, plasma creatinine, and a higher proportion 
with diabetes mellitus than rural Indians. By contrast, female migrant Australian Indians had 
a lower LDL-C, LDL:HDL ratio, and rates of current and past tobacco smoking. There was no 
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difference in age, waist:hip ratio, DBP, TC, or rates of prior CVD or hypertension. Several 
characteristics that were previously shown to be different when comparing populations 
overall where no longer statistically significantly different when comparing females by 
population, including waist:hip ratio, DBP,TG and rates of hypertension (Table 4.4) 
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Table 4.1 – Characteristics of migrant Australian Indians compared with rural Indians. 
 
 
Characteristic 
Migrant Indians 
 (N = 341) 
Rural Indians 
 (N = 303) 
¥p-value 
Sex , male 174 (51%) 128 (43%) 0.041 
Age, years 50.3 (14.8) 50.3 (15.8) 0.944 
Height, m 1.63 (0.09) 1.56 (0.10) <0.001 
Weight, kg 67.5 (11.4) 52.9 (12.4) <0.001 
BMI, kg/m2 25.3 (3.8) 21.6 (4.4) <0.001 
Waist, cm 88.5 (10.9) 80.0 (12.8) <0.001 
Hip, cm 100.8 (8.8) 92.0 (10.4) <0.001 
Waist:hip ratio 0.88 (0.09) 0.85 (0.10) <0.001 
SBP, mmHg 129 (19) 120 (19) <0.001 
DBP, mmHg 76 (11) 75 (11) 0.040 
Pulse pressure, mmHg 53 (15) 46 (15) <0.001 
Prior CVD 18 (5.3%) 15 (5.5%) 0.915 
Diabetes mellitus 52 (15.2%) 15 (5.5%) <0.001 
Hypertension 85 (24.9%) 54 (18.2%) 0.042 
Total cholesterol, mmol/L 5.0 (1.0) 4.9 (1.1) 0.165 
LDL-cholesterol, mmol/L 3.0 (0.8) 3.4 (0.9) <0.001 
HDL-cholesterol, mmol/L 1.35 (0.34) 0.87 (0.14) <0.001 
TG#, mmol/L 1.30 (0.80) 1.18 (1.00) 0.014 
LDL:HDL ratio 2.3 (0.8) 3.9 (1.1) <0.001 
Glucose#, mmol/L 4.8 (0.9) 4.1 (1.0) <0.001 
Creatinine, μmol/L 73.8 (16.5) 60.8 (15.1) <0.001 
Current smoking 13 (3.8%) 61 (22.6%) <0.001 
Past smoking 29 (8.5%) 36 (13.3%) 0.057 
Mean IMT#, mm 0.69 (0.21) 0.71 (0.25) 0.111 
Maximum IMT#, mm 0.91 (0.30) 0.95 (0.29) 0.385 
 
Continuous variables are expressed as mean ± SD except #median ± IQR, and categorical variables expressed as 
count (and valid %). ¥P-value for comparison to N=303 rural Indians in Andhra Pradesh, India (6). #Non-normally 
distributed parameters (TG, glucose, mean and maximum IMT) were Ln transformed prior to statistical analyses.  
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Table 4.2 – Characteristics of migrant Australian Indians by sex. 
 
 
Characteristic 
Males 
 (N = 174) 
Females 
 (N = 167) 
¥p-value 
Age, years 50.5 (14.7) 50.0 (15.0) 0.736 
Height, m 1.70 (0.06) 1.57 (0.07) <0.001 
Weight, kg 71.8 (10.9) 63.1 (10.1) <0.001 
BMI, kg/m2 24.8 (3.3) 25.8 (4.3) 0.015 
Waist, cm 93.0 (8.9) 83.7 (10.9) <0.001 
Hip, cm 99.3 (7.4) 102.4 (9.9) 0.001 
Waist:hip ratio 0.94 (0.05) 0.82 (0.07) <0.001 
SBP, mmHg 131 (17) 127 (21) 0.049 
DBP, mmHg 80 (10) 75 (11) 0.006 
Pulse pressure, mmHg 53 (14) 53 (16) 0.754 
Heart rate, bpm 69 (10) 72 (9) 0.001 
Prior cardiovascular disease 12 (6.9%) 6 (3.6%) 0.173 
Diabetes mellitus 32 (18.4%) 20 (12.0%) 0.100 
Hypertension 49 (28.2%) 36 (21.6%) 0.159 
Total cholesterol, mmol/L 5.0 (1.0) 5.0 (1.0) 0.474 
LDL-cholesterol, mmol/L 3.0 (0.9) 2.9 (0.8) 0.297 
HDL-cholesterol, mmol/L 1.22 (0.27) 1.48 (0.36) <0.001 
TG#, mmol/L 1.4 (0.9) 1.3 (0.8) 0.003 
LDL:HDL ratio 2.56 (0.86) 2.07 (0.74) <0.001 
Glucose#, mmol/L 4.9 (0.9) 4.6 (1.0) 0.004 
HbA1c, %  5.9 (0.8) 5.8 (0.7) 0.333 
Creatinine, μmol/L 83.9 (15.7) 63.5 (9.3) <0.001 
Current smoking 12 (6.9%) 1 (0.6%) 0.002 
Past smoking 27 (15.5%) 2 (1.2%) <0.001 
Mean IMT#, mm 0.71 (0.20) 0.67 (0.21) 0.022 
Maximum IMT#, mm 0.95 (0.27) 0.88 (0.29) 0.025 
 
Continuous variables are expressed as mean ± SD except #median ± IQR, and categorical variables expressed as 
count (and valid %). ¥P-values are from comparisons of differences between the sexes. #Non-normally distributed 
parameters (TG, glucose, mean and maximum IMT) were Ln transformed prior to statistical analyses.  
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Table 4.3 – Characteristics of male migrant Australian Indians compared with rural Indians. 
 
 
Characteristic 
Migrant Indians 
(N = 174) 
Rural Indians 
(N = 128) 
¥p-value 
Age, years 50.5 (14.7) 51.8 (16.2) 0.475 
Height, m 1.70 (0.06) 1.63 (0.09) <0.001 
Weight, kg 71.8 (10.9) 56.2 (13.0) <0.001 
BMI, kg/m2 24.8 (3.3) 20.9 (4.1) <0.001 
Waist, cm 93.0 (8.9) 81.3 (13.5) <0.001 
Hip, cm 99.3 (7.4) 88.3 (8.8) <0.001 
Waist:hip ratio 0.94 (0.05) 0.91 (0.07) 0.001 
SBP, mmHg 131 (17) 123 (19) <0.001 
DBP, mmHg 78 (10) 75 (11) 0.033 
Pulse pressure, mmHg 53 (14) 47 (15) <0.001 
Prior cardiovascular disease  12 (6.9%) 11 (9.4%) 0.437 
Diabetes mellitus 32 (18.4%) 9 (7.8%) 0.011 
Hypertension 49 (28.2%) 23 (18.3%) 0.047 
Total cholesterol, mmol/L 5.0 (1.0) 4.7 (1.1) 0.046 
LDL-cholesterol, mmol/L 3.0 (0.9) 3.2 (0.8) 0.071 
HDL-cholesterol, mmol/L 1.22 (0.27) 0.86 (0.15) <0.001 
TG#, mmol/L 1.4 (0.8) 1.2 (1.1) 0.020 
LDL:HDL ratio 2.6 (0.9) 3.8 (1.1) <0.001 
Glucose#, mmol/L 4.9 (0.9) 4.1 (1.0) <0.001 
Creatinine, μmol/L 83.9 (15.7) 69.7 (14.4) <0.001 
Current smoking 12 (6.9%) 54 (45.8%) <0.001 
Past smoking 27 (15.5%) 27 (22.9%) 0.112 
Mean IMT#, mm 0.71 (0.20) 0.74 (0.27) 0.251 
Maximum IMT#, mm 0.95 (0.27) 1.01 (0.33) 0.317 
 
Continuous variables are expressed as mean ± SD except #median ± IQR, and categorical variables expressed as 
count (and valid %). ¥P-value for comparison to N=128 rural Indian males in Andhra Pradesh, India (6). #Non-
normally distributed parameters (TG, glucose, mean and maximum IMT) were Ln transformed prior to statistical 
analyses.  
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Table 4.4 – Characteristics of female migrant Australian Indians compared with rural Indians.  
 
 
Characteristic 
Migrant Indians 
 (N = 167) 
Rural India 
 (N = 170) 
¥p-value 
Age, years 50.0 (15.0)  49.2 (15.5) 0.657 
Height, m 1.57 (0.07) 1.51 (0.07) <0.001 
Weight, kg 63.1 (10.1) 50.5 (11.5) <0.001 
BMI, kg/m2 25.8 (4.3) 22.1 (4.6) <0.001 
Waist, cm 83.8 (10.9) 77.2 (12.0) <0.001 
Hip, cm 102.4 (10.0) 94.7 (10.7) <0.001 
Waist:hip ratio 0.82 (0.07) 0.81 (0.09) 0.234 
SBP, mmHg 127 (21) 119 (19) <0.001 
DBP, mmHg 75 (11) 74 (10) 0.594 
Pulse pressure, mmHg 53 (16) 45 (15) <0.001 
Prior cardiovascular disease 6 (0.4) 4 (2.5) 0.587 
Diabetes mellitus 20 (12.0) 6 (3.8) 0.007 
Hypertension 36 (21.6) 31 (18.3) 0.461 
Total cholesterol, mmol/L 5.0 (1.0) 5.0 (1.0) 0.775 
LDL-cholesterol, mmol/L 2.9 (0.8) 3.5 (0.9) <0.001 
HDL-cholesterol, mmol/L 1.48 (0.36) 0.87 (0.14) <0.001 
TG#, mmol/L 1.3 (0.8) 1.2 (1.0) 0.429 
LDL:HDL ratio 2.1 (0.7) 4.1 (1.1) <0.001 
Glucose#, mmol/L 4.6 (1.0) 4.1 (0.9) <0.001 
Creatinine, μmol/L 63.5 (9.3) 54.0 (11.9) <0.001 
Current smoking 1 (0.6%) 7 (4.6%) 0.027 
Past smoking 2 (1.2%) 9 (5.9%) 0.022 
Mean IMT#, mm 0.67 (0.21) 0.69 (0.21) 0.221 
Maximum IMT#, mm 0.88 (0.29) 0.92 (0.25) 0.230 
 
Continuous variables are expressed as mean ± SD or #median ± IQR, and categorical variables expressed as count 
(and valid %). ¥P-value for comparison to N=170 rural Indian females in Andhra Pradesh, India (6). #Non-normally 
distributed parameters (TG, glucose, mean and maximum IMT) were Ln transformed prior to statistical analyses. 
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4.3.3 Participant characteristics by age group 
Characteristics for migrant Australian Indians by age group (≤ 39, 40-49, 50-59, ≥ 60 years) and 
by sex are shown in Tables 4.5-4.8. Anthropometric data are shown in Table 4.5 and 
statistically significant differences in weight, BMI, waist circumference and waist:hip ratio 
were shown when comparing migrant Australian Indians to a reference population of rural 
Indians in Andhra Pradesh (6); with the exception of waist circumference for males aged 50-
59 years, and waist:hip ratio in middle-aged to elderly subjects. Haemodynamic characteristics 
are shown in Table 4.6. SBP and PP were higher in migrant Australian Indians overall across all 
age groups, compared with the rural Indians. DBP was higher in migrant Australian Indians 
aged 50-59 years. Age- and sex-specific differences between populations were noted for SBP 
and PP, but not DBP.  
 
Biochemical characteristics by age group and sex are shown in Table 4.7 and 4.8. TC was higher 
in migrant Australian Indians aged 40-49 years, overall, but not in any other age group. Male 
migrant Australian Indians aged ≤ 39 and 40-49 years had a higher TC when compared with 
the reference population of rural Indians; however, there was no difference in TC when 
comparing females by population, across different age groups (Table 4.7). LDL-C was lower in 
migrant Australian Indians across all age groups (except those aged 40-49 years), overall, 
when compared to rural Indians; this was due to lower LDL-C in female subjects. Elderly 
migrant Australian Indian males (aged ≥ 60 years) had lower LDL-C compared with rural Indian 
males, and males from other age groups had similar LDL-C levels when comparing populations. 
(Table 4.7). Strikingly, HDL-C was higher in migrant Australian Indians across all age groups 
and in both sexes, compared with rural Indians (Table 4.7). LDL-HDL ratio was also lower in 
migrant Australian Indians across all age groups and in both sexes, compared with rural 
Indians (Table 4.8). Fasting blood glucose was higher in migrant Australian Indians across all 
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age groups in both sexes (with the exception of females aged 40-49 years), compared with 
rural Indians (Table 4.8). Plasma creatinine was higher in migrant Australian Indians across all 
age groups and in both sexes (with the exception of females aged ≥ 60 years), compared with 
rural Indians (Table 4.8).  
 
4.3.4 Comparison of carotid intima-media thickness 
Mean carotid IMT in migrant Australian Indians was 0.71 ± 0.25 mm (median ± IQR) and 
maximum carotid IMT was 0.91 ± 0.30 mm (median ± IQR) (Table 4.1). When compared with 
the reference of population of rural Indians in Andhra Pradesh, there was no statistically 
significant difference in mean or maximum carotid IMT; Table 4.1 (for p-values) and section 
4.4 – Discussion (for absolute mean and maximum IMT values for rural Indians). There was no 
different in mean or maximum IMT when comparing migrant Australian Indians rural Indians, 
according to sex (Tables 4.3 and 4.4, for p-values).  
 
Statistically significant differences were shown for mean and maximum IMT when comparing 
migrant Australian Indians by sex. Mean carotid IMT was higher in male migrant Australian 
Indians (median ± IQR; 0.71 ± 0.20 mm) than in females (0.67 ± 0.21 mm) (p=0.022) (Table 
4.2). Similarly, maximum carotid IMT was higher in male migrant Australian Indians (0.95 ± 
0.27 mm) than in females (0.88 ± 0.29 mm) (p=0.025) (Table 4.2). 
 
Mean and maximum carotid IMT by age group (≤ 39, 40-49, 50-59, ≥ 60 years) and sex is shown 
in Table 4.9. Figures 4.1 and 4.2 show mean and maximum carotid IMT in migrant Australian 
Indians by age group. Figures 4.3 and 4.4 show mean and maximum carotid IMT in migrant 
Australian Indians by sex and age group. Mean carotid IMT was lower in migrant Australian 
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Indians aged 40-49 years, overall, compared with the reference population of rural Indians in 
Andhra Pradesh; and when separated according to sex, mean carotid IMT was lower in 
younger migrant Australian Indian females (aged ≤ 39 years and 40-49 years) compared with 
rural Indians. There was no difference in mean or maximum carotid IMT when comparing 
migrant Australian Indian males with rural Indian males, in any age group (Table 4.9). Similarly, 
maximum carotid IMT was lower in younger migrant Australian Indian females (aged ≤ 39 
years and 40-49 years) compared with rural Indian females, which accounted for the 
statistically significant difference in maximum IMT in those aged 50-59 years and ≥ 60 years, 
overall, when comparing migrant Australian Indians and rural Indians (Table 4.9).
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Table 4.5 – Anthropometry by age group (≤ 39, 40-49, 50-59, ≥ 60 years) and sex in migrant Australian Indians. 
 
  Overall Males Females 
Variable Age group n Mean SD 
 
¥p-value n Mean 
 
SD 
 
¥p-value 
 
n 
 
Mean 
 
SD 
 
¥p-value 
Weight ≤ 39 y 84 66.9 14.3 <0.001 37 75.7 13.9 <0.001 46 59.7 9.9 <0.001 
 40-49 y 99 67.9 9.4 <0.001 59 71.6 7.8 <0.001 41 62.9 9.3 <0.001 
 50-59 y 58 67.5 10.5 <0.001 27 71.2 12.2 0.020 33 64.7 7.6 <0.001 
 ≥ 60 y 88 67.6 11.3 <0.001 49 69.2 10.6 <0.001 45 65.1 11.6 <0.001 
BMI ≤ 39 y 84 24.5 4.1 <0.001 37 25.5 4.3 <0.001 46 23.6 3.9 0.027 
 40-49 y 99 24.7 3.0 <0.001 59 24.3 2.6 <0.001 41 25.2 3.5 <0.001 
 50-59 y 58 26.1 3.4 <0.001 27 25.4 3.4 0.012 33 26.6 3.4 <0.001 
 ≥ 60 y 88 26.3 4.4 <0.001 49 24.5 3.0 <0.001 45 27.9 4.9 <0.001 
Waist ≤ 39 y 84 84.9 12.6 <0.001 37 92.0 11.8 <0.001 46 79.1 10.0 0.062 
 40-49 y 99 88.5 9.0 <0.001 59 92.3 6.0 <0.001 41 83.3 10.1 0.012 
 50-59 y 58 89.0 9.0 0.002 27 93.3 9.3 0.111 33 85.5 6.8 0.001 
 ≥ 60 y 88 91.7 11.6 <0.001 49 94.5 9.1 <0.001 45 87.8 13.0 0.017 
W:H ratio ≤ 39 y 84 0.86 0.09 0.006 37 0.92 0.05 <0.001 46 0.81 0.07 0.511 
 40-49 y 99 0.89 0.08 <0.001 59 0.94 0.05 0.077 41 0.84 0.08 0.013 
 50-59 y 58 0.87 0.07 0.991 27 0.93 0.04 0.457 33 0.82 0.05 0.453 
 ≥ 60 y 88 0.89 0.10 0.789 49 0.95 0.05 0.045 45 0.81 0.08 0.284 
 
Weight (kg); BMI (kg/m2); Waist (cm); W:H ratio = waist:hip ratio. Age group: (y) = years. ¥P-value for comparison of migrant Australian Indians to a reference population of rural Indians in 
Andhra Pradesh, India (6). 
 
 
129 
 
 
Table 4.6 – Haemodynamic characteristics by age group (≤ 39, 40-49, 50-59, ≥ 60 years) and sex in migrant Australian Indians. 
  Overall Males Females 
Variable Age group n Mean SD ¥p-value n Mean SD ¥p-value n Mean SD ¥p-value 
SBP ≤ 39 y 84 119 15 <0.001 37 123 14 0.004 47 116 15 0.013 
 40-49 y 99 123 13 0.044 58 126 13 0.284 41 117 12 0.416 
 50-59 y 58 133 16 0.001 26 132 15 0.170 33 134 18 0.002 
 ≥ 60 y 88 144 20 0.001 47 144 19 0.001 42 142 23 0.208 
DBP ≤ 39 y 84 72 11 0.776 37 75 9 0.221 47 70 12 0.511 
 40-49 y 99 75 10 0.877 58 77 11 0.849 41 71 9 0.155 
 50-59 y 58 80 10 0.027 26 81 10 0.167 33 80 11 0.087 
 ≥ 60 y 88 79 10 0.087 47 80 10 0.181 42 80 9 0.293 
PP ≤ 39 y 84 47 11 <0.001 37 48 11 0.002 47 46 12 <0.001 
 40-49 y 99 48 10 0.016 58 49 10 0.265 41 47 9 0.027 
 50-59 y 58 52 11 0.009 26 51 8 0.490 33 54 13 0.006 
 ≥ 60 y 88 65 18 0.006 47 64 17 0.002 42 64 20 0.373 
 
SBP = systolic blood pressure, DBP = diastolic blood pressure, PP = pulse pressure (SBP – DBP). Age group: (y) = year. ¥P-value for comparison to of migrant Australian Indians to a reference 
population rural Indians in Andhra Pradesh, India (6). 
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Table 4.7 – Biochemical characteristics (TC, LDL-C, HDL-C, TG) by age group (≤39, 40-49, 50-59, ≥ 60 years) and sex in migrant Australian Indians. 
  Overall Males Females 
Variable Age group n Value Error ¥p-value n Value Error ¥p-value n Value Error ¥p-value 
TC ≤ 39 y 84 4.8 1.0 0.101 37 5.0 1.0 0.007 47 4.6 0.9 0.870 
 40-49 y 99 5.3 0.9 0.024 58 5.2 1.0 0.001 41 5.3 0.8 0.645 
 50-59 y 58 5.1 1.1 0.892 26 4.9 0.9 0.433 33 5.3 1.1 0.323 
 ≥ 60 y 88 4.7 0.9 0.047 47 4.5 0.8 0.262 42 5.0 1.0 0.078 
LDL-C ≤ 39 y 84 2.8 0.8 0.002 37 3.0 0.8 0.897 47 2.6 0.8 <0.001 
 40-49 y 99 3.3 0.8 0.735 58 3.3 0.9 0.357 41 3.2 0.7 0.238 
 50-59 y 58 3.0 0.8 0.014 26 3.0 0.7 0.161 33 3.0 0.9 0.043 
 ≥ 60 y 88 2.7 0.8 <0.001 47 2.6 0.8 <0.001 42 2.8 0.8 <0.001 
HDL-C ≤ 39 y 84 1.43 0.40 <0.001 37 1.31 0.32 <0.001 47 1.52 0.38 <0.001 
 40-49 y 99 1.31 0.32 <0.001 58 1.21 0.24 <0.001 41 1.44 0.38 <0.001 
 50-59 y 58 1.33 0.29 <0.001 26 1.19 0.26 <0.001 33 1.43 0.26 <0.001 
 ≥ 60 y 88 1.34 0.36 <0.001 47 1.19 0.28 <0.001 42 1.50 0.38 <0.001 
TG# ≤ 39 y 84 1.0 0.6 0.466 37 1.2 0.6 0.047 47 0.9 0.7 0.269 
 40-49 y 99 1.5 0.9 0.023 58 1.6 1.0 0.002 41 1.3 1.0 0.993 
 50-59 y 58 1.5 0.9 0.465 26 1.6 0.9 0.660 33 1.5 0.9 0.140 
 ≥ 60 y 88 1.4 0.7 0.682 47 1.4 0.7 0.596 42 1.5 0.8 0.979 
 
Values are reported as mean (SD), or #median (IQR) for log transformed variables. TC = Total cholesterol (mmol/L); LDL-C = LDL-cholesterol (mmol/L); HDL-C = HDL-cholesterol (mmol/L); TG = 
triglycerides (mmol/L). Age group: (y) = years. ¥P-value for comparison of migrant Australian Indians to a reference population to rural Indians in Andhra Pradesh, India (6).
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Table 4.8 – Biochemical characteristics (LDL:HDL ratio, glucose and plasma creatinine) by age group (≤ 39, 40-49, 50-59, ≥ 60 years) and sex in migrant 
Australian Indians. 
  Overall Males Females 
Variable Age group n Value Error ¥p-value n Value Error ¥p-value n Value Error ¥p-value 
LDL:HDL ≤ 39 y 84 2.12 0.87 <0.001 37 2.47 0.93 <0.001 47 1.85 0.72 <0.001 
 40-49 y 99 2.64 0.88 <0.001 58 2.79 0.88 <0.001 41 2.41 0.84 <0.001 
 50-59 y 58 2.36 0.67 <0.001 26 2.60 0.68 <0.001 33 2.17 0.62 <0.001 
 ≥ 60 y 88 2.14 0.75 <0.001 47 2.32 0.81 <0.001 42 1.94 0.63 <0.001 
Glucose# ≤ 39 y 84 4.5 0.9 <0.001 37 4.7 0.8 0.013 47 4.3 0.6 0.002 
 40-49 y 99 4.7 0.8 <0.001 58 5.0 0.7 <0.001 41 4.5 1.0 0.333 
 50-59 y 58 5.2 1.0 <0.001 26 5.2 0.9 <0.001 33 4.9 1.0 0.019 
 ≥ 60 y 88 5.2 1.3 <0.001 47 5.3 1.5 0.020 42 5.2 1.4 <0.001 
Creatinine ≤ 39 y 84 71.6 16.0 <0.001 37 86.0 10.4 <0.001 47 60.3 9.0 <0.001 
 40-49 y 99 74.0 12.4 <0.001 58 80.9 9.8 0.007 41 64.0 8.5 <0.001 
 50-59 y 58 71.1 13.4 0.005 26 82.8 9.6 0.022 33 61.8 7.5 0.002 
 ≥ 60 y 88 78.3 19.9 <0.001 47 88.4 21.9 <0.001 42 67.4 10.3 0.069 
 
Values are reported as mean (SD), or #median (IQR) for log transformed variables.  LDL:HDL = LDL-cholesterol:HDL-cholesterol ratio; Glucose (mmol/L); Creatinine (mmol/L). Age group: (y) = 
years. ¥P-value for comparison of migrant Australian Indians to a reference population to rural Indians in Andhra Pradesh, India (6). 
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Table 4.9 – Mean and maximum IMT by age group (≤ 39, 40-49, 50-59, ≥ 60 years) in migrant Australian Indians. 
 
  Overall Males Females 
Variable Age group n Median IQR ¥p-value n Median IQR ¥p-value n Median IQR ¥p-value 
Mean IMT ≤ 39 y 85 0.58 0.10 0.097 37 0.61 0.12 0.691 47 0.56 0.11 0.003 
 40-49 y 100 0.66 0.13 0.019 59 0.68 0.12 0.503 41 0.61 0.12 0.001 
 50-59 y 61 0.75 0.13 0.321 27 0.75 0.13 0.155 34 0.75 0.11 0.990 
 ≥ 60 y 94 0.86 0.24 0.477 49 0.87 0.23 0.391 45 0.84 0.18 0.854 
Max IMT ≤ 39 y 85 0.81 0.19 0.003 37 0.82 0.19 0.901 47 0.71 0.13 <0.001 
 40-49 y 100 0.91 0.23 0.008 59 0.88 0.19 0.291 41 0.83 0.16 0.001 
 50-59 y 61 1.00 0.2 0.438 27 1.01 0.24 0.325 34 0.96 0.23 0.890 
 ≥ 60 y 94 1.12 0.35 0.520 49 1.12 0.37 0.987 45 1.10 0.35 0.397 
 
Mean and maximum IMT were log transformed for statistical analyses. Values are reported as median and interquartile range (IQR); units (mm). Age group: (y) = year. ¥P-value for comparison 
of migrant Australian Indians to a reference population to rural Indians in Andhra Pradesh, India (6). 
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Figure 4.1 – Mean IMT by age group (≤ 39, 40-49, 50-59, ≥ 60 years) in migrant Australian 
Indians. 
Figure 4.2 – Maximum IMT by age group (≤ 39, 40-49, 50-59, ≥ 60 years) in migrant 
Australian Indians. 
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Figure 4.3 – Mean IMT by age group (≤ 39, 40-49, 50-59, ≥ 60 years) and sex in migrant 
Australian Indians. 
 
Figure 4.4 – Maximum IMT by age group (≤ 39, 40-49, 50-59, ≥ 60 years) and sex in migrant 
Australian Indians.  
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4.3.5 Association between carotid intima-media thickness and traditional CVD risk factors 
In migrant Australian-Indians, mean carotid IMT (Ln) was significantly associated with age, 
male sex, weight, BMI, waist and hip circumference, waist:hip ratio, SBP, DBP, PP, HDL-C, TG 
(Ln), fasting glucose (Ln), plasma creatinine, prior CVD, diabetes mellitus and hypertension 
(Table 4.10). The linear association between important traditional CVD risk factors and carotid 
IMT is shown in Figures 4.5-4.10. A reference population of rural Indians in Andhra Pradesh 
was used for comparison. Characteristics found to be significantly associated with carotid IMT 
in rural Indians has previously been published (6), and is summarised in brief in the discussion 
section of this Chapter. Testing for an interaction between population (i.e. migrant Australians 
Indians versus rural Indians) and characteristics found statistically significant interactions for 
TC (p<0.001), LDL-C (p<0.001), HDL-C (p<0.001), fasting glucose (Ln) (p=0.024) and plasma 
creatinine (p=0.004) and carotid IMT (Table 4.10). In our multivariable model, independent 
predictors of mean carotid IMT in migrant Australian-Indians included: age (β=0.047; 
p<0.001), male sex (β=-0.037, p=0.048), BMI (β=0.006; p=0.010), hypertension (β=0.078; 
p=0.001), and current or past smoking (β=0.054; p= 0.048) (Table 4.11).  
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Table 4.10 – Linear regression coefficients for the relation of mean carotid IMT and subject 
characteristics in migrant Australian Indians. 
Characteristic 
Migrant Australian 
Indians 
β (95% CI) 
 
¥p-value 
#p-value for 
interaction 
Age, 5-years 0.055 (0.049, 0.061) <0.001 0.892 
Height, m -0.002 (-0.005, 0.001) 0.144 0.296 
Weight, kg 0.003 (0.001, 0.005) 0.003 0.907 
BMI, kg/m2 0.015 (0.009, 0.021) <0.001 0.201 
Waist circumference, cm 0.007 (0.005, 0.009) <0.001 0.639 
Hip circumference, cm 0.006 (0.004, 0.009) <0.001 0.051 
Waist:hip ratio 0.562 (0.280, 0.843) <0.001 0.265 
SBP, mmHg 0.005 (0.004, 0.006) <0.001 0.701 
DBP, mmHg 0.004 (0.002, 0.007) <0.001 0.451 
Pulse pressure, mmHg 0.006 (0.004, 0.007) <0.001 0.136 
Total cholesterol, mmol/L -0.014 (-0.039, 0.011) 0.278 <0.001 
LDL-cholesterol, mmol/L -0.025 (-0.054, 0.005) 0.104 <0.001 
HDL-cholesterol, mmol/L -0.092 (-0.164, -0.020) 0.012 <0.001 
Ln TG , mmol/L 0.122 (0.068, 0.175) <0.001 0.597 
LDL/HDL ratio 0.003 (-0.027, 0.030 0.854 0.432 
Ln Glucose, mmol/L 0.063 (0.042, 0.085) <0.001 0.024 
Creatinine, μmol/L 0.002 (0.000, 0.003) 0.011 0.004 
Sex, male 0.057 (0.008, 0.160) 0.022 0.975 
Prior CVD 0.227 (0.120, 0.334) <0.001 0.654 
Diabetes mellitus 0.175 (0.109, 0.241) <0.001 0.610 
Hypertension 0.258 (0.208, 0.307) <0.001 0.271 
Past/present smoking 0.057 (-0.018, 0.132) 0.132 0.261 
 
β (change in Ln IMT, µm) per 1 unit of variable. ¥P-value for comparison to a reference population of N=303 rural 
Indians in Andhra Pradesh, India (6). #P-value for interaction (characteristic*population), comparing migrant 
Australian Indians and rural Indians. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood 
pressure; TG = triglycerides. 
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Figure 4.5 – Relationship between mean carotid IMT and a) age, b) weight and c) BMI in migrant Australian Indians. 
 
 
 
 
 
 
a)   b) c) 
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Figure 4.6 – Relationship between mean carotid IMT and a) waist circumference, b) waist:hip ratio and c) plasma creatinine in migrant Australian Indians. 
  
a) b) c) 
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Figure 4.7 – Relationship between mean carotid IMT and a) SBP, b) DBP and c) PP in migrant Australian Indians. 
 
 
 
 
 
 
  
a) b) c) 
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Figu  re 4.8 – Relationship between mean carotid IMT and a) TC, b) LDL-C and c) HDL-C in migrant Australian Indians. 
 
 
 
 
 
 
 
 
a) b) c) 
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Figure 4.9 – Relationship between mean carotid IMT and a) LDL-HDL ratio, b) Ln TG and c) Ln glucose in migrant Australian Indians. 
 
 
 
 
 
 
  
a) b) c) 
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Figure 4.10 – Mean carotid IMT according to clinical history: a) prior CVD, b) diabetes, c) hypertension and d) smoking status in migrant Australian Indians. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
c) d) 
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Table 4.11 – Multivariable regression coefficients for independent predictors of mean carotid IMT in 
migrant Australian Indians. 
 
Characteristic β (95% CI) p-value 
Age, 5-years 0.047 (0.040, 0.054) <0.001 
Sex, male -0.037 (-0.074, 0.000) 0.048 
BMI, kg/m2 0.006 (0.001, 0.011) 0.010 
Hypertension 0.078 (0.031, 0.125) 0.001 
Past or present smoking  0.054 (0.000, 0.108) 0.048 
 
 
Predictors in the model: age – 5 years, sex (male), prior CVD, diabetes mellitus, hypertension, smoking status, waist:hip ratio, 
BMI, LDL-C, HDL-C, TG (Ln), SBP, fasting glucose (Ln), creatinine. 
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4.4 Discussion 
When comparing migrant Australian Indians with a reference population of rural Indians living in Andhra 
Pradesh, India (6), there was no difference in carotid IMT, despite statistically significant differences in a 
number of traditional CVD risk factors between these two populations – including favourable changes in 
LDL-C, HDL-C, LDL:HDL ratio, and rates of tobacco smoking, and unfavourable changes in BMI, waist:hip 
ratio, SBP, DBP and PP, fasting glucose, plasma creatinine, TG, and the prevalence of diabetes and 
hypertension in migrant Australian Indians, compared with rural Indians. In our multivariable model age, 
male sex, BMI, hypertension and past or present tobacco smoking were independent predictors of mean 
carotid IMT in migrant Australian Indians, suggesting important associations between these traditional 
risk factors and subclinical vascular disease in South-Asian Indian migrants living in Australia.   
 
In this study, we reported traditional CVD risk factor levels in a convenience sample of South-Asian Indian 
migrants in Australia. Using a previously published reference population of rural Indians in Andhra 
Pradesh, India (6) for comparison, we found striking differences in numerous participant characteristics 
between these two populations. Migrant Australian Indians had a higher height (mean ± SD; 1.63 ± 0.09 
m, versus 1.56 ± 0.10 m; p<0.001), weight (67.5 ± 11.4 kg, versus 52.9 ± 12.4 kg; p<0.001), BMI (25.3 ± 3.8 
kg/m2, versus 21.6 ± 4.4 kg/m2; p<0.001), waist circumference (88.5 ± 10.9 cm, versus 80.0 ± 12.8 cm; 
p<0.001), hip circumference (100.8 ± 8.8 cm, versus 92.0 ± 10.4 cm; p<0.001), waist:hip ratio (0.88 ± 0.09, 
versus 0.85 ± 0.09; p<0.001), SBP (129 ± 19 mmHg, versus 120 ± 19 mmHg; p<0.001), DBP (76 ± 11 mmHg, 
versus 75 ± 11 mmHg; p=0.040), PP (53 ± 15 mmHg, versus 46 ± 15 mmHg; p<0.001), HDL-C (1.35 ± 0.34 
mmol/L, versus 0.87 ± 0.14 mmol/L; p<0.001), TG (median ± IQR; 1.30 ± 0.80 mmol/L; p=0.014), fasting 
glucose (median ± IQR; 4.8 ± 0.9 mmol/L, versus 4.1 ± 1.0 mmol/L; p<0.001), plasma creatinine (mean ± 
SD; 73.8 ± 16.5 µmol/L, versus 60.8 ± 15.1 µmol/L; p<0.001), and a higher proportion of participants with 
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diabetes mellitus (15.2%, versus 5.5%; p<0.001) and hypertension (24.9%, versus 18.2%; p=0.042) 
compared with rural Indians (6). By contrast, migrant Australian Indians had a lower LDL-C (mean ± SD; 
3.0 ± 0.8 mmol/L, versus 3.4 ± 0.9 mmol/L; p<0.001), LDL:HDL ratio (2.3 ± 0.8, versus 3.9 ± 1.1; p<0.001) 
and a lower rate of current tobacco smoking (3.8%, versus 22.6%; p<0.001). There was no difference in 
age (mean ± SD; 50.3 ± 14.8 years in migrant Indians, versus 50.3 ± 15.8 years in rural Indians; p=0.944); 
TC (5.0 ± 1.0 mmol/L, versus 4.9 ± 1.1 mmol/L; p=0.165) and the proportion of participants with a prior 
history of CVD (5.3 %, versus 5.5%; p=0.915); however, there was a higher proportion of males in the 
migrant Indian population (51% versus 43%; p=0.041), which may have introduced a potential bias 
towards higher mean anthropometric values and other traditional CVD risk factors in migrant Australian 
Indians.   
 
We have previously investigated associations between traditional CVD risk factors and carotid IMT in 
South-Asian Indians from rural Andhra Pradesh compared with Caucasians in Perth, Australia (6). In this 
study, we found higher levels of carotid IMT in rural Indians and, surprisingly, greater adverse effects of 
cholesterol and diabetes on carotid IMT, when compared with Caucasians, providing a potential 
explanation for the higher prevalence of CVD observed in South-Asian Indians compared with other ethnic 
groups, in migrant studies (73-76). The surprising finding no difference in carotid IMT in migrant 
Australian-Indians compared with rural Indians, despite multiple differences in CVD risk factors may be 
reflected by the complex interaction of these traditional risk factors and their association with carotid 
IMT. Indeed, we found both favourable and unfavourable changes in traditional CVD risk factor levels in 
migrants migrant Australian Indians.  
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In rural Indians, univariate analyses founds statistically significant linear associations between mean 
carotid IMT and age – 5 years (β=0.056; p<0.001), sex – male (β=0.059; p=0.041), weight (β=0.003; 
p=0.008), BMI (β=0.009; p=0.004), waist circumference (β=0.006; p<0.001), waist:hip ratio (β=0.786; 
p<0.001), SBP (β=0.006; p<0.001), DBP (β=0.003; p=0.024), PP (β=0.008; p<0.001), TC (β=0.074; p<0.001), 
LDL-C (β=0.065; p<0.001), HDL-C (β=0.354; p<0.001), TG (Ln) (β=0.142; p<0.001), fasting glucose (Ln) 
(β=0.031; p=0.001), creatinine (β=0.005; p<0.001), prior CVD (β=0.190; p=0.003), diabetes mellitus 
(β=0.211; p=0.001), hypertension (β=0.221; p<0.001) and past or present tobacco smoking (β=0.112; 
p<0.001) (6). Height (p=0.939), hip circumference (p=0.057), and LDL:HDL ratio (p=0.162) were found not 
to be linearly associated with carotid IMT in rural Indians (6). Characteristic with statistically significant 
linear associations with carotid IMT in migrant Australian Indians are listed in Table 4.10. 
 
While mean carotid IMT in migrant Australian Indians (median ± IQR; 0.69 ± 0.21 mm) and rural Indians 
(0.71 ± 0.25 mm) (6) were similar (p=0.111), there were a few notable differences in the strength of linear 
associations between traditional CVD risk factors and mean carotid IMT when testing for an interaction 
between study population and participant characteristics. In migrant Australian Indians, there was a 
stronger linear association between fasting glucose and mean carotid IMT (p-value for interaction=0.024). 
Similarly, in migrant Australian Indians there was a stronger linear association between plasma creatinine 
and carotid IMT (p-value for interaction=0.004). There was also a trend towards a stronger linear 
association between hip circumference and carotid IMT in migrant Australian Indians, compared with 
rural Indians, that failed to reach statistical significance at 2p<0.05 (p-value for interaction=0.051).  
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By contrast, there were opposite linear associations between HDL-C, TC, and LDL-C when comparing the 
two populations. In migrant Australian Indians, HDL-C had a statistically significant inverse linear 
association with mean carotid IMT (β= -0.092; p<0.012), while in rural Indians TC had a significant direct 
linear association with carotid IMT (β= +0.354; p<0.001) (p-value for interaction<0.001). While TC and LDL-
C were not significantly associated with mean carotid IMT in migrant Australian Indians in our univariate 
model, testing for an interaction between study population and TC and LDL-C revealed a statically 
significant difference in the association between these traditional CVD risk factors and carotid IMT:  i.e. in 
rural Indians, there was a direct linear association between carotid IMT and TC (p-value for 
interaction<0.001) and LDL-C (p-value for interaction<0.001), compared with a non-significant inverse 
association in migrant Australian Indians, suggesting potentially important differences in the susceptibility 
to lipoprotein levels in different populations of South-Asian Indians.  
 
Differences in HDL-C levels and its association with carotid IMT among different populations of South 
Asian-Indians may have important clinical consequences. We have previously reported a striking 
difference in HDL-C levels between rural Indians in Andhra Pradesh and Caucasians in Perth, Australia (6). 
Possible explanations for population-based differences in HDL-C levels may include differences in dietary 
fat intake, alcohol consumption, physical activity, cholesterol particle size and density, background levels 
of inflammation, genetic differences, and the effects of intrauterine malnutrition, which may persist into 
adulthood. Interestingly, our previous finding of a greater adverse effect of diabetes on carotid IMT in 
rural Indians compared with Caucasians in Australia (p-value for interaction=0.04) (6) was not observed 
in this study of migrant Australian Indians compared with rural Indians (p-value for interaction= 0.610). 
The reason for differences in the susceptibility of carotid IMT to diabetes among different populations but 
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it may be genetically determined, or influenced by a complex interplay between multiple traditional risk 
factors that were not apparent in this study. 
 
Our multivariable model identified age, male sex, BMI, hypertension and past or present tobacco smoking 
as independent predictors of mean carotid IMT in migrant Australian Indians (Table 4.11). In our previous 
study of rural Indians, independent predictors of mean carotid IMT included age (β=0.047; p<0.001), male 
sex (β=0.079; p=0.010), waist:hip ratio (β=0.324; p=0.010), diabetes mellitus (β=0.098; p=0.031), past or 
present tobacco smoking (β=0.056, p=0.039) and plasma creatinine (β=0.002; p=0.003) (6). [Predictors in 
this model included: age – 5 years, sex, prior CVD, diabetes mellitus, hypertension, tobacco smoking status 
– past or present, waist:hip ratio, BMI, LDL-C, HDL-C, TG (Ln), SBP, fasting glucose (Ln) and plasma 
creatinine]. Combined, this data suggests potentially important differences in the association between 
traditional CVD risk factors and carotid IMT (a marker of subclinical vascular disease), in different 
populations of South-Asian Indians.  
 
Several studies have shown differences in rates of CVD in migrants Indians. In the Singapore 
Cardiovascular Cohort Study, Indians had a higher mortality from ischaemic heart disease (IHD) compared 
with other ethnic groups (75). The age-standardised relative risk of IHD deaths for Indians versus Chinese 
was 3.8 and 3.4, for males and females, aged 30-69 years; and for Indians versus Malays the relative risk 
of IHD deaths was 1.9 and 1.6, for males and females. More adverse levels of traditional CVD risk factors 
were also shown in Indians this study: including higher rates of diabetes mellitus and lower a HDL-C level 
(78). In the Study of Health Assessment and Risk in Ethnic groups (SHARE) – a population-based study of 
3 ethnic groups in Canada: South Asian Indians, Chinese and Europeans – Indians had the highest 
prevalence of CVD, as well as an increased prevalence of glucose intolerance, TC, LDL-C, TG and lower 
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HDL-C, compared with other groups (73). In SHARE, Europeans had higher carotid IMT when compared 
with Asian Indians or Chinese, suggesting other factor may play a role in increased CVD mortality. 
 
A study by Whincup P.H. et.al., in 2002 compared cardiovascular risk factors in British children aged 8 to 
11 years, of South Asian Indian and European descent and found higher TG levels and a tendency towards 
insulin resistance and stronger relationship between adiposity and insulin concentration in Asians (79). 
This may implicate early exposure to risk factors in Indian migrants, later predisposing to early onset of 
atherosclerosis-related events. No comparative data has been available for a migrant Indian population 
In Australia until now.   
 
Woo K.S. et.al. have previously investigated the effects of “westernisation” on carotid IMT and 
associations with traditional cardiovascular risk factors in Chinese adults in rural Southern China, Hong 
Kong and Australia (80). In this study, urban Chinese in Hong Kong had a higher levels of HDL-C and lower 
BP compared with rural Chinese. Despite these findings, carotid IMT was lower in rural Chinese compared 
with the other groups. The effects of cigarette smoking, HDL-C and TG on carotid IMT were greater in 
urban Chinese compared with rural Chinese, suggesting “westernisation” in this population is associated 
with an increase in the extent of subclinical vascular disease. Differences in diet were thought to play a 
role in higher carotid IMT in this study. The consumption of green tea rich in antioxidants (flavonoids), 
vegetables and fish are associated with a lower intake of saturated fat, and higher levels of soy protein, 
and may have contributed to the observed differences in lipoproteins levels. Similar to the CATHAY study, 
we did not collected dietary information apart from how often subjects consumed fresh fruits and 
vegetables. Thus, a role of diet in promoting differences in HDL-C remains speculative. 
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Limitations 
There were a number of limitations to this study. First, this was a cross-sectional study of two populations, 
living in different countries. Due to the cross-sectional nature of the study, it was not possible to 
investigate incidence of risk factors for CVD, or disease events. The APRHI study of subjects in rural Andhra 
Pradesh had a different team of investigators. While methods used by both teams were standardised, 
there remains some potential for systematic measurement error and reporting bias as a result of this 
approach. Methods for the handing and preparation of biochemical samples were similar in both counties, 
including storage (on ice) and time to sample processing (i.e. within 6 hours). Biochemical analyses, 
however, were conducted by different methods (described in section 4.2.3). While regional differences in 
methods of biochemical processing were unavoidable, quality control and standardisation was ensured 
by concurrently running quality assurance materials with study samples, as recommended by the Royal 
College of Pathologists, Australia, quality control program.  
 
Second, different sonographers performed ultrasound scans for the assessment of carotid IMT in India 
and Australia. Furthermore, all ultrasound scans in India were obtained with a portable, laptop-based 
ultrasound (i.e. Teratek Terason 3000; described in chapter 3), whereas ultrasound scans were obtained 
using the Teratatek Terason 3000, if performed outside of a clinic-type environment – e.g. in suburban 
medical centres and community halls – and with the Philips ATL 5000, if performed with the research clinic 
at the Royal Prince Alfred Hospital, Camperdown. In chapter 3, we conducted an inter-machine validation 
study comparing the Philips ATL 5000 and the Teratek Terason 3000 ultrasound machines, and found good 
agreement for IMT measurements when comparing machine types; thus, there was minimal bias 
introduced when using a particular machine type. The potential for measurement error for IMT 
measurements, using different machine types, was reduced by adopting a standardised methodological 
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approach to carotid IMT scanning (as described in chapter 2). Furthermore, a single, experienced observer 
performed all IMT measurements (for both populations), and was blinded to the identity of the subjects.  
 
Third, subjects in rural India and Australia were recruited by different methods, potentially leading to 
selection bias. The Govidari distict in rural Andhra Pradesh was chosen as the site for the cross-sectional 
study in India, due to the availability of recent census data. This allowed for a selection of a representative 
sample of people in the area, stratified according to age and sex. By contrast, subjects in Australia were 
recruited by advertising materials displayed local festivals, community centres, medical centres, 
announcements on community radio and by work-of-mouth. Thus, migrant Indians within Australia 
recruited to participate were not selected by random. Members of the same family were often studied, 
as well as family friends potentially from the same socioeconomic background. This was unavoidable due 
to the limited target population size, within Sydney, Australia.  
 
Fourth, there was a difference in the proportion of males and females when comparing populations, 
potentially confounding the study results. To explore any potential sex bias, we examined the association 
of traditional risk factors with carotid IMT for males and females, separately. The reason for the inclusion 
of higher numbers of females in the rural Indian population are not know, but may relate to higher 
numbers of females reported on the census in the Godvari district.  
 
Finally, several characteristics relating to clinical history were obtained by self-report – e.g. a prior history 
of CVD, hypertension, diabetes mellitus, and cigarette smoking status. In the design of the medical history 
questionnaire, considerable effort was taken to ensure accuracy language and translation from English 
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into Telugu (the local language) and back-translation into English, to resolve issues with understanding 
(6,81). There was a potential for under-reporting an accurate medical history in rural India, due to limited 
medical knowledge, difficulties with accessing medical services for a diagnosis to be established. Subjects 
were given an opportunity to discuss the meaning of any questions on the questionnaire, prior to leaving. 
Given the likelihood of fewer encounters for ‘preventative’ health with health care workers, in rural India, 
likely further increased by a decline in socio-economic status, some bias in reporting medical histories was 
expected. Some data has been collected on combined household income, level of education, occupation 
and household expenditure on healthcare and medications, in both cohorts; thus, an analysis on the effect 
of socio-economic status on health encounters and accuracy of a self-reported medical history, using the 
limited physical examination and investigations conducted, might be possible.   
 
4.5  Conclusion 
When comparing migrant Australian Indians and rural Indians in Andhra Pradesh, there was no difference 
in carotid IMT suggesting the dietary and other lifestyle influences of ‘westernisation’ had no measurable 
effect on subclinical vascular disease in South-Asian Indians migrants in Australia. By contrast, 
‘westernisation’ appeared to have a profound effect on multiple traditional CVD risk levels in migrant 
Australian Indians compared with rural Indians, including favourable changes in LDL-C, HDL-C, LDL:HDL 
ratio, and rates of tobacco smoking, and unfavourable changes in BMI, waist:hip ratio, SBP, DBP, PP, 
fasting glucose, plasma creatinine, TG, and the prevalence of diabetes mellitus and hypertension. There 
were important differences in the strength of association between carotid IMT and fasting glucose, plasma 
creatinine, HDL-C, TC and LDL-C when comparing populations. While age, male sex and past or present 
tobacco smoking were independent predictors of carotid IMT in both populations, BMI and hypertension 
were also independent predictors of carotid IMT in migrant Australian Indians but not in rural Indians; and 
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waist:hip ratio, plasma creatinine and diabetes mellitus were independent predictors of carotid IMT in 
rural Indians but not in migrant Australian Indians. These population-based differences in susceptibility to 
traditional CVD risk factors suggest potentially important differences in therapeutic targets in the primary 
and secondary prevention of CVD. Further population surveillance is required to determine the prevalence 
and incidence of traditional CVD risks factors and their impact on CVD events, mortality and morbidity, in 
different populations of South-Asian Indians. In addition, studies exploring the effectiveness of strategies 
targeting these risk factors, and appropriate therapeutic targets, are required.  
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CHAPTER 5:  
 
Correlation Between Novel Measures of Arterial Structure and Function and 
Traditional Cardiovascular Risk Factors in Children Aged 8 years: CardioCAPS 
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5.1 Introduction 
Clinical manifestations of CVD in childhood and adolescence are exceedingly uncommon; however, there 
is substantial evidence to support claims that the origins of atherosclerosis are in childhood. The Bogalusa 
Heart Study (83) and the Pathobiological Determinants of Atherosclerosis in Young (PDAY) study (84) have 
both established the extent of atherosclerosis in children and adolescents at autopsy. These studies have 
shown that as the number of risk factors for CVD increase, there is a commensurate increase in aortic and 
coronary atherosclerosis. 
 
More recently, a number of studies have identified early life events (or exposures) that appear to be 
associated with an increased arterial wall thickness, suggesting an acceleration in mechanisms promoting 
premature subclinical vascular disease, with possible consequences on CVD risk later in life. As examples, 
intrauterine growth restriction has been shown to be associated with increased aortic IMT in newborns 
(85), and impaired fetal growth and pre-birth (< 37 weeks gestation) have been shown to increase carotid 
IMT in young adults (86). Similarly, we have shown that early weight gain from birth to 18 months of age 
is associated with a greater carotid artery wall thickness (87).  
 
Despite these studies, there is a general lack of understanding of the effects of traditional CVD risk factors 
on various measures of subclinical vascular disease in early childhood. We have previously explored the 
association between CVD risk factors and mean carotid IMT in a cohort of 403 children, aged 8 years (88), 
in a cardiovascular substudy of the Childhood Asthma Prevention Study (CAPS). In this chapter, novel 
aspects of arterial function and structure in this group of community-based children are presented, 
including an assessment of mean:max carotid IMT, difference in maximum and mean carotid IMT, and 
minimum:mean carotid IMT (as markers of ‘heterogeneity’ in the intima-medial thickness), and radial and 
 157 
 
carotid augmentation index, pulse wave velocity, carotid artery distensibility, and carotid extra-medial 
thickness. The interrelation between these novel measures of arterial function and structure and 
traditional CVD risk factors in 8 year old children is also explored. In addition, we aimed to document the 
normal range of values of these novel vascular parameters in healthy community-based children.  
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5.2 Methods 
5.2.1 Subjects and study design 
The subjects enrolled in this study were healthy 8-year old children from the Western and South-Western 
areas of Sydney, Australia. They were enrolled prior to birth into the Childhood Asthma Prevention Study 
(CAPS), a randomised controlled trial exploring two interventions (tested in a 2x2 factorial design): i) a 
dietary intervention of omega-3-fatty acid (‘active’) versus polyunsaturated fatty acid (‘control’) 
supplementation, from birth to 5 years of age; and ii) a house dust mite avoidance intervention of active 
avoidance versus no avoidance. Recruitment was targeted at pregnant women whose unborn children 
had at least one parent or sibling with current asthma or wheezing. Exclusion criteria included babies from 
multiple births, gestational age of less than 36 weeks, hospitalisation of more than 1 week, or serious 
illness.  Details of CAPS subjects and study design, including a detailed description of the two interventions 
and methods of randomisation and blinding, has been published (89,90). 
 
616 subjects were initially enrolled to participate in CAPS between September 1997 and December 1999. 
Children were followed-up at 18 months, 3 years, 5 years and 8 years of age. At 8 years, families were 
invited to participate in the study presented in this chapter, examining childhood determinants of 
cardiovascular disease: CardioCAPS. 410 (67%) children and their legal guardians provided consent and 
attended testing for the cardiovascular study: 5 subjects were excluded (2 with a diagnosis of T1DM, 2 
who consented but did not wish to complete the cardiovascular testing, and 1 outside of the pre-specified 
age range of 8.0 ± 0.5 years at the time of the 8-year testing schedule). Thus, 405 children (aged 8.0 ± 0.1 
years; 51% male) were included in this analysis. These children were representative of the initial cohort, 
and were shown to have similar birth weight, gestational age, and proportions of males and females. A 
similar number of males and females received omega-3-fatty acid supplementation (‘active diet’) and this 
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did not influence the measures of arterial function or structure. This study was approved by the Human 
Research Ethics Committees of the University of Sydney, the Children’s Hospital at Westmead, Liverpool 
Hospital, and the Western and South Western Area Health Services, in New South Wales, Australia. 
Parents (or guardians) provided written informed consent on behalf of their children.  
 
5.2.2 Carotid intima-media thickness assessment 
Methods used for the assessment of carotid IMT have been described in Chapter 2. Carotid artery 
ultrasound scans were obtained using the Teratek Terason 3000, portable, laptop-based ultrasound 
machine, previously validated in Chapter 3. Mean carotid IMT was measured as the average of accepted 
single point-to-point measurements (described in section 2.2.3 – IMT analysis). Maximum and minimum 
IMT were calculated as the maximum and minimum of the accepted single point-to-point measurements, 
respectively. These values were used to calculate the novel measures of IMT, including maximum:mean 
carotid IMT ratio (i.e. maximum IMT / mean IMT) , the difference in maximum and minimum carotid IMT 
(i.e. maximum IMT – minimum IMT) and the minimum:mean IMT ratio (i.e. minimum IMT / mean IMT). 
Carotid artery ultrasound scans were performed immediately prior to the measurement of carotid and 
radial artery tonometry. 
 
5.2.3  Carotid and radial pulse waveform analysis 
Left carotid and radial artery pressure waveforms were obtained non-invasively by high-fidelity 
applanation tonometry, using an SPC-301 non-invasive tonometer (Millar Instruments, Houston, Texas, 
USA) and SphygmoCor Version 7.1 pulse wave analysis system (AtCor Medical, Itasca, Illinois, USA). 
Methods used for the assessment of pulse waveform analysis have previously been published (91,92). In 
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brief, 10 seconds of artery pulse waveforms were continuously recorded at each site and an ensemble-
averaged waveform was generated. This waveform was calibrated to the mean and diastolic BP. Multiple 
recordings were taken until representative waveforms were obtained. Satisfactory radial artery 
waveforms were available in 386 participants (19 were excluded as they were technically unsatisfactory). 
Carotid artery waveform analysis was introduced to the study protocol after commencement of the study, 
and 269 participants had satisfactory carotid artery waveforms available (6 were excluded as they were 
technically unsatisfactory). Augmentation index (AIx) in this study was corrected to a heart rate of 75 bpm 
(i.e. AIx75), as variability in heart rate has been shown to affect augmentation index in adults (93).   
 
 
5.2.4  Carotid–radial pulse wave velocity 
Methods used for the assessment of carotid-radial pulse wave velocity (PWVcar-rad) have previously been 
published (91,92). PWVcar-rad was determined from sequentially measured ECG-gated left carotid and 
radial artery waveforms (described above), using the foot-to-foot method to calculate pulse travel time. 
The pulse travel distance (i.e. the estimated distance from carotid to the radial artery) was determined by 
measuring the distance between the suprasternal notch and each recording site, using a tape measure 
over the body surface.  Measurements were performed in duplicate and reported in cm. The mean PWVcar-
rad from multiple representative waveforms artery pulse waveforms (described above) was used in this 
analysis.  
 
5.2.5  Carotid artery distensibility 
Methods for the assessment of carotid artery distensibility have previously been published (91,92). In 
brief, the best quality 5 second carotid artery ultrasound scans of the left common carotid artery 
(described above – section 5.2.2 – Carotid intima-media thickness) were used. The carotid artery diameter 
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was measured 1 cm proximal to the edge of the carotid bulb in end-systole and end-diastole. 
Measurements were for 3 consecutive cardiac cycles, and the mean values obtained were used in this 
analysis. Satisfactory images were obtained in 390 participants (15 were excluded as they were technically 
unsatisfactory). The measured carotid artery diameters and derived carotid pulse pressure (PP) (91) were 
used to calculate carotid artery distensibility ([end-systolic diameter – end-diastolic diameter] / carotid 
PP), expressed as a percentage per 10 mmHg of change in BP.  
 
5.2.6  Carotid extra-medial thickness 
Methods used for the assessment of carotid extra-medial thickness (EMT) have previously been published 
(94,95). In brief, the distance from the carotid media-adventitia interface to the jugular-lumen interface 
was measured with semi-automated software (MATH SR Version 2.0, Metris, France), using carotid artery 
ultrasound images collected for the assessment of carotid IMT (described in section 5.2.2). Measurements 
were taken 1.0-1.5 cm proximal to the carotid bulb, at end-diastole from 2 cardiac cycles. The average of 
2 measurements was used in this analysis. Carotid EMT was measured in the left common carotid artery 
in 364 participants and in the right common carotid artery in 323 participants, resulting in satisfactory 
images in 389 participants. Inter- and intra-observer variability for the assessment of carotid EMT has 
been described elsewhere (95).  
 
5.2.7 Anthropometry, blood pressure and medical history 
Height was measured to the nearest 0.5 cm and weight measured to the nearest 0.1 kg using a portable 
stadiometer and calibrated electronic scales. BMI was calculated as weight (kg)/height (m)2. Waist and hip 
circumference were measured at end-expiration. Anthropometry was routinely assessed by the same two 
investigators rehearsed in methods for accurately obtaining height, weight, waist and hip circumferences. 
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BP was measured from the brachial artery using an oscillometric blood pressure monitor (Welch Allyn 
Vital Signs). BP readings were routinely taken in the left arm after lying supine for 10 minutes. Repeated 
BP measurements were obtained 10-20 minutes later. If there was a variance of ≥ 10 mmHg between the 
two BP readings, a third BP was measured and the average of the two closest readings was included in 
the final analyses.  
 
Recent medical histories were collected from the parents of children at the time of vascular testing. A 
parental history cardiovascular disease, diabetes mellitus, hypertension or hypercholesterolaemia was 
taken. Family histories were usually obtained from the mother or father, but in a few cases the history 
was reported by a grandparent. If questions were not answerable at the time of testing, a follow-up 
interview was arranged during a home visit. An extensive medical history had been collected for study 
participants, from birth to 8 years of age. 
 
5.2.8 Blood sampling and biochemical analysis 
Non-fasting venous blood samples were obtained in 328 children (81%): the main reason for declining 
venepuncture was fear of needles. Plasma and serum samples were stored at -20 °C (or -80 °C for the 
assessment of apolipoprotein, bilirubin and asymmetric dimethylarginine; ADMA) until analysis. TC, HDL-
C and TG were measured using standard enzymatic procedures. High-sensitivity c-reactive protein (CRP) 
was measured using an immunoturbidometric method. Non-HDL-C (i.e. TC minus HDL-C) was estimated 
from non-fasting samples. Apolipoprotein (ApoB) and apolipoprotein A1 (ApoA1) were measured by 
immunoturbidimetry. Bilirubin was assessed by colourimetric assay.  ADMA was measured by enzyme-
linked immunosorbent assay (ELISA). 
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5.2.9 Statistics 
Characteristics were expressed as count (and percentages) for categorical variables, and mean (SD) or 
median (IQR) for normally distributed and non-normally distributed variables, respectively. TG, bilirubin, 
hs-CRP, maximum:mean carotid IMT ratio and difference in maximum and mean carotid IMT were 
positively skewed and log transformed (Ln) for analyses. Minimum:mean IMT ratio was negatively skewed 
and was reflected by subtraction of the original value from a constant, 1.95 (i.e. 1 + the maximum value 
of the variable in the dataset) and Ln transformed prior to analysis. Groups were compared by 
independent samples t tests or chi-squared tests. A two-tailed p-value < 0.05 was considered significant. 
Associations between subject characteristics and various measures of carotid IMT and other measures of 
arterial function and structure were assessed by univariate linear regression. Independent predictors of 
the different measures of arterial function and structure were assessed in separate multivariable models 
for each measure, using backward stepwise linear regression. Variables were entered into the model 
where p<0.100 (shown by linear regression), excluding related variables. Beta coefficients (β) and p-values 
are shown. All statistical analyses were performed using SPSS (version 22.0). 
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5.3 Results 
5.3.1 Novel measures of arterial structure and function in children aged 8 years 
Maximum:mean carotid IMT ratio was 1.29 ± 0.10 (median ± IQR), difference in maximum and minimum 
carotid IMT was 0.27 ± 0.10 mm, and minimum:mean carotid IMT ratio was 0.84 ± 0.04 (Table 5.1). There 
was no difference in these measures of carotid IMT when comparing males and female subjects (Table 
5.1). Radial AIx75 was -39 ± 11 % (mean ± SD), carotid AIx75 was -12 ± 9 % and PWVcar-rad was 6.7 ± 1.1 
m/s (Table 5.2). Carotid artery distensibility was 6.0 ± 1.7 % per 10 mmHg. Mean carotid EMT was 0.73 ± 
0.08 mm and maximum carotid EMT was 0.80 ± 0.09 mm. When comparing subjects by sex, radial AIx75 
was higher in females (mean ± SD; -37 ± 10 %) vs (-41 ± 12 %) (p=0.003), as was carotid AIx75 (9 ± 8 % vs 
-14 ± 9 %) (p<0.001), and carotid artery distensibility (6.2 ± 1.8 % per 10 mmHg vs 5.8 ± 1.5 % per 10 
mmHg) (p=0.011). By contrast, mean carotid EMT was higher in males (0.74 ± 0.09) vs females (0.71 ± 0.08 
mm) (p=0.001), and similarly maximum carotid EMT was higher in males (0.81 ± 0.09) vs females (0.70 ± 
0.08) (p=0.002). When comparing subjects by sex, there was no difference in PWVcar-rad (p=0.983) (Table 
5.2).  
 
5.3.2 Association between markers of heterogeneity in carotid IMT and traditional CVD risk factors 
Maximum:mean carotid IMT ratio (Ln) was associated with birth weight and length, TC, non-HDL-C, TG 
(Ln), and ADMA (Ln) (Table 5.3; Figures 5.3-5.4). In the multivariable model, birth length (β=0.003; 
p=0.018), TG (Ln) (β=0.011; p=0.018) and ADMA (Ln) (β=-0.151; p=0.004) were independent predictors of 
maximum:mean carotid IMT ratio (Ln). Difference in maximum and minimum carotid IMT was associated 
with birth weight and length, TC and ADMA (Ln) (Table 5.3; Figure 5.5). In the multivariable model, birth 
length (β=0.012; p=0.008), TC (β=0.033; p=0.043) and ADMA (Ln) (β=-0.151; p=0.004) were independent 
predictors of difference in maximum and minimum carotid IMT (Table 5.6). Minimum:mean carotid IMT 
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ratio was shown to be associated with height, TC, HDL-C and ApoA1 (Table 5.3; Figure 5.6); however, in 
the multivariable model only height (β=-0.081; p=0.014) and HDL-C (β=0.013; p=0.007) were independent 
predictors of minimum:mean carotid IMT ratio (Table 5.7).   
 
5.3.3 Association between other measures of arterial structure and function and traditional CVD risk 
factors 
 
Radial AIx75 was associated with sex (male), height, weight, BMI, waist circumference, waist:hip ratio, 
SBP, DBP, heart rate, birth weight, birth length, breast feeding at 6 months and ApoB (Table 5.8). In the 
multivariable model, sex (male) (β=3.363; p=0.004), height (β=-62.258; p<0.001), BMI (β=-0.587; 
p=0.005), heart rate (β=0.140; p=0.021) and ADMA (Ln) (β=-5.306; p=0.035) were independent predictors 
or radial AIx75 (Table 5.10). PWVcar-rad was associated with DBP (Table 5.8); however, none of the 
characteristics included in our multivariable model were shown to be independent predictors of PWVcar-
rad (Table 5.11).   
 
Carotid artery distensibility was associated with sex (male), SBP and DBP (Table 5.8). In our multivariable 
model, sex (male) (β=0.483; p=0.003), SBP (β=-0.075; p<0.001), and heart rate (β=-0.019; p=0.023) were 
independent predictors of carotid artery distensibility (Table 5.12). Mean carotid EMT was associated with 
sex (male), height, weight, BMI, waist circumference, SBP, DBP and head circumference (Table 5.9). In the 
multivariable model, sex (male) (β=-0.025; p=0.003), height (β=0.219; p=0.003) and SBP (β=-0.075; 
p<0.001) were independent predictors of mean carotid EMT (Table 5.13). Maximum carotid EMT was 
associated with sex (male), height, weight, BMI, SBP, DBP and head circumference (Table 5.9). Similar to 
mean carotid EMT, sex (male) (β=-0.025; p=0.004), height (β=0.206; p=0.008) and SBP (β=0.001; p=0.075) 
were independent predictors of maximum carotid IMT (Table 5.14).  
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5.3.4 Interrelation between carotid IMT and other measures of arterial structure and function 
There was a statistically significant positive linear association between mean carotid IMT and mean and 
maximum carotid EMT (Table 5.9); however, none of the other measures of vascular function or structure 
included in this study (including radial AIx75, carotid AIx75, PWVcar-rad and carotid artery distensibility) 
were associated with mean carotid IMT (Tables 5.8 and 5.9). Similarly, maximum and minimum carotid 
IMT were found to be positively associated with mean and maximum carotid EMT. The remaining 
measures of carotid IMT explored in this chapter (i.e. maximum:mean carotid IMT ratio, difference in 
maximum and minimum carotid IMT and minimum:mean carotid IMT ratio) were not associated with 
mean or maximum carotid IMT (Table 5.9), or any other the other measures of vascular function or 
structure (Tables 5.8 and 5.9).  
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Table 5.1 – Carotid artery intima-media thickness in children aged 8 years. 
Characteristic 
Total Cohort 
(N=405) 
Males 
(N=207) 
Females 
(N=198) ¥p-value 
Mean IMT (mm) 0.59 (0.06) 0.60 (0.07) 0.59 (0.06) 0.272 
Maximum IMT (mm) 0.77 (0.08)  0.77 (0.08) 0.76 (0.08) 0.352 
Minimum IMT (mm) 0.49 (0.06) 0.50 (0.06) 0.49 (0.06) 0.331 
Maximum:mean IMT ratio# [median (IQR)] 1.29 (0.10) 1.29 (0.10) 1.29 (0.10) 0.782 
Maximum-minimum IMT# (mm) [median (IQR)] 0.27 (0.07) 0.27 (0.07) 0.27 (0.06) 0.551 
Minimum:mean IMT ratioγ [median (IQR)] 0.84 (0.04) 0.84 (0.05) 0.84 (0.04) 0.763 
 
Characteristics are expressed as mean (SD), or median (IQR) where indicated. #Ln transformed prior to statistical analyses. 
γReflected (i.e. 1.96 minus the original value) and Ln transformed prior to statistical analyses. ¥P-value for comparison of 
characteristics by sex. 
 
 
 
Table 5.2 – Other measures of arterial function and structure in children aged 8 years.  
Characteristic Total Cohort Males Females ¥p-value 
Radial AIx75 (%) -39 (11) -41 (12) -37 (10) 0.003 
Carotid AIx75 (%) -12 (9) -14 (9) -9 (8) <0.001 
PWVcar-rad (m/s) 6.7 (1.1) 6.7 (1.1) 6.7 (1.1) 0.983 
Carotid artery disensibility (% per 10 mmHg)  6.0 (1.7) 5.8 (1.5) 6.2 (1.8) 0.011 
Mean carotid EMT (mm) 0.73 (0.08) 0.74 (0.09) 0.71 (0.08) 0.001 
Maximum carotid EMT (mm) 0.80 (0.09) 0.81 (0.09) 0.79 (0.08) 0.002 
 
Characteristics are expressed as mean ± SD. ¥P-value for comparison of characteristics by sex. AIx75 = augmentation index 
corrected to a heart rate of 75 beats per minute. PWVcar-rad = pulse wave velocity (carotid-to-radial). EMT = extra-medial 
thickness.   
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Table 5.3 – Univariate regression analysis for minimum carotid IMT, maximum:mean IMT ratio, 
minimum:mean IMT ratioγ, and difference in maximum-mean IMT in children aged 8 years .  
 
Maximum:mean 
IMT ratio# 
Difference in max 
and min IMT# 
Minimum:mean IMT  
ratioγ 
Characteristics β p-value β p-value β p-value 
Sex (male) 0.002 0.782 0.012 0.551 0.001 0.763 
Height (m) -0.049 0.336 -0.257 0.135 -0.071 0.009 
Weight (kg) 0.000 0.620 0.001 0.730 0.000 0.451 
Body-mass index (kg/m2) 0.001 0.292 0.004 0.266 0.000 0.802 
Waist circumference (cm) 0.000 0.847 -0.001 0.689 0.000 0.329 
Waist-to-hip ratio 0.033 0.580 0.059 0.770 -0.006 0.857 
Systolic BP (mmHg) -0.001 0.133 -0.002 0.100 0.000 0.237 
Diastolic BP (mmHg) 0.001 0.204 0.002 0.374 0.000 0.531 
Heart rate, (bpm) 0.000 0.420 0.001 0.279 0.000 0.546 
Birth weight (kg) 0.014 0.020 0.053 0.009 0.005 0.153 
Birth length (cm) 0.002 0.049 0.010 0.016 0.001 0.160 
Head circumference (cm) 0.003 0.163 0.009 0.193 0.000 0.670 
Gestational age (weeks) 0.002 0.481 0.001 0.907 -0.001 0.294 
Breast Feeding at 6 months -0.014 0.462 0.005 0.820 0.003 0.428 
Gestational diabetes 0.011 0.357 0.031 0.456 0.000 0.962 
Pre-eclampsia 0.020 0.353 0.012 0.864 -0.018 0.121 
Hypertension in pregnancy 0.006 0.649 0.013 0.756 -0.002 0.762 
Smoking in pregnancy 0.004 0.527 0.017 0.462 0.004 0.348 
Total cholesterol (mmol/L) 0.010 0.047 0.040 0.015 0.006 0.016 
HDL-C (mmol/L) -0.001 0.934 0.028 0.362 0.014 0.007 
Non-HDL-C (mmol/L) 0.010 0.048 0.031 0.060 0.002 0.355 
Triglycerides (Ln, mmol/L) 0.017 0.021 0.029 0.065 0.001 0.783 
ApoA1 (g/L) 0.002 0.905 0.051 0.331 0.024 0.006 
ApoB (g/L) 0.022 0.326 0.080 0.292 0.004 0.760 
ADMA (Ln, µmol/L) -0.049 0.001 -0.156 0.002 0.131 0.131 
Parent with CVD -0.007 0.668 -0.012 0.830 0.865 0.865 
 
β = change per 1 unit of variable. #Ln transformed. γReflected (i.e. 1.96 minus the original value) and Ln transformed prior to 
statistical analyses. 
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Figure 5.1 – Relationship between maximum:mean carotid IMT ratio# and a) TC, b) non-HDL-C  and c) TG#  in children aged 8 years.  
 
 
 
 
 
 
 
 
#Ln transformed. 
 
a) b) c) 
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Figure 5.2 – Relationship between maximum:mean carotid IMT ratio# and a) birth weight, b) birth length and c) ADMA# in children aged 8 years. 
 
 
 
 
 
 
 
 
 
#Ln transformed.  
a) b) c) 
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Figure 5.3 – Relationship between difference in maximum and minimum carotid IMT# and a) TC, b) ADMA#, c) birth weight and d) birth length in 
children aged 8 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
c) d) 
#Ln Transformed. 
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Figure 5.4 – Relationship between minimum:mean carotid IMT ratioγ and a) height, b) TC, c), HDL-C and d) ApoA1 in children aged 8 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
c) d) 
#Reflected (i.e. 1.96 
minus original value) and 
Ln Transformed. 
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Table 5.4 – Multivariate regression analysis of maximum:mean carotid IMT ratio# in children aged 8 years. 
 
Characteristics β p-value 
Birth length (cm) 0.003 0.018 
TG (Ln, mmol/L) 0.011 0.018 
ADMA (µmol/L) -0.050 0.001 
 
Adjusted r2 = 0.067; Variables excluded by backward stepwise method: birth weight (p=0.582) and TC (p=0.969). β-coefficient 
represents the change per 1 unit change in the explanatory variable. #Ln transformed. 
 
 
 
 
 
Table 5.5 – Multivariate regression analysis of difference in maximum and minimum carotid IMT# children 
aged 8 years. 
 
Characteristics β p-value 
SBP (mmHg) -0.003 0.098 
Birth length (cm) 0.012 0.008 
TC (mmol/L) 0.033 0.043 
ADMA (µmol/L) -0.151 0.004 
 
Adjusted r2 = 0.063; Variables excluded by backward stepwise method: birth weight (p=0.578), TG (Ln) (p=0.974) and Non-HDL-C 
(p=0.261). ß-coefficient represents the change per 1 unit change in the explanatory variable. #Ln transformed. 
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Table 5.6 – Multivariate regression analysis of minimum:mean carotid IMTγ ratio in children aged 8 years. 
 
Characteristics β p-value 
Height (m) -0.081 0.014 
HDL-C (mmol/L) 0.013 0.007 
 
Adjusted r2 = 0.035; Variables excluded by backward stepwise method: TC (p=0.930). ß-coefficient represents the change in mean 
IMT in mm per 1 unit change in the explanatory variable. γReflected (i.e. 1.96 minus the original value) and Ln transformed. 
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Table 5.7 – Univariate regression analysis for Radial AIx75, Carotid AIx75, PWVb and carotid artery 
distensibility in children aged 8 years.  
 
Radial AIx75 
(%) 
Carotid AIx75 
 (%) 
PWVcar-rad  
(m/s) 
Carotid artery 
distensibility  
(% per 10 mmHg) 
Characteristics β p-value β p-value β p-value Β p-value 
Sex (male) 3.307 0.003 5.396 <0.001 0.003 0.983 0.437 0.011 
Height (m) -79.71 <0.001 -37.570 <0.001 -1.180 0.303 0.432 0.774 
Weight (kg) -0.644 <0.001 -0.308 <0.001 -0.015 0.133 -0.005 0.693 
Body-mass index (kg/m2) -1.018 <0.001 -0.454 0.013 -0.033 0.131 -0.019 0.508 
Waist circumference (cm) -0.449 <0.001 -0.210 0.005 -0.014 0.112 -0.002 0.846 
Waist-to-hip ratio -24.344 <0.001 -5.450 0.623 0.465 0.731 1.899 0.285 
Systolic BP (mmHg) -0.359 <0.001 -0.063 0.436 0.012 0.237 -0.071 <0.001 
Diastolic BP (mmHg) 0.223 <0.001 0.412 <0.001 0.030 0.015 0.034 0.029 
Heart rate, (bpm) 0.244 <0.001 0.144 0.010 0.004 0.561 -0.016 0.064 
Birth weight (kg) -4.788 <0.001 -3.895 <0.001 -0.123 0.367 -0.169 0.345 
Birth length (cm) -0.514 0.031 -0.451 0.046 -0.038 0.170 -0.054 0.137 
Head circumference (cm) -0.508 0.196 -1.006 0.005 -0.062 0.158 -0.038 0.510 
Gestational age (weeks) 0.274 0.540 0.180 0.695 -0.023 0.690 -0.007 0.916 
Breast Feeding at 6 months -2.53 0.027 -1.950 0.077 -0.265 0.050 0.025 0.885 
Gestational diabetes 1.413 0.563 -2.498 0.321 -0.510 0.103 0.396 0.276 
Pre-eclampsia 0.841 0.843 -0.044 0.993 0.581 0.296 0.303 0.663 
Hypertension in pregnancy 1.126 0.652 1.154 0.624 0.096 0.734 0.078 0.838 
Smoking in pregnancy -0.252 0.854 0.323 0.795 0.190 0.212 -0.339 0.103 
Total cholesterol (mmol/L) 1.569 0.085 0.504 0.564 0.168 0.098 0.008 0.952 
HDL-C (mmol/L) -0.239 0.888 0.289 0.867 0.190 0.340 0.067 0.794 
Non-HDL-C (mmol/L) 1.737 0.056 0.453 0.593 0.117 0.240 -0.014 0.920 
Triglycerides (Ln, mmol/L) 1.424 0.294 -0.117 0.933 -0.026 0.875 0.281 0.173 
ApoA1 (g/L) -0.702 0.805 -0.266 0.927 0.383 0.242 0.327 0.455 
ApoB (g/L) 10.540 0.012 1.713 0.670 0.351 0.450 -0.573 0.357 
ADMA (Ln, µmol/L) -5.081 0.077 1.140 0.703 -0.380 0.266 -0.366 0.397 
Parent with CVD -0.229 0.944 -0.865 0.752 0.550 0.090 0.351 0.462 
 
ß-coefficient represents the change per 1 unit change in the explanatory variable. 
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Table 5.8 – Univariate regression analysis for mean and maximum carotid extra-medial thickness in 
children aged 8 years.  
 
Mean carotid EMT 
(mm) 
Max carotid EMT 
 (mm) 
Characteristics β p-value β p-value 
Sex (male) -0.027 0.001 -0.027 0.002 
Height (m) 0.267 0.001 0.251 0.001 
Weight (kg) 0.002 0.001 0.002 0.002 
Body-mass index (kg/m2) 0.003 0.020 0.003 0.029 
Waist circumference (cm) 0.001 0.034 0.001 0.053 
Waist-to-hip ratio -0.033 0.700 -0.050 0.574 
Systolic BP (mmHg) 0.002 0.008 0.002 0.015 
Diastolic BP (mmHg) 0.002 0.020 0.002 0.018 
Heart rate, (bpm) 0.000 0.461 0.000 0.382 
Birth weight (kg) 0.007 0.406 0.007 0.415 
Birth length (cm) 0.002 0.183 0.002 0.169 
Head circumference (cm) 0.006 0.040 0.006 0.033 
Gestational age (weeks) -0.005 0.117 -0.005 0.139 
Breast Feeding at 6 months -0.006 0.452 -0.009 0.333 
Gestational diabetes 0.028 0.116 0.026 0.155 
Pre-eclampsia 0.019 0.540 0.006 0.853 
Hypertension in pregnancy 0.029 0.101 0.026 0.157 
Smoking in pregnancy 0.008 0.461 0.007 0.536 
Total cholesterol (mmol/L) -0.002 0.724 -0.004 0.598 
HDL-C (mmol/L) -0.012 0.355 -0.011 0.414 
Non-HDL-C (mmol/L) 0.001 0.918 -0.001 0.908 
Triglycerides (Ln, mmol/L) -0.002 0.868 -0.003 0.759 
ApoA1 (g/L) -0.001 0.961 0.005 0.829 
ApoB (g/L) -0.011 0.744 -0.016 0.630 
ADMA (Ln, µmol/L) -0.002 0.932 -0.005 0.812 
Parent with CVD 0.028 0.238 0.026 0.283 
 
      ß-coefficient represents the change per 1 unit change in the explanatory variable. 
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Table 5.9 – Multivariate regression analysis of radial AIx75 in children aged 8 years. 
 
Characteristics β p-value 
Sex (male) 3.363 0.004 
Height (m) -62.258 <0.001 
BMI (kg/m2) -0.587 0.005 
Heart rate (bpm) 0.140 0.021 
ADMA (µmol/L) -5.306 0.035 
Breast feeding at 6 months -1.984 0.078 
ApoB 6.306 0.098 
 
Adjusted r2 = 0.246; Variables excluded by backward stepwise method: non-HDL-C (p=0.240), birth weight (p=0.871), TC 
(p=0.385), waist circumference (p=0.175) and SBP (p=0.784). β-coefficient represents the change per 1 unit change in the 
explanatory variable.  
 
 
 
 
Table 5.10 – Multivariate regression analysis of PWVcar-rad in children aged 8 years. 
 
Characteristics β p-value 
DBP (mmHg) 0.024 0.084 
TC (mmol/L) 0.168 0.098 
 
Adjusted r2 = 0.017; Variables excluded by backward stepwise method: breast feeding at 6 months (p=0.995) and parent with 
CVD (p=0.984). β-coefficient represents the change per 1 unit change in the explanatory variable.  
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Table 5.11 – Multivariate regression analysis of carotid artery distensibility in children aged 8 years. 
Characteristics β p-value 
Sex (male) 0.483 0.003 
SBP (mmHg) -0.075 <0.001 
Heart rate (bpm) -0.019 0.023 
 
Adjusted r2 = 0.111; β-coefficient represents the change per 1 unit change in the explanatory variable.  
 
 
 
 
Table 5.12 – Multivariate regression analysis of mean carotid EMT in children aged 8 years. 
Characteristics β p-value 
Sex (male) -0.025 0.003 
Height (m) 0.219 0.003 
SBP (mmHg) 0.001 0.051 
 
Adjusted r2 = 0.058; Variables excluded by backward stepwise method: BMI (p=0.748) and head circumference at birth (p=0.870). 
β-coefficient represents the change per 1 unit change in the explanatory variable.  
 
 
 
 
Table 5.13 – Multivariate regression analysis of maximum carotid EMT in children aged 8 years. 
Characteristics β p-value 
Sex (male) -0.025 0.004 
Height (m) 0.206 0.008 
SBP (mmHg) 0.001 0.075 
 
Adjusted r2 = 0.049; Variables excluded by backward stepwise method: BMI (p=0.748) and head circumference at birth (p=0.870). 
β-coefficient represents the change per 1 unit change in the explanatory variable.  
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Table 5.14 – Correlation between radial Aix75, carotid AIx75 and PWVcar-rad and carotid IMT in children aged 8 years. 
 Radial AIx75 (%) Carotid AIx75 (%) PWVcar-rad (m/s) 
 N R β p-value N R β p-value N R β p-value 
Mean carotid IMT (mm) 384 -0.055 -0.001 0.281 268 -0.059 -0.001 0.336 276 -0.031 -0.002 0.586 
Maximum carotid IMT (mm) 384 -0.026 -0.001 0.613 268 -0.054 0.000 0.379 276 -0.033 -0.002 0.742 
Minimum carotid IMT (mm) 384 -0.095 -0.001 0.063 268 -0.056 0.000 0.363 276 -0.056 -0.002 0.796 
Maximum:mean IMT ratio# 384 0.058 0.000 0.261 268 -0.003 0.000 0.963 276 0.009 0.000 0.540 
Diff in max and min IMT (mm) # 384 0.089 0.002 0.081 268 0.002 0.000 0.969 276 0.027 0.004 0.678 
Minimum:mean IMT ratioγ 384 0.112 0.001 0.028 268 -0.013 0.000 0.826 276 0.056 0.001 0.545 
 
R = Pearson’s correlation coefficient. AIx75 = augmentation index (corrected for a heart rate of 75 bmp); PWV = pulse wave velocity. ß-coefficient represents the change per 1 unit 
change in the explanatory variable. #Ln transformed. γReflected (i.e. 1.96 minus the original value) and Ln transformed. 
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Table 5.15 – Correlation between carotid artery distensibility, mean and maximum carotid EMT and carotid IMT in children aged 8 years. 
 Carotid artery distensibility (% per 
10 mmHg) 
Mean carotid EMT (mm) Maximum carotid EMT (mm) 
 N R β p-value N R β p-value N R β p-value 
Mean carotid IMT (mm) 381 -0.028 -0.001 0.586 389 0.222 0.170 <0.001 389 0.207 0.152 <0.001 
Maximum carotid IMT (mm) 381 -0.017 -0.001 0.742 389 0.227 0.219 <0.001 389 0.200 0.185 <0.001 
Minimum carotid IMT (mm) 381 -0.013 0.000 0.796 389 0.184 0.132 <0.001 389 0.173 0.119 0.001 
Maximum:mean IMT ratio# 381 0.031 0.001 0.540 389 -0.008 -0.005 0.882 389 -0.027 -0.018 0.597 
Diff in max and min IMT# (mm) 381 0.021 0.002 0.678 389 0.002 0.004 0.976 389 -0.017 -0.039 0.743 
Minimum:mean IMT ratioγ 381 -0.031 -0.001 0.545 389 0.020 0.008 0.691 389 0.014 0.005 0.780 
 
R = Pearson’s correlation coefficient. EMT = extra medial thickness. ß-coefficient represents the change per 1 unit change in the explanatory variable. #Ln transformed. γReflected 
(i.e. 1.96 minus the original value) and Ln transformed. 
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Figure 5.5 – Relationship between mean carotid IMT and a) mean carotid EMT and b) maximum carotid EMT in children aged 8 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a) b) 
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Figure 5.6 – Relationship between maximum carotid IMT and a) mean carotid EMT and b) maximum carotid EMT in children aged 8 years. 
 
 
 
 
 
 
 
 
a) b) 
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Figure 5.7 – Relationship between minimum carotid IMT and a) mean carotid EMT and b) maximum carotid EMT in children aged 8 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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Table 5.16 – Correlation between different measures of carotid IMT in children aged 8 years: mean IMT, 
maximum IMT and minimum carotid IMT. 
 Mean IMT (mm) Maximum IMT (mm) Minimum IMT (mm) 
 R β p-value R β p-value R β p-value 
Mean IMT (mm) 1 - - 0.842 0.665 <0.001 0.936 1.005 <0.001 
Maximum IMT (mm) 0.842 1.065 <0.001 1 - - 0.713 0.969 <0.001 
Minimum IMT (mm) 0.936 0.871 <0.001 0.713 0.525 <0.001 1 - - 
Maximum:mean IMT ratio# -0.347 -0.324 <0.001 0.209 0.154 <0.001 -0.461 -0.461 <0.001 
Diff in max and min IMT# (mm) -0.317 -0.994 <0.001 0.201 0.498 <0.001 -0.525 -1.765 <0.001 
Minimum:mean IMT ratioγ -0.138 -0.069 0.005 0.104 0.041 <0.001 -0.470 -0.252 <0.001 
 
R = Pearson’s correlation coefficient. ß-coefficient represents the change per 1 unit change in the explanatory variable. #Ln 
transformed. γReflected (i.e. 1.96 minus the original value) and Ln transformed. 
 
 
 
Table 5.17 – Correlation between different measures of carotid IMT in children aged 8 years: 
maximum:mean IMT ratio#, difference in maximum and minimum IMT# and minimum:mean carotid IMT 
ratio. 
 Maximum:mean IMT 
ratio# 
Diff in max and min IMT# 
(mm) 
Minimum:mean IMT 
ratioγ 
 R β p-value R β p-value R β p-value 
Mean IMT (mm) -0.347 -0.372 <0.001 -0.317 -0.101 <0.001 -0.138 -0.276 0.005 
Maximum IMT (mm) 0.209 0.283 <0.001 0.201 0.081 <0.001 0.104 0.263 0.036 
Minimum IMT (mm) -0.461 -0.460 <0.001 -0.525 -0.156 <0.001 -0.470 -0.874 <0.001 
Maximum:mean IMT ratio# 1 - - 0.938 0.279 <0.001 0.445 0.831 <0.001 
Diff in max and min IMT# (mm) 0.938 3.151 <0.001 1 - - 0.702 4.397 <0.001 
Minimum:mean IMT ratioγ 0.445 0.239 <0.001 0.702 0.112 <0.001 1 - - 
 
R = Pearson’s correlation coefficient. ß-coefficient represents the change per 1 unit change in the explanatory variable. #Ln 
transformed. γReflected (i.e. 1.96 minus the original value) and Ln transformed.
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5.4 Discussion 
We explored novel aspects of arterial function and structure in a community-based group of children aged 
8 years. Maximum:mean carotid IMT ratio was independently associated with birth length, TG (Ln) and 
ADMA (Ln), an endogenous inhibitor of nitric oxide synthesis. The difference in maximum and minimum 
carotid IMT was independently associated with birth length, TC and ADMA (Ln), and minimum:mean 
carotid IMT ratio was independently associated with height and HDL-C. Radial AIx75 was independently 
associated with sex, height, BMI, heart rate, and ADMA (Ln), carotid artery distensibility was 
independently associated with sex, SBP and heart rate; both of which are measures of arterial stiffness. 
Carotid EMT was independently associated with sex, height and SBP. There was a statistically significant 
correlation between mean carotid IMT and EMT, but not any of the other measures of arterial function 
and structure included in this study.   
 
Maximum:mean carotid IMT ratio, the difference in maximum and minimum carotid IMT and 
minimum:mean carotid IMT ratio were used as measures of heterogeneity in carotid artery wall thickness. 
More established measures of subclinical vascular disease (such as mean and maximum carotid IMT) are 
independently associated with MI, stroke and CHD deaths in adults (22-26). Aspects of the methods used 
for calculating mean and maximum carotid IMT may potentially limit their ability to detect statistically 
important associations with traditional CVD risk factors. As described in Chapter 2, mean carotid is 
calculated as an average of single point-to-point measurements (up to a maximum of 200), while 
maximum carotid IMT is calculated as the largest single point-to-point measurement. Using these 
methods, mean carotid IMT has a tendency to reduce measurement variability (in part by reducing 
measurement error) at the cost of an ability to measure heterogeneity in the artery wall thickness, and 
maximum carotid IMT permits some assessment of variability (by reporting the thickest point), but this 
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measure is independent of the overall IMT. Similarly, minimum carotid IMT is a single point-to-point 
measure that reports the smallest IMT value. Minimum IMT is rarely reported in clinical trials as the 
literature has consistently shown an association between a higher IMT and increased risk of CVD events.   
 
Novel measures of carotid IMT, such as maximum:mean carotid IMT ratio, difference in maximum and 
minimum carotid IMT and minimum:mean carotid IMT ratio, may better account for variability in the 
carotid artery wall, by using an estimate of the variability of IMT relative to the average value (i.e. mean 
carotid IMT) expressed as a ratio, or by reporting the absolute difference in the maximum and minimum 
carotid IMT. While these novel measures incorporate single point-to-point measurements (i.e. maximum 
and minimum), which are potentially subject to a higher degree of measurement error – described in 
Chapter 3, the analyses of variability in repeated measurement of maximum carotid IMT in this cohort of 
8 year old children (using the Teratek Terason 3000 portable ultrasound machine) showed good 
agreement. Similar results were obtained for minimum carotid IMT (data not shown). Very few studies 
have attempted to study heterogeneity in carotid IMT. A study by Baldassarre D. et.al. (96), used standard 
error of mean (SEM) as a marker of heterogeneity; however, this is potentially problematic as SEM 
increases in proportion with mean carotid IMT.   
 
In our study, we found a statistically significant association between maximum:mean carotid IMT ratio 
and birth weight, birth length, TC, non-HDL-C, TG (Ln), and ADMA (Ln). In the multivariable model, birth 
length, TG (Ln) and ADMA (Ln) were independent predictors of maximum:mean carotid IMT ratio. When 
exploring minimum:mean carotid IMT ratio, there was a statistically significant association with height (at 
age 8 years), TC, HDL-C and ApoA1; however, in the multivariable model, only height and HDL-C were 
independent predictors of minimum:mean carotid IMT ratio. The difference in maximum and minimum 
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carotid IMT had a statistically significant association with birth weight, birth length, TC and ADMA (Ln). In 
the multivariable model, birth length, TC and ADMA (Ln) were independent predictors of the difference 
in maximum and minimum carotid IMT – suggesting these factors may be important childhood predictors 
of increased risk of CVD in adulthood. By contrast, mean carotid IMT was associated with SBP, DBP, HDL-
C, ADMA (Ln), and a parent with a history of CVD; however, in the multivariable model, only SBP, HDL-C 
and ADMA (Ln) were independent predictors of mean carotid IMT (88). Maximum carotid IMT was 
significantly associated with SBP, DBP, HDL-C, and a parent with a history CVD, but in the multivariable 
model the only independent predictor of maximum carotid IMT was HDL-C (88). There was no difference 
in any of these measures of carotid IMT when comparing subjects by sex, or treatment group (i.e. dietary 
intervention or house dust mite avoidance intervention).  
 
The characteristics of subjects participating in this study have previously been published (88,91,92). In 
brief, height was 1.28 ± 0.06 m (mean ± SD), weight 29.1 ± 6.7 kg, BMI was 17.6 ± 3.1 kg/m2, waist:hip 
ratio was 0.84 ± 0.05, SBP was 101 ± 7 mmHg, DBP was 60 ± 6 mmHg, heart rate was 81 ± 10 beats per 
minute, TC was 4.4 ± 0.7 mmol/L, HDL-C was 1.46 ± 0.37 mmol/L, non-HDL-C was 3.0 ± 0.7 mmol/L, ApoA1 
was 2.3 ± 0.6 g/L, ADMA was 0.91 ± 0.22 umol/L (median ± IQR), TG was 1.2 ± 0.7 mmol/L (median ± IQR), 
gestational age was 39.6 ± 1.3 weeks (mean ± SD), birth weight was 3.5 ± 0.49 kg, 41.7% were breast fed, 
23% of mothers smoked during pregnancy, 5.9% had hypertension in pregnancy, 2.0 % had pre-eclampsia, 
5.9% had gestational diabetes, 2.0% had a mother with diabetes mellitus, 6.4% had a mother with 
hypercholesterolaemia, and 3.5% had a parent with a prior history of CVD. As described in the thesis of 
Dr Julian Ayer (PhD – USYD, 2010), the prevalence of many of these traditional CVD risk factors in this 
community-based population of children aged 8-years was indeed relatively low; nonetheless, potentially 
important associations between mean and maximum carotid IMT and SBP, HDL-C and ADMA were 
identified. Novel measures of carotid IMT heterogeneity, such as maximum:mean carotid IMT ratio, 
 188 
 
minimum:mean carotid IMT ratio, and the difference in maximum and minimum carotid IMT, provide new 
and potentially important information on additional CVD risk factors in childhood, which are not evident 
from an assessment of mean and maximum carotid IMT.  
 
We also explored the association between traditional CVD risk factors and other measures of arterial 
function and structure and in this community-based cohort of children. Radial AIx75, a measure of arterial 
stiffness, was associated with sex, height, weight, BMI, waist circumference, waist:hip ratio, SBP, DBP, 
heart rate, birth weight, birth length, ApoB and breast feeding at 6 months. In the multivariable model, 
sex, height, BMI, heart rate and ADMA (Ln) were independent predictors of radial AIx75. The association 
between carotid AIx75 and traditional CVD risk factors in our cohort of 8 year-old children has been 
previously published (91), and independent predictors of carotid AIx75 included sex, heart rate, DBP and 
height. Carotid artery distensibility, a reciprocal measure of arterial stiffness relating to the degree of 
change in arterial diameter in response to distending pressure, was associated with sex, SBP and DBP; 
however, in the multivariable model sex, SBP and heart rate were independent predictors of carotid artery 
distensibility.  PWVcar-rad was not independently associated with any of the factors included in this study.  
These findings highlight important factors associated with arterial stiffness and distensibility in early 
childhood, with potential health implications later in life. It is uncertain whether strategies targeting these 
and other risk factors associated with measures of arterial stiffness – e.g. lifestyle intervention or 
pharmacotherapy for elevated BP in childhood – has the potential to reverse arterial stiffness. In this 
study, radial AIx75 identified additional risk factors associated with arterial stiffness – i.e. BMI and ADMA 
– that were not independent predictors of carotid AIx75. Algorithms for determining augmentation of the 
arterial pulse from peripheral blood pressure measurements have not been validated in this age group; 
therefore, this data should be interpreted with some caution. Similar to measures of carotid IMT, there 
was no difference in any of these measures of arterial function or structure when comparing children by 
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dietary intervention (omega-3 fatty acid versus polyunsaturated fatty acid supplementation) or house 
dust mite avoidance intervention (‘active’ dust mite avoidance versus no avoidance). 
 
Carotid EMT is a non-invasive measure of carotid artery wall thickness that incorporates the adventita and 
peri-adventitial tissue (94); this novel measure may provide additional information regarding structural 
changes in the vasculature that are not appreciated from an assessment of carotid IMT. In this study, 
mean carotid EMT was associated with sex, height, weight, BMI, waist circumference, SBP and head 
circumference at birth. In the multivariable model, sex, SBP and heart rate, were independent predictors 
of mean carotid IMT. Similar factors were associated with maximum carotid EMT. A detailed analysis of 
the association between traditional CVD risk factors and carotid EMT in our community-based cohort of 
children aged 8 years has been published (95). In adults, carotid EMT has been shown to be higher in those 
with dyslipidaemia and T2DM, and the strongest determinants of EMT were diabetes, HDL-C and SBP, 
independent of carotid IMT, age and sex. Carotid EMT has not been studied in prospective clinical trials 
incorporating clinical endpoints – such as MI, stroke or CVD deaths – thus, the clinical significance of this 
potentially novel measure of subclinical vascular disease has not yet been established. Notwithstanding, 
carotid EMT and markers of IMT heterogeneity have identified additional potentially CVD risk factors, 
within the first decade of life. 
 
ADMA is an endogenous inhibitor of nitric oxide synthase (NOS), an enzyme that regulates the production 
of nitric oxide (NO). NO is produced by endothelial cells and plays an important role in promoting vascular 
protection via the regulation of inflammation, haemostasis, thrombotic potential, oxidation, and arterial 
vasodilatory function. Elevated levels of ADMA have been shown to correlate with cardiovascular risk 
factors in adults (97,98). Furthermore, ADMA has been shown to be an independent risk factor for CVD 
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(99) and correlates with the severity and extent of coronary atherosclerosis (100). ADMA levels are 
influenced by dimethylarginine dimethylaminohydrolase (DDAH), the enzyme responsible for the 
degradation of ADMA. Dysregulation of DDAH has been associated with elevated levels of oxidised-LDL 
and inflammatory cytokines (101) – factors known to promote atherosclerotic disease burden.  
 
An independent association between ADMA and measures arterial function and structure in this study, 
including mean carotid IMT and markers of carotid IMT heterogeneity, suggests a role for this inhibitor of 
NOS in the early pathogenesis of atherosclerosis. Very few studies to date have investigated ADMA and 
the association with traditional CVD risk factors in children. A study by Goonasekera C. et.al. (102), 
reported elevated levels of ADMA in hypertensive compared with normotensive children at 9 years of age. 
A study by Jehlicka P. et.al. (103), reported elevated levels of ADMA in pubertal children with familial 
hypercholesterolaemia, but not in children with T1DM. A study by Hasanoglu A. et.al. (104), showed 
higher levels of ADMA and carotid IMT in prepubertal children with familial hypercholesterolaemia. This 
is the first report of an independent association between ADMA and markers of carotid IMT heterogeneity 
in apparently healthy children within the first decade of life, highlighting a potential role for ADMA in the 
early progression of subclinical vascular disease.   
 
We have previously reported an independent association between HDL-C and mean carotid IMT in this 
cohort of 8-year old children (88). Here, we show that HDL-C is also an independent predictor of 
minimum:mean carotid IMT ratio, but not the other markers of carotid IMT heterogeneity investigated in 
this study. This finding of an independent association between HDL-C and subclinical vascular disease is 
consistent with other reports in young adults (105). HDL-C has an important role in protection against 
premature CVD. It is responsible for reverse cholesterol transport, and has number of potent anti-
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inflammatory and antioxidant effects – including promoting NO production by endothelial cells, 
decreasing adhesion molecule expression and monocyte activation, inhibiting platelet activation and 
endothelial cell death, and inhibiting lipid oxidation (106-108): properties that are also anti-atherogenic. 
Recently, it has been found that maternal cigarette smoking in utero reduces HDL-C later in childhood 
(109), and environmental tobacco smoke exposure reduces HDL-C levels in both children and adults, in a 
dose dependent manner (110). Autopsy studies in children and adolescents – The Bogalusa Heart Study 
(83) and the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study (84) – found that 
lower HDL-C was associated with a greater histological progression of aortic and carotid atherosclerosis. 
Combined, these data suggest that early exposure to risk factors that lower HDL-C promote the 
progression of subclinical vascular disease, and may lead to an increase in CVD risk later in life. TG were 
independently associated with maximum:mean carotid IMT ratio, and this may suggest an important role 
for this traditional CVD risk factor in early childhood, with implications later in life. 
 
SBP was associated with several measures of arterial wall thickening (including mean and maximum 
carotid EMT, and mean carotid IMT) and arterial stiffness in this cohort of children aged 8-years. This 
finding suggests a potentially damaging effect of small, but statistically significant, elevations in SBP in the 
first decade of life. A recent study by Juhola, J. et.al. (111) studied the effects of BP levels on carotid IMT 
in children and found that persistently elevated BP from childhood into adulthood had higher carotid IMT; 
however, but if BP had reduced prior to adulthood then IMT was reduced. This finding has important 
clinical implications, as it suggests there may be some potential for reversibility in subclinical vascular 
disease later in life, if BP levels are normalised during childhood or early adolescence. It is uncertain 
whether BP lowering in childhood can influence arterial stiffness.  
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Numerous epidemiological studies have shown a lower prevalence of CVD in populations with a high 
dietary fish intake (112-118); by contrast, other studies have shown no beneficial effect (119-122). A single 
study reported an inverse association between fish consumption and 25-year mortality from CHD across 
several populations, but when accounting for confounders (including the consumption of saturated fatty 
acids, flavonoids, and cigarette smoking) the association was not significant (121). There are number of 
possible explanations for a lack of consistent beneficial effects of regular fish consumption including 
differences in residual confounders (such as lifestyle), variability in study factors (as examples, the 
consumption fatty versus lean fish, differences in methods for estimating fish intake, a bias towards 
studying populations with high rates of fish consumption, or differences in the consumption of 
methylmercury – a potentially hazardous environment contaminant), and the use of different study 
populations (123). 
 
Recent large-scale randomised controlled trials of omega-3 fatty acid supplementation versus placebo in 
adults at risk of CVD have shown no beneficial effects on CVD outcomes: a trial of 12,513 patients with 
multiple CVD risk factors or atherosclerotic vascular disease assigned to omega-3 fatty acids or placebo 
showed no effect on CVD mortality or morbidity over 5 years (124), and similarly a trial of 12,536 patients 
with impaired fasting glucose, impaired glucose tolerance, or diabetes, assigned to ethyl esters of omega-
3 fatty acids or placebo and to either insulin glargine or standard care (using a 2x2 factorial design) showed 
no effect on CVD events, despite a statistically significant improvement in TG levels (125). Studies in adults 
have shown improvement in some CVD risk factors with omega-3 fatty acids, including a dose-dependent 
lowering of blood pressure in hypertensive subjects (126-128), and decreased serum TG (129). 
Postprandial triglyceridaemia is also substantially improved by long-term omega-3 fatty acid consumption 
(130,131). Omega-3 fatty acids have consistently been shown to decrease collagen-induced platelet 
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aggregation (132,133); however, the effects on other factors in thrombosis and haemostasis (e.g. Factor 
VII, fibrinogen, von Willebrand factor and thrombomodulin) have been somewhat variable (134-138).  
 
There is recent evidence from clinical studies in children that early nutritional interventions may lead to 
improvement in important CVD risk factors, such as blood pressure, arterial stiffness, and lipid and 
lipoprotein levels, later in life (139-141).  Omega-3 fatty acid supplementation in childhood has not been 
extensively studied. A study by Forsyth JS et.al. of bottle-fed infants receiving a formula enriched with 
omega-3 fatty acids compared with standard formula over the first 4 months of life showed lower DBP at 
age 6 years (142). A study by Damsgaard CT et.al. of infants who received fish-oil supplements compared 
to no supplementation from 9 to 12 months of age reported a trend towards lower SBP (P=0.05) (143); 
however, there was a potential attenuation of effect after cessation of dietary supplementation. In our 
study, omega-3 (n-3) fatty acid dietary supplementation had no effect on any of the measures of arterial 
function and structure investigated in this thesis, compared with polyunsaturated (n-6; ‘control’) diet, 
which may relate to an attenuation of effects after cessation of supplementation, as there was no 
measurable effect on any haemodynamic or biochemical characteristics, when measured at 8 years of 
age.  
 
Limitations 
There were a number of limitations to this study. First, the study participants were originally recruited 
into CAPS, an asthma prevention trial in children with a positive family history of asthma in a parent or a 
sibling. There was no difference in any of the measures of vascular function or structure, or in other 
characteristics included in this study, when comparing those with and without a diagnosis of asthma. 
While our study aimed to explore novel measures of arterial function and structure and the association 
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with traditional CVD risk factors, there was a low prevalence of traditional risk factors in this community-
based cohort of children aged 8-years. Despite this potential limitation, statistically significant association 
between novel measures of arterial function and structure and traditional CVD risk factors were identified 
in this study. Due to the cross-sectional design of cardioCAPS, the incidence of traditional CVD risk factors 
in this cohort of children could not be studied. 
 
Second, this study involved two interventions (in a 2 x 2 factorial design), administered from birth to age 
5 years – including a dietary intervention of omega-3 fatty acid supplementation versus a polyunsaturated 
(‘control’) diet, and dust mite avoidance versus no avoidance (‘controls’). While there was no statistically 
significant difference in any of the measures of arterial function and structure at 8 years of age for either 
intervention, it is difficult to exclude a potential confounding effect of these interventions on other 
parameters – e.g. levels of inflammation, as a result of atopy. In CAPS, the dust mite avoidance 
intervention had no effect on measures of arterial function or structure, or the incidence of asthma, but 
significantly increased the incidence of eczema (a chronic inflammatory skin condition) at 5 years (144). 
The mechanism for this finding is not known. There are no published reports on the effects of eczema on 
carotid IMT. 
 
Third, only 67% of the original cohort of children in CAPS underwent testing in CardioCAPS. While a 
selection bias is possible due to the high number of subjects that were lost-to-follow-up, the 
characteristics of the children participating in CardioCAPS were similar to the remaining cohort; thus, a 
significant selection bias was considered unlikely. Fourth, non-fasting blood samples were collected in this 
study. This was due to the need for testing to be conducted throughout the day to increase attendance 
rates. Finally, subjects with extremely low birth weight (< 2.5 kg) were excluded from this study. While an 
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association between birth weight carotid IMT was not identified, an association between very low birth 
weight and carotid IMT cannot be excluded. 
 
5.5  Conclusion 
In this cohort of community-based children aged 8-years, we have found potentially important 
independent predictors of novel markers of arterial function and structure, including carotid IMT 
heterogeneity and arterial stiffness. These findings highlight potentially important associations between 
the presence of these traditional risk factors in early childhood and early structural and functional changes 
in the arterial wall, which may potentially contribute to the onset of premature atherosclerosis, in 
adulthood. Interventions targeting risk factors identified in this study may help to improve arterial 
structure and function and reduce the risk of premature CVD. Further study of these novel markers of 
carotid IMT heterogeneity is required to determine their clinical significance and potential value for 
predicting CVD events in later life. 
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CHAPTER 6:  
 
Fenofibrate Effects on Carotid Artery Intima-Media Thickness in Adults with Type-
2 Diabetes Mellitus: a FIELD Substudy 
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Preface 
The following 3 chapters report results from the prospectively planned vascular substudies of the large, 
multicentre Fenofibrate and Event Lowering in Type 2 Diabetes (FIELD) trial, of 9,795 patients with T2DM, 
followed for 5 years for major cardiovascular events, after randomisation to the lipid-modulating 
peroxisome proliferator-activated receptor-alpha-(PPARα) agonist, fenofibrate, or matching placebo 
(145). My role, and the role of other contributors has been described in the acknowledgements section. 
Chapter 6 reports findings from the FIELD IMT vascular substudy, exploring the effects of fenofibrate 
compared with placebo on carotid IMT, at 2 and 4 years, in a subset of 387 representative subjects from 
the FIELD trial. Chapter 7, reports findings from the FIELD FMD vascular substudy, investigating factors 
associated with impaired arterial function in 193 representative subjects from the FIELD trial. Chapter 8 
reports the effects of fenofibrate compared with placebo on arterial endothelial function, at 4 months 
and 2 years, in the 193 representative subjects studied in Chapter 7. Regarding these FIELD substudies, 
the descriptions of the overall study appears in this Chapter; subsequent chapters focus on FMD methods 
and specific results of the FMD substudy. 
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6.1 Introduction 
CVD is the leading cause of mortality and morbidity in patients with T2DM and diabetes confers a 2- to 4-
fold increase in cardiovascular event rates (146-148). The presence of additional traditional risk factors, 
e.g. hypertension or dyslipidaemia, further increase the atherosclerotic disease burden. Dyslipidaemia is 
highly prevalent in T2DM and is characterised by an abnormal lipoprotein pattern: low HDL-C, high TG and 
the presence of smaller, dense LDL-C particles. Despite improvement in CVD mortality from the use of 
statins, there remains considerable residual risk of CVD events in patients with T2DM with lipid and 
lipoprotein abnormalities.  
 
Fibrates, a class of lipid-modifying peroxisome proliferator-activated receptor-α (PPAR-α) agonists, can 
improve lipid and lipoprotein abnormalities, in particular those defined by dyslipidaemia. The lipid and 
lipoprotein-modifying effects of fibrates vary according to the population; however, in a meta-analysis of 
randomised controlled trials, fenofibrate lowered TG by 40%, TC by 13% and LDL-cholesterol by 11%, and 
raised HDL-cholesterol by 10% (149). Fibrates (also have non-lipid-modifying effects, which may regulate 
other pathways implicated in the pathogenesis of atherosclerosis. PPAR-α is expressed in the vasculature 
by arterial endothelial and smooth muscle cells, and fibrates have been shown to increase eNOS protein 
and messenger RNA levels (150-152), and decrease ADMA (an endogenous inhibitor of NOS) (153), leading 
to an increase in NO bioavailability. The vascular effects of fibrates are described in further detail in 
Chapter 8. 
 
Several studies have suggested a potential benefit from fibrate therapy on clinical endpoints in defined 
population groups. The Helsinki Heart study of gemfibrozil use in men with hypercholesterolaemia 
without prior coronary disease showed that fibrates lowered coronary events more in those with diabetes 
than in those without diabetes, in post-hoc analysis (154). Furthermore, the reduction in coronary events 
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observed was higher than that expected from LDL-cholesterol lowering alone. The Veterans Affairs High-
Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) of patients with coronary heart disease and 
low HDL-cholesterol levels showed that gemfibrozil lowered recurrent coronary events more in those with 
compared to those without diabetes or insulin resistance (155). The Bezafibrate Infarct Prevention (BIP) 
trial of patients with prior myocardial infarction also showed that fibrate reduced the rate of recurrent 
myocardial infarction more in those with metabolic syndrome (156). Furthermore, in the Diabetes 
Atherosclerosis Intervention Study (DAIS), fenofibrate reduced the progression of angiographically- 
documented coronary disease in patients with T2DM (157). Despite this, there has been limited evidence 
in support of the use of fibrates for improving clinical cardiovascular endpoints, such as CVD mortality or 
events, in patients with diabetes.  
 
The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a multi-centre trial 
designed to investigate the potential effects of fenofibrate on cardiovascular mortality and events in 
patients with T2DM. This study showed a significant reduction in total CVD events on fenofibrate, mostly 
due to a reduction in non-fatal events and coronary revascularisations (145). In addition, various 
substudies of the FIELD study, exploring microvascular clinical endpoints – such as diabetic retinopathy 
(158), nephropathy (159-161), and amputations (162) – reported important fenofibrate-related benefits.  
 
Vascular substudies were prospectively planned in the FIELD study design to investigate possible 
mechanisms explaining the potential arterial benefits of fenofibrate in this population. In this chapter, the 
results of the FIELD IMT vascular substudy are described. The aim of this substudy was to investigate the 
effect of fenofibrate (versus matched placebo) on the progression of carotid IMT, as a measure of 
subclinical vascular disease. The primary study endpoint was the difference in carotid IMT between 
treatment groups at 4 years, expressed as a change from baseline.  
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6.2  Methods 
6.2.1 Subjects 
A detailed description of the FIELD study subjects has been published (145,163,164). In brief, the FIELD 
study was a multinational, double-blind, placebo-controlled randomized trial involving 9,795 patients in 
63 sites in Australia, New Zealand and Finland, investigating the effects of comicronised fenofibrate (200 
mg) versus placebo on fatal and non-fatal coronary events in patients with T2DM, aged 50-75 years. 
Eligibility included a diagnosis of T2DM according to WHO criteria; age at diagnosis of T2DM of > 35 years; 
an initial plasma TC level between 3.0-6.5 mmol/L; TC to HDL-C ratio > 4.0, or TG level of 1.0-5.0 mmol/L. 
Exclusion criteria included renal impairment (plasma creatinine >130 µmol/L); chronic liver or 
symptomatic gall bladder disease; any recent cardiovascular event within the 3 months prior to study 
recruitment; a recent history of drug or alcohol abuse; current use of lipid-lowering medications, or prior 
exposure to fenofibrate. 
 
Of the 9,795 subjects in the FIELD study, 6,051 were randomised in 39 sites within Australia. Seven sites 
were chosen to participate in the FIELD IMT vascular substudy, based on demonstrated expertise in 
conducting carotid artery ultrasound scans. At these sites, subjects were randomised to receive either 
fenofibrate or matching placebo and subsequently invited to participate in the vascular substudy. 
Eligibility into the IMT vascular substudy required a baseline ultrasound scan of suitable quality to 
accurately assess IMT. At baseline, 422 subjects had carotid artery ultrasound scans performed. Of these, 
387 (91%) were considered of acceptable quality for inclusion into the IMT vascular substudy. At 2 years, 
333 subjects (86%) were studied and included in the IMT analyses. At 4 years follow-up, 338 subjects 
(87%) were studied. Subjects who were lost to follow-up or had declined participation at 2 years were 
again contacted, if possible, and invited to participate in the IMT vascular substudy at 4 years. 
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Comparing the 422 patients in this vascular substudy with the remaining 9,373 subjects in the FIELD 
cohort, there were no significant differences in sex, age at visit 1, duration of diabetes, BMI, waist:hip 
ratio, prior history of CVD, hypertension, cigarette smoking status, insulin, TG, homocysteine, or urinary 
albumin. There were minor statistically significant differences in the SBP (139 mmHg in the vascular 
substudy versus 141 mmHg for the entire FIELD cohort, p<0.01), DBP (81 mmHg versus 82 mmHg, p<0.01), 
prior history of angina (8.5% versus 12.3%, p=0.02), history of diabetic retinopathy (5.2% versus 8.4%, 
p=0.02), history of diabetic neuropathy (10.7% versus 14.4%, p=0.03), TC (4.87 mmol/L versus 5.04 
mmol/L, p<0.001), LDL-C (2.91 mmol/L versus 3.07 mmol/L, p<0.001), HDL-C (1.06 mmol/L versus 1.10 
mmol/L, p<0.01), fasting glucose (8.28 mmol/L versus 8.45 mmol/L, p=0.02), HbA1c (6.75% versus  6.85%, 
p=0.04), plasma creatinine (75.45 µmol/L versus 77.66 umol/L, p<0.01), and subjects reporting regular 
use of angiotensin II receptor antagonists (10.9% versus 5.1%, p<0.001) and β-blockers (10.9% versus 
14.7%, p=0.03) (Table 6.1). 
 
A detailed clinical history was obtained in all subjects. A prior history of CVD included any one of the 
following: MI, angina (stable or unstable), stroke, claudication or PVD, or arterial revascularisations 
(including CABG, PTCA or peripheral revascularisations). A family history of CVD was defined as CVD in a 
first degree relative before the age of 55 years.  Smoking history was recorded as present (current 
smoker), past (ex-smoker) or never smoker, based on self-report. History of hypertension, age at diagnosis 
of T2DM and the presence of diabetes complications were also obtained by self-report. The method of 
diabetes control was documented as any one of the following: diet only, oral hypoglycaemic agents only 
(distinguishing those using metformin, a sulfonylurea, both metformin and a sulfonylurea, or another class 
of oral agent alone or in combination with other agents), diet and insulin, or diet and oral hypoglycaemic 
agents and insulin. This study was approved by the NHMRC of Australia ethics committee and the relevant 
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Institutional ethics committees at each study site. All subjects gave written, informed consent, and 
participation was entirely voluntary.  
 
6.2.2 Study design 
The FIELD study design has been previously described (145,163,164). Eligible subjects underwent a 16-
week run-in period (consisting of 4-weeks of dietary intervention, followed by 6-weeks of single-blinded 
placebo-only and then 6-weeks single-blinded comicronised fenofibrate 200 mg once daily). After the run-
in period, subjects were randomised to receive either fenofibrate 200 mg comicronised formulation or 
matching placebo. Randomisation was performed with stratification for important prognostic factors, 
including age, sex, prior MI, lipid levels and urinary albumin excretion. The IMT vascular substudy was 
designed to end at 4 years after randomisation. Assuming a mean baseline IMT of 0.83 ± 0.14 mm (mean 
± SD), a total study sample size of 200 subjects per group provided > 80% power (2p < 0.05) to detect a 
0.04 mm change in IMT between treatment groups.  The primary study endpoint was the difference in 
IMT between treatment groups at 4 years, expressed as a change from baseline. Analyses included those 
who had dropped-in to statin therapy, or dropped-out from fenofibrate (or placebo), after randomisation. 
Subjects who had commenced statin therapy before 2 years were removed from the analyses at 2 and 4 
years, and subjects who had dropped-in to statins between 2 and 4 years were removed from the analyses 
at 4 years. 
 
6.2.3 Carotid intima-media thickness assessment 
Methods used for the assessment of carotid IMT were described in detail in Chapter 2. Carotid artery 
ultrasound images were obtained using a clinic-based, mainframe ultrasound machine, at various 
participating substudy sites. IMT studies were recorded to super-VHS video tape for later off-line analysis 
by a single experienced observer, using validated, semi-automated edge-detection software. Inter- and 
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intra-observer variability for carotid IMT measurements in the FIELD IMT vascular substudy was described 
in Chapter 3.  
 
6.2.4 Laboratory measures 
Venous blood and urine samples were analysed at a central reference laboratory and details of these 
analyses have been published (145,163). Fasting blood samples at baseline were taken prior to 
randomisation (and before the ‘active run-in’ phase). The central laboratory participated in the National 
Quality Assurance scheme and was aligned for lipid and HbA1c analyses though the Canadian External 
Quality Assurance Laboratory in Vancouver. Methods used to measure lipids were accredited by the 
Centre for Disease Control’s Lipid Standardisation Program. 
 
6.2.5 Statistics 
Baseline characteristics were expressed as percentages for categorical variables, and as mean (SD) or 
median (IQR) for normally distributed and non-normally distributed variables, respectively. TG, creatinine, 
glucose, HbA1c, urine ACR and Lp(a) levels were highly skewed and log transformed for analyses. Groups 
were compared by independent-sample t tests or ANOVA for multiple-category analyses. The Tukey test 
was used to compare the difference between each pair of means, to adjust for multiple testing. Statistical 
evaluation of changes from baseline was performed by analysis of covariance (ANCOVA) models, with 
treatment group as a factor adjusted for baseline IMT value. Beta coefficients (β) and 95%CI are shown. 
A two-tailed p-value < 0.05 was considered significant. All analyses were performed according to the 
intention-to-treat principle, using SAS (version 9.2).   
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6.3 Results 
6.3.1 Baseline characteristics of subjects 
Subjects in the FIELD IMT vascular substudy were aged 63 ± 7 years (mean ± SD). 63% were male and the 
duration of diagnosed diabetes was 4 years (median; IQR, 2-8 years). Fasting blood glucose was 8.3 
mmol/L (median; IQR, 6.8-10.0) and HbA1c was 6.8% (IQR, 6.1-7.6). 290 subjects (69%) were on oral 
hypoglycaemic agents: metformin (23%), sulfonylureas (16%), both metformin and sulfonylureas (28%), 
other oral agents in combination with metformin and/or sulfonylureas (6%). 18 subjects (4%) were taking 
insulin daily. 225 (53%) were taking antihypertensive agents. 83 (20%) had had a prior history of CVD. 256 
(61%) were past or present cigarette smokers, and the number of cigarettes smoked per day was 15 
(median; IQR, 5-30). 22 (5%) had a history of diabetic retinopathy, 45 (11%) had diabetic neuropathy, and 
8  (2%) had diabetic nephropathy. Urinary ACR was 1.05 mg/mmol (IQR, 0.50-3.20); 96 subjects (23%) had 
microalbuminuria and 16 subjects (4%) had macroalbuminuria. 175 (42%) had dyslipidaemia (defined as 
low HDL, in males: <1.03 mmol/L, females: <1.29 mmol/L, and high TG ≥1.7 mmol/L). Baseline 
characteristics for FIELD IMT vascular substudy subjects compared with the remaining FIELD cohort are 
shown in Table 6.1. 
 
Baseline characteristics for subjects in the FIELD IMT vascular substudy assigned to fenofibrate (N = 197) 
or to placebo (N = 225) are shown in Table 6.2. There were minor statistically significant differences in SBP 
(fenofibrate: 137 ± 14 mmHg versus placebo: 140 ± 14 mmHg; p=0.02) and plasma creatinine (fenofibrate: 
77.9 ± 15.7 µmol/L versus placebo: 74.2 ±14.9 µmol/L; p=0.02), when comparing baseline characteristics 
in the two treatment groups. There were no statistically significant differences in any other baseline 
characteristics when comparing groups. 
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6.3.2 Primary study endpoint – IMT at 4 years 
There was no statistically significant difference in mean carotid IMT at 4 years on fenofibrate compared 
with placebo [absolute mean difference, +0.012 mm (95%CI: -0.014, 0.038); p=0.35 by ANCOVA; adjusted 
for IMT at baseline]. Similarly, there was no statistically significant difference in maximum IMT at 4 years 
on fenofibrate compared with placebo, [mean difference, +0.012 mm (95%CI: -0.020, 0.044); p=0.45] 
(Table 6.3) (Figure 6.1). 
 
6.3.3 Other results at 4 years 
Allocation to fenofibrate resulted in statistically significant differences in several lipid parameters 
measured at 4 years: TC [mean difference, -0.535 mmol/L (95%CI: -0.69, -0.38), p<0.001]; LDL-C [-0.270 
mmol/L (95%CI: -0.66, 0.12), p<0.001]; TG log [-0.413 mmol/L (95%CI: -0.49, -0.34), p<0.001] (Table 6.4) 
(Figure 6.1). Fenofibrate also significantly reduced fasting plasma glucose after 4 years of treatment 
compared with placebo [-0.062 mmol/L (95%CI: -0.12, -0.01), p=0.02] (Table 6.4) (Figure 6.3). There was 
no statistically significant difference in HDL-C at 4 years (Table 6.4); however, there was a statistically 
significant increase in HDL-C at 4 months [+0.05 mmol/L (95%CI: 0.02, 0.09), p=0.005] (described in 
Chapter 7), and at 2 years. Fenofibrate caused statistically significant increases in plasma creatinine at 2 
and 4 years; however, this result was likely due to an increase in muscle turn-over in response to 
fenofibrate therapy, rather than a decline in renal function (145,163). Changes in laboratory parameters 
in the FIELD IMT vascular substudy were similar to those reported in the main FIELD study (145). None of 
the other parameters measured at 4 years were significantly different between treatment groups.  
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6.3.4 Results at 2 years 
There was no statistically significant difference in mean IMT at 2 years on fenofibrate compared with 
placebo [+0.007 mm (95%CI: -0.018, 0.032), p=0.59]. Similarly, there was no statistically significant 
difference in maximum IMT at 2 years between treatment groups [+0.016 mm (95%CI: -0.013, 0.045), 
p=0.28] (Table 6.3) (Figure 6.1). Fenofibrate resulted in statistically significant differences in lipid 
parameters at 2 years: TC [-0.558 mmol/L (95%CI: -0.71, -0.41), p<0.001]; LDL-C [-0.350 mmol/L (95%CI: -
0.48, -0.22), p<0.001]; HDL-C [+0.055 mmol/L (95%CI: 0.02, 0.09), p<0.01]; and TG log [-0.393 mmol/L 
(95%CI: -0.46, -0.32), p<0.001] (Table 6.4) (Figure 6.1). No other parameters measured at 2 years 
(including glucose, HbA1c, ACR, SBP or DBP) were significantly different between the treatment groups: 
with the exception of plasma creatinine (described in Section 6.3.3) (Table 6.4).  Changes in laboratory 
parameters at 2 years in this vascular substudy were again similar to those published in the main FIELD 
study (145). 
 
6.3.5 Exploratory analyses 
Further exploratory analyses were undertaken to investigate the effect of fenofibrate (versus placebo) on 
carotid IMT in patients with dyslipidaemia [defined as the presence of low HDL-C (males: <1.03 mmol/L, 
females: <1.29 mmol/L) with high TG (≥1.7 mmol/L)] compared to those without dyslipidaemia. These 
analyses revealed no statistically significant difference between IMT (mean or maximum) in those with or 
without dyslipidaemia, at 2 or 4 years (Table 6.5). Testing for the interaction between treatment groups 
and dysplipidaemia status did not show any statistically significant benefit from treatment with 
fenofibrate (versus placebo) (Table 6.5). Figure 6.6 shows a non-significant trend towards favourable 
carotid IMT in those assigned to fenofibrate, at 2 and 4 years compared with placebo, with stronger effect 
sizes observed for maximum IMT compared with mean IMT. Separate analyses were conducted to exclude 
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subjects who had dropped-in to statin therapy or dropped-out of fenofibrate (or placebo), and these 
analyses did not alter the FIELD IMT vascular substudy results (data not shown). 
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Table 6.1 - Baseline characteristics of FIELD IMT vascular substudy subjects compared with the remaining 
FIELD cohort. 
Characteristics 
FIELD Cohort 
Minus Substudy 
 (N=9373) 
Substudy 
 (N=422) 
General characteristics   
Sex - Male 5872 (62.6%) 266 (63.0%) 
Age at visit 1 (years, mean[SD]) 62 (7) 63 (7) 
Diabetes duration (years, median[IQR]) 5 (2-10) 4 (2-8) 
BMI (kg/m2, median[IQR]) 29.8 (26.8-33.6) 29.7 (26.8-33.0) 
Waist-to-hip ratio (median[IQR]) 0.94 (0.88-0.98) 0.94 (0.89-0.99) 
Waist measurement (cm) 103 (95-112) 103 (95-110) 
SBP (mmHg) 140 (15) ¥ 139 (14) 
DBP (mmHg) 82 (9) ¥ 81 (8) 
Heart rate (bpm) 72 (9) † 73 (9) 
Clinical history   
Prior CVD 2048 (21.8%) 83 (19.7%) 
Prior myocardial infarction 463 (4.9%) 22 (5.2%) 
Prior stroke 333 (3.6%) 14 (3.3%) 
Prior angina 1151 (12.3%)† 36 (8.5%) 
Prior peripheral vascular disease 676 (7.2%) 36 (8.5%) 
History of hypertension 5304 (56.6%) 242 (57.3%) 
Patients treated for hypertension 4696 (50.1%) 225 (53.3%) 
Smoking (past and present) 5610 (59.9%) 256 (60.7%) 
Never smoked 3763 (40.1%) 166 (39.3%) 
Ex-smokers 4729 (50.5%) 215 (50.9%) 
Current smokers 881 (9.4%) 41 (9.7%) 
No. of cigarettes per day (median[IQR]) 15 (7-20) 15 (5-30) 
History of diabetic retinopathy 792 (8.4%)† 22 (5.2%) 
History of diabetic neuropathy 1350 (14.4%)† 45 (10.7%) 
History of diabetic nephropathy 271 (2.9%) 8 (1.9%) 
Laboratory data   
Total cholesterol (mmol/L) 5.0 (0.7) ¥ 4.9 (0.7) 
LDL-cholesterol (mmol/L) 3.1 (0.7) ¥ 2.9 (0.7) 
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Characteristics 
FIELD Cohort 
Minus Substudy 
 (N=9373) 
Substudy 
 (N=422) 
HDL-cholesterol (mmol/L) 1.10 (0.26) ¥ 1.06 (0.24) 
Triglycerides (mmol/L, median[IQR]) 1.7 (1.3-2.3) 1.8 (1.4-2.4) 
Lipoprotein-a (mg/L, median[IQR]) 91.0 (36.0-260.0) 89.0 (34.0-240.0) 
Glucose (mmol/L, fasting, median[IQR]) 8.5 (7.0-10.3) † 8.3 (6.8-10.0) 
HbA1c (%, median[IQR]) 6.9 (6.1-7.8) † 6.8 (6.1-7.6) 
Insulin (mU/L, median[IQR])) 12.0 (8.0-18.3) 13.0 (9.0-19.0) 
Creatinine (µmol/L) 77.7 (15.8) ¥ 75.5 (15.3) 
Homocysteine (µmol/L,median[IQR]) 9.5 (8.0-11.5) 9.5 (8.0-11.3) 
ACR (mg/mmol, median[IQR])) 1.10 (0.60-2.95) 1.05 (0.50-3.20) 
Microalbuminuria ## 2008 (21.5%) 96 (22.7%) 
Macroalbuminuria ## 388 (4.2%) 16 (3.8%) 
Dyslipidaemia *** 3535 (37.7%) 175 (41.5%) 
Baseline cardiovascular medications   
Any antithrombotic 2945 (31.4%) 123 (29.1%) 
Aspirin 2713 (28.9%) 116 (27.5%) 
Angiotensin II receptor antagonist 476 (5.1%) ¥ 46 (10.9%) 
ACE inhibitor 3143 (33.5%) 138 (32.7%) 
Beta blockers 1376 (14.7%)† 46 (10.9%) 
Calcium antagonist 1798 (19.2%) 94 (22.3%) 
Diuretic 1413 (15.1%) 72 (17.1%) 
Nitrate 533 (5.7%) 17 (4.0%) 
Blood-Glucose-Lowering Medications   
Diet 2494 (26.6%) 114 (27.0%) 
Metformin alone 1624 (17.3%) 97 (23.0%) 
Sulfonylurea alone 1543 (16.5%) 68 (16.1%) 
Metformin + Sulfonylurea 2201 (23.5%) 119 (28.2%) 
Metformin and/or Sulfonylurea and other 164 (1.7%) 6 (1.4%) 
Insulin alone 602 (6.4%) 5 (1.2%) 
Insulin + oral agent 726 (7.7%) 13 (3.1%) 
Continuous data are expressed as mean (SD) or median (IQR) and categorical data as the number of subjects (valid %). † P < 
0.05;   ¥ P < 0.01. ## Microalbuminuria is defined as urine ACR ≥2.5 mg/mmol in men and ≥3.5 mg/mmol in women and 
macroalbuminuria as ≥25 mg/mmol in men and ≥35 mg/mmol in women. *** Dyslipidaemia – low HDL-C (Male: <1.03, 
Female: <1.29) and high TG (≥1.7) 
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Table 6.2 - Baseline characteristics of FIELD IMT vascular substudy subjects assigned to placebo or to 
fenofibrate. 
Characteristics 
Placebo 
(N=225) 
Fenofibrate 
(N=197) 
General characteristics   
Sex - Male 139 (61.8%) 127 (64.5%) 
Age at visit 1 (years) 62 (7) 63 (7) 
Diabetes duration (years, median[IQR]) 4 (2-8) 5 (2-10) 
BMI (kg/m2, median[IQR]) 29.8 (27.2-32.5) 29.1 (26.1-32.8) 
Waist-to-hip ratio(median[IQR]) 0.94 (0.89-0.98) 0.94 (0.89-0.99) 
Waist measurement (cm) 103 (94-110) 102 (95-110) 
SBP (mmHg) 140 (14) † 137 (14) 
DBP (mmHg) 82 (8) 80 (8) 
Heart rate (bpm) 74 (9) 73 (8) 
Clinical history   
Prior CVD 43 (21.4%) 31 (16.7%) 
Prior myocardial infarction 9 (4.5%) 12 (6.5%) 
Prior stroke 10 (5.0%) 4 (2.2%) 
Prior angina 15 (7.5%) 17 (9.1%) 
Prior peripheral vascular disease 15 (7.5%) 15 (8.1%) 
History of hypertension 112 (55.7%) 106 (57.0%) 
Patients treated for hypertension 105 (52.2%) 97 (52.2%) 
Smoking (past and present) 123 (54.7%) 115 (58.4%) 
Never smoked 78 (38.8%) 71 (38.2%) 
Ex-smokers 101 (50.2%) 100 (53.8%) 
Current smokers 22 (10.9%) 15 (8.1%) 
No. of cigarettes per day (median[IQR]) 10 (5-25) 15 (1-20) 
History of diabetic retinopathy 12 (6.0%) 9 (4.8%) 
History of diabetic neuropathy 17 (8.5%) 22 (11.8%) 
History of diabetic nephropathy 3 (1.5%) 5 (2.7%) 
Laboratory data   
Total cholesterol (mmol/L) 4.8 (0.7) 4.9 (0.7) 
LDL-cholesterol (mmol/L) 2.8 (0.7) 3.0 (0.7) 
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Characteristics 
Placebo 
(N=225) 
Fenofibrate 
(N=197) 
HDL-cholesterol (mmol/L) 1.07 (0.25) 1.05 (0.24) 
Triglycerides (mmol/L, median[IQR]) 1.8 (1.4-2.4) 1.7 (1.4-2.3) 
Lipoprotein-a (mg/L, median[IQR]) 84.0 (32.0-250.0) 100.5 (49.0-245.0) 
Glucose (mmol/L, fasting, median[IQR]) 8.0 (6.6-9.5) 8.3 (6.9-10.0) 
HbA1c (mmol/L,median[IQR]) 6.6 (5.9-7.4) 6.9 (6.1-7.6) 
Insulin (mU/L, median[IQR]) 14.0 (9.0-20.0) 12.0 (8.0-17.0) 
Creatinine (µmol/L) 74.2 (14.9) † 77.9 (15.7) 
Homocysteine (µmol/L,median[IQR]) 9.6 (8.1-11.1) 9.5 (7.8-11.7) 
ACR (mg/mmol, median[IQR]) 1.05 (0.50-2.75) 1.03 (0.55-3.20) 
Microalbuminuria ## 41 (20.4%) 45 (24.2%) 
Macroalbuminuria ## 8 (4.0%) 6 (3.2%) 
Dyslipidaemia *** 81 (40.3%) 77 (41.4%) 
Baseline cardiovascular medications   
Any antithrombotic 60 (29.9%) 51 (27.4%) 
Aspirin 56 (27.9%) 48 (25.8%) 
Angiotensin II receptor antagonist 25 (12.4%) 18 (9.7%) 
ACE inhibitor 59 (29.4%) 64 (34.4%) 
Beta blockers 26 (12.9%) 16 (8.6%) 
Calcium antagonist 44 (21.9%) 39 (21.0%) 
Diuretic 37 (18.4%) 31 (16.7%) 
Nitrate 7 (3.5%) 8 (4.3%) 
Blood-Glucose-Lowering Medications   
Diet 61 (30.3%) 47 (25.3%) 
Metformin alone 44 (21.9%) 42 (22.6%) 
Sulfonylurea alone 32 (15.9%) 31 (16.7%) 
Metformin + Sulfonylurea 51 (25.4%) 56 (30.1%) 
Metformin and/or Sulfonylurea and other 4 (2.0%) 2 (1.1%) 
Insulin alone 1 (0.5%) 4 (2.2%) 
Insulin + oral agent 8 (4.0%) 4 (2.2%) 
 
 Continuous data are expressed as mean (SD) or median (IQR) and categorical data as the number of subjects (valid %). 
† P < 0.05. ## Microalbuminuria is defined as urine ACR ≥2.5 mg/mmol in men and ≥3.5 mg/mmol in women and 
macroalbuminuria as ≥25 mg/mmol in men and ≥35 mg/mmol in women. *** Dyslipidaemia – low HDL-C (Male: <1.03, 
Female: <1.29) and high TG (≥1.7). 
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Table 6.3 - Effect of fenofibrate versus placebo on carotid IMT at 2 and 4 years. 
 Placebo Fenofibrate Unadjusted Adjusted** 
Variable  Visit n Mean SD n Mean SD 
Mean 
Diff* 95% CI 
P value 
(t-test) Estimate 95% CI 
P value 
(ANCOVA) 
Mean IMT Baseline 201 0.89 0.19 186 0.90 0.19 0.009 (-0.032, 0.050) 0.67    
 2 Years 174 0.91 0.16 159 0.93 0.19 0.023 (-0.016, 0.062) 0.25 0.007 (-0.018, 0.032) 0.59 
 4 Years 181 0.92 0.17 157 0.94 0.17 0.023 (-0.015, 0.061) 0.24 0.012 (-0.014, 0.038) 0.35 
Maximum IMT Baseline 201 1.18 0.26 185 1.18 0.25 0.006 (-0.035, 0.048) 0.76    
 2 Years 174 1.18 0.21 159 1.21 0.26 0.027 (-0.013, 0.067) 0.19 0.016 (-0.013, 0.045) 0.28 
 4 Years 181 1.20 0.24 157 1.23 0.25 0.020 (-0.022, 0.062) 0.35 0.012 (-0.020, 0.044) 0.45 
 
*    Fenofibrate minus Placebo. Groups were compared with independent-sample t-tests. IMT was log transformed for statistical analyses (unadjusted and adjusted).  
**   ANCOVA model adjusted for IMT data at baseline. 
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Table 6.4 - Effect of fenofibrate versus placebo on laboratory measures and blood pressure at 2 and 4 years. 
 
 Placebo Fenofibrate Unadjusted Adjusted** 
Variable Visit n Mean SD n Mean SD 
Mean 
Diff* 95% CI 
P value 
(t-test) Estimate 95% CI 
P value 
(ANCOVA) 
TC Baseline 201 4.81 0.68 186 4.90 0.68 0.095 (-0.04,0.23) 0.17    
 2 Years 184 4.73 0.90 163 4.28 0.78 -0.454 (-0.63,-0.28) <0.001 -0.558 (-0.71,-0.41) <0.001 
 4 Years 182 4.57 0.82 158 4.10 0.80 -0.467 (-0.64,-0.29) <0.001 -0.535 (-0.69,-0.38) <0.001 
HDL-C Baseline 201 1.07 0.25 186 1.05 0.24 -0.018 (-0.07,0.03) 0.46    
 2 Years 184 1.05 0.25 163 1.11 0.29 0.058 (0.00,0.11) 0.05 0.055 (0.02,0.09) <0.01 
 4 Years 40 1.09 0.26 24 1.18 0.35 0.090 (-0.06,0.24) 0.24 0.002 (-0.09,0.10) 0.96 
LDL-C Baseline 201 2.84 0.65 186 2.97 0.70 0.134 (-0.00,0.27) 0.05     
 2 Years 182 2.80 0.77 162 2.57 0.68 -0.229 (-0.38,-0.07) <0.01 -0.350 (-0.48,-0.22)  <0.001 
 4 Years 40 2.71 0.92 24 2.46 0.63 -0.253 (-0.68,0.17) 0.24 -0.270 (-0.66,0.12)  <0.001 
TG #(log) Baseline 201 2.04 1.24 186 1.94 0.80 -0.013 (-0.09,0.07) 0.76     
 2 Years 184 1.93 0.94 163 1.30 0.79 -0.412 (-0.50,-0.32) <0.001 -0.393 (-0.46,-0.32)  <0.001 
 4 Years 182 1.98 0.89 158 1.29 0.61 -0.436 (-0.53,-0.34) <0.001 -0.413 (-0.49,-0.34)  <0.001 
SBP Baseline 201 140.0 14.2 186 136.7 13.5 -3.302 (-6.07,-0.54) 0.02     
 2 Years 187 136.4 15.8 170 134.8 15.8 -1.674 (-4.96,1.62) 0.32 0.124 (-2.77,3.02)  0.93 
 4 Years 183 138.9 16.8 160 135.0 16.8 -3.910 (-7.48,-0.34) 0.03 -2.289 (-5.61,1.03)  0.18 
DBP Baseline 201 81.6 8.3 186 80.1 8.4 -1.500 (-3.17,0.17) 0.08     
 2 Years 187 78.5 9.4 170 77.0 8.4 -1.546 (-3.41,0.32) 0.11 -0.711 (-2.34,0.92)  0.39 
 4 Years 183 79.8 10.0 160 77.4 9.7 -2.442 (-4.53,-0.35) 0.02 -1.697 (-3.61,0.22)  0.08 
Glucose #(log) Baseline 201 8.37 2.43 186 8.72 2.44 0.043 (-0.01,0.10) 0.12     
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 Placebo Fenofibrate Unadjusted Adjusted** 
Variable Visit n Mean SD n Mean SD 
Mean 
Diff* 95% CI 
P value 
(t-test) Estimate 95% CI 
P value 
(ANCOVA) 
 2 Years 178 8.77 2.57 161 8.88 2.98 0.004 (-0.06,0.07) 0.90 -0.020 (-0.07,0.03)  0.46 
 4 Years 180 8.65 2.87 155 8.24 2.74 -0.048 (-0.11,0.02) 0.14 -0.062 (-0.12,-0.01)  0.024 
HbA1c #(log) Baseline 201 6.77 1.27 186 6.99 1.28 0.032 (-0.00,0.07) 0.07     
 2 Years 184 6.94 1.42 163 7.26 1.37 0.046 (0.01,0.09) 0.02 0.022 (-0.01,0.05)  0.11 
 4 Years 180 6.95 1.30 157 7.12 1.21 0.027 (-0.01,0.06) 0.15 0.011 (-0.02,0.04)  0.44 
ACR #(log) Baseline 201 5.52 19.76 186 6.48 32.87 0.012 (-0.25,0.28) 0.93     
 2 Years 176 2.97 7.18 157 3.94 12.45 -0.055 (-0.34,0.23) 0.70 -0.058 (-0.26,0.14)  0.57 
Creatinine #(log) Baseline 201 74.19 14.94 186 77.87 15.70 0.048 (0.01,0.09) 0.02     
 2 Years 184 73.86 19.07 163 88.04 22.75 0.172 (0.12,0.22) <0.001 0.134 (0.10,0.16)  <0.001 
 4 Years 182 81.44 24.70 158 97.11 38.36 0.160 (0.10,0.22) <0.001 0.120 (0.08,0.16)  <0.001 
 
*   Fenofibrate minus Placebo. Groups were compared with independent-sample t-tests. **ANCOVA Model adjusted for laboratory measure at baseline.  #Log transformed for unadjusted and 
adjusted analysis. TC = total cholesterol; HDL-C = high-density lipoprotein; LDL-C = low-density lipoprotein; TG = triglyceride; SBP = systolic blood pressure; DBP = diastolic blood pressure; ACR 
= albumin:creatinine ratio 
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Figure 6.1 – Effect of fenofibrate versus placebo on: a) IMT (mean), b) IMT (maximum), c) HDL-C and LDL-C, d) TG. Data expressed as mean difference between 
fenofibrate and placebo groups ± 95%CI.  
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Figure 6.2 – Effect of fenofibrate versus placebo on: a) SBP, b) DBP, c) Creatinine (log), d) ACR (log). Data expressed as mean difference between fenofibrate 
and placebo groups ± 95%CI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-10
-8
-6
-4
-2
0
2
4
6
8
10
Baseline 2 Years 4 Years
-5
-4
-3
-2
-1
0
1
2
3
4
5
Baseline 2 Years 4 Years
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
Baseline 2 Years 4 Years
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
Baseline 2 Years
Values at baseline are the unadjusted mean difference (fenofibrate minus placebo). Estimates at 2 and 4 years are adjusted for the parameter at baseline. 
a) SBP  b) DBP  
c) Creatinine (log)  d) ACR  
 217 
 
Figure 6.3 – Effect of fenofibrate versus placebo on: a) Glucose (log), b) HbA1c (log). Data expressed as mean difference between fenofibrate and placebo 
groups ± 95%CI.  
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Table 6.5 - Difference in carotid IMT between treatment groups at 2 years or 4 years, expressed as a change from baseline (log-transformed data), in 
subjects with and without dyslipidaemia#. 
 
 No dyslipidemia #Dyslipidemia 
Test for interaction 
Trt*Dyslipidemia 
Variable Visit N Estimate* 95%CI p-value N Estimate* 95%CI p-value p-value 
Mean IMT (log) 2 years 199 0.017 (-0.018, 0.051) 0.35 134 -0.007 (-0.042, 0.027) 0.68 0.36 
Mean IMT (log) 4 years 205 0.023 (-0.014, 0.059) 0.22 133 -0.005 (-0.040, 0.029) 0.76 0.30 
Maximum IMT (log) 2 years 199 0.021 (-0.018, 0.061) 0.28 134 0.009 (-0.036, 0.054) 0.70 0.68 
Maximum IMT (log) 4 years 205 0.027 (-0.018, 0.072) 0.24 133 -0.013 (-0.057, 0.031) 0.56 0.23 
 
 
Adjusted analysis (ANCOVA**) N = Number of subjects with and without dyslipidaemia (with IMT data at baseline, and 2 or 4 years). # Dyslipidaemia = Low HDL (Males: <1.03 mmol/L, Females: 
<1.29 mmol/L) with high TG (≥1.7 mmol/L). 
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Figure 6.4 – Mean carotid IMT at baseline in subjects with and without dyslipidaemia#. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 – Maximum carotid IMT at baseline in subjects with and without dyslipidaemia#. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box plots show median (of maximum IMT); 25th, 50th and 75th percentiles; and inner fences (95% of all values). 
# Dyslipidaemia = Low HDL (Males: <1.03 mmol/L, Females: <1.29 mmol/L) with high TG (≥1.7 mmol/L).
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Figure 6.6 – Effect of fenofibrate on IMT at 2 years and 4 years (adjusted for baseline IMT) in subjects with and without dyslipidaemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dyslipidaemia = Low HDL (Males: <1.03 mmol/L, Females: <1.29 mmol/L) with high TG (≥1.7 mmol/L); x-axis shows β-value (using ‘log-transformed IMT’ – mean or maximum, as 
specified). P-value (for interaction) from ANCOVA. 
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6.4 Discussion 
We investigated the effects of fenofibrate compared with placebo on carotid IMT at 2 and 4 years, in a 
subset of representative adults with T2DM from the FIELD study. Treatment with fenofibrate was not 
associated with improved carotid IMT at 2 or 4 years, compared with placebo, despite statistically 
significant improvements in TC, LDL-C, and TG at 2 and 4 years, and HDL-C at 4 months and 2 years. Sub-
group analysis revealed a non-significant trend towards favourable IMT in those with dyslipidaemia on 
fenofibrate at 2 and 4 years, compared with placebo. While this relationship was not statistically 
significant, it is consistent with reports of a greater reduction in CVD events in patients with dyslipidaemia 
receiving fenofibrate in the main FIELD study (145).  
 
A lack of improvement in carotid IMT on fenofibrate in subjects with T2DM suggests the observed benefit 
in several clinical endpoints in the main FIELD study were due to factors other than an improvement in 
the extent of subclinical vascular disease. Carotid IMT is a well-established and reproducible method for 
the assessment of subclinical vascular disease that correlates with CVD events (62-67), and numerous 
randomised controlled trials have used carotid IMT as the primary study endpoint, to study the efficacy 
of lipid-modifying therapies (165-168).  Two other studies have investigated the effects of fibrates on 
carotid IMT in subjects with T2DM and report conflicting results. In the St. Mary’s Ealing Northwick Park 
Diabetes and Cardiovascular Disease Prevention (SENDCAP) study, bezafibrate had no effect on carotid 
IMT at 3 years in subjects with T2DM compared with placebo, despite a lower 3-year cumulative incidence 
rate of coronary heart disease events (169). However, in a study of 40 subjects with T2DM and 
hyperlipidaemia, gemfibrozil showed a slower progression in maximum IMT (IMT increase: 5% over 1-
year), compared with diet-only (IMT increase: 15 % over 1-year) (170). An important limitation of this 
study of gemfibrozil was the lack of a placebo group for comparison.  
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An analysis of the effects of fenofibrate compared with placebo on carotid IMT was also conducted in a 
smaller subset of 170 subjects participating in the FIELD study in Finland, to investigate associations 
between carotid IMT and markers of inflammation and arterial stiffness, at baseline and 5 years. In this 
analysis, fenofibrate similarly had no effect on carotid IMT when compared with placebo (171). An 
important limitation of the analysis conducted in the Finnish cohort was likely insufficient power to detect 
significant differences in carotid IMT, when comparing treatment groups. According to our power 
calculations: assuming a mean baseline IMT of 0.83 ± 0.14 mm (mean ± SD) and a total study sample size 
of 200 subjects per group provided > 80% power (2p < 0.05) to detect a 0.04 mm change in IMT between 
treatment groups. The vascular substudy conducted in the Finnish cohort of the FIELD study was designed 
separately, and had significant methodological differences. Thus, a pooled analysis of data from these 
related studies was not possible.  
 
The effects of fenofibrate on carotid IMT have previously been investigated but not in subjects with T2DM. 
In a study by Zhu S. et.al. (172), patients with essential hypertension and mild hyperlipidaemia showed no 
improvement in carotid IMT on fenofibrate, at 2 years, when compared with placebo, despite a slower 
rate of carotid plaque formation and a reduced incidence of stroke on fenofibrate. A study by Chironi G. 
et.al. (173), comparing the effects of combined statin and fibrate therapy versus fenofibrate only, in 
subjects with dyslipidaemia, showed a higher carotid IMT in the fenofibrate only group, suggesting a 
potential benefit of combined statin and fenofibrate therapy for reducing CVD risk in patients with 
dyslipidaemia. This latter study did not include a placebo group to compare the effects of no active 
treatment on carotid IMT in patients with dyslipidaemia. 
 
We have previously published our findings on the determinants of carotid IMT in this cohort of FIELD IMT 
vascular substudy subjects, at baseline (174). In this report, carotid IMT was shown to be independently 
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associated with age, sex, TG, TC, duration of diabetes and urinary ACR. Subgroup analysis of ACR tertiles 
found that ACR > 0.65 mg/mol (i.e. 1/5 the standard threshold for microalbuminuria) was associated with 
a clinically significant difference in IMT, in support of other studies showing that a urinary ACR within the 
“normal” range is associated with an increase in CVD mortality in T2DM (175). Numerous other studies 
have reported higher carotid IMT in patients with T2DM (32-34,176). 
 
Fenofibrate modifies lipid and lipoprotein metabolism via antagonism of PPAR-α. Specific regions of the 
fenofibrate molecule structurally mimic fatty acids and prostanoids (fatty acid derivatives) – the 
endogenous ligands for the PPAR-α transcription factor (177). Genes regulated by PPAR-α include those 
encoding for apolipoprotein (Apo)C-III, A-I and A-II, lecithin cholesterol acyltransferase, lipoprotein lipase, 
acyl coenzyme A synthetase, fatty acid translocase, and fatty acid transport protein (177,178). Fenofibrate 
is a prodrug that is rapidly hydrolysed into fenofibric acid (the active agent) after absorption, and a 
micronized with improved absorption was used in the FIELD study (145).  
 
Fibrates are proven effective in lowering TG and raising HDL-C. The effects of fibrates on LDL-C are 
variable, but in general result in modest reductions in LDL-C, and increased LDL particle size and reduced 
density - properties that are less atherogenic. The magnitude of the lipid-modifying effects of fibrates vary 
and is dependent on pre-treatment lipid and lipoprotein levels and the population receiving therapy. A 
recent meta-analysis of randomised controlled trials of fibrates reported a decrease in TG by 40%, LDL-C 
by 11%, and an increase in HDL-C of 10% (179). In the main FIELD study, fenofibrate reduced TG by 29%, 
LDL-C by 12%, and increased HDL-C by a modest 5%, at 4 months, and these differences diminished over 
time when re-measured at 2 and 4 years (145). The changes in lipid and lipoproteins observed in this IMT 
vascular substudy were similar to those in the main FIELD study. 
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A possible mechanism for the observed improvement in non-fatal CVD events and silent AMI on 
fenofibrate in the FIELD study, despite a lack of benefit on the extent of subclinical vascular disease, may 
relate to effects of fenofibrate on atherosclerotic plaque composition. In a study by Corti R. et.al. (180), 
rabbits with experimentally induced atherosclerotic lesions in the abdominal aorta were randomised to 
fenofibrate versus placebo for 6 months and had MRI scans to measure vessel wall thickness, before and 
after treatment.  Rabbits assigned to placebo showed a 15% increase in vessel wall area at the site of 
arterial injury, whereas rabbits assigned to fenofibrate showed a 11% reduction in vessel wall area. 
Histopathology showed a decrease in macrophage content and an increase in smooth muscle cell and 
collagen content of atherosclerotic lesions on fenofibrate compared with placebo, suggesting fenofibrate 
may lead to plaque regression and a change in plaque composition, reflecting a more “stable” plaque 
phenotype. A study by Jeanpierre E. et.al. (181), similarly used a rabbit model of experimentally induced 
atherosclerotic lesions and investigated the effects of short-term fenofibrate therapy (4 weeks); in this 
study, fenofibrate reduced tissue factor expression at the site of arterial injury by 42%, and improved re-
endothelialisation by 51%, suggesting a reduction on plaque thrombogenicity – which may promote a 
more “stable” plaque phenotype. We are unaware of any data on the effects of fenofibrate on plaque 
stability in humans or in animal models of diabetes.   
 
Studies using clinical endpoint studies have consistently shown a greater benefit from fibrates in patients 
with dyslipidaemia or features of metabolic syndrome (156,182,183). In the FIELD study, subjects with 
dyslipidaemia had the largest effect of fenofibrate in reducing CVD risk (145). In this IMT vascular 
substudy, there was a non-significant trend towards improved carotid IMT on fenofibrate in subjects with 
dyslipidaemia. The proportion of subjects in the FIELD study with dyslipidaemia was 38%; thus, our IMT 
vascular substudy may have had insufficient power to detect statistically significant differences in carotid 
IMT on fenofibrate compared with placebo, in those with and without dyslipidaemia.  
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Limitations 
There were a number of limitations to this study. First, subjects participating in the FIELD study had a 
relatively short duration of T2DM. As the risk of CVD increases with a longer duration of diabetes, a shorter 
duration may have contributed to a lesser degree of structural abnormalities in the artery wall. Second, 
this representative group of adults with T2DM had fairly well controlled diabetes (HbA1c: IQR, 6.0-7.6%), 
with no clear indication for lipid-lowering therapy, according to guidelines for the management of 
cardiovascular risk factors at the time of study enrolment. Third, 422 subjects had carotid ultrasound scans 
performed at baseline, prior to treatment allocation; however, only 384 (91%) were of suitable quality for 
inclusion in the analysis, due to technical factors. This may also have reduced study power. Fourth, some 
characteristics relating to clinical history were obtained by self-report, including age at diagnosis of 
diabetes, the presence or absence of some diabetes-related complications, a prior history of CVD, 
hypertension, and cigarette smoking status. These characteristics were potentially open to reporting or 
recall bias; however, it is unlikely that these characteristics had any significant effect on the results, owing 
to its randomised, double-blinded design. Fifth, the post-hoc analyses exploring the effects of fenofibrate 
on carotid IMT in subjects with and without dyslipidaemia were likely underpowered to detect statistically 
significant differences and, thus, caution is required when interpreting these results.  Finally, this was a 
study of large artery structure, and at the time of study design it was not known that the main significant 
benefits of fenofibrate found in the FIELD study would be reported in the microvasculature. The effects 
of fenofibrate on microvascular reactivity are not known and would be of interest for further study.  
 
6.5 Conclusion 
Fenofibrate was not associated with improved carotid IMT in adults with T2DM when compared with 
placebo, despite statistically significant improvements in TC, LDL-C and TG at 2 and 4 years, and improved 
HDL-C at 4 months and 2 years. These results suggest that the long-term, beneficial effects of fenofibrate 
 226 
 
reported in the main FIELD study were mediated via mechanisms other than an improvement in the level 
of subclinical vascular disease in large arteries. Studies targeting the mechanisms for the observed clinical 
benefit in microvascular and macrovascular endpoints in the main FIELD study are required, in particular, 
exploring the effects of additional therapies alone or in combination with fenofibrate (such as statins) for 
reducing the risk of atherosclerosis-related events in T2DM in those with dyslipidaemia. 
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CHAPTER 7:  
 
Baseline Determinants of Arterial Function in Adults with Type-2 Diabetes 
Mellitus: a FIELD Substudy. 
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7.1 Introduction 
Vascular reactivity is a key determinant of outcomes from CVD. The healthy arterial endothelium 
maintains a thromboresistant and dilated vessel, via the secretion of multiple mediators, such as NO and 
prostacyclin. In disease states such as atherosclerosis, or in the presence of its major risk factors, arterial 
reactivity is impaired and this has been linked to adverse cardiovascular outcomes  (44,55). In diabetes 
mellitus, in particular, the abnormality in arterial physiology extends beyond endothelial dysfunction, as 
smooth muscle-dependent relaxation is also significantly impaired (184-186). This is likely to be involved 
in disease pathogenesis and may also have important therapeutic implications, as certain drugs for the 
relief of coronary insufficiency depend on smooth muscle dilator effects (e.g. nitrates and calcium channel 
blockers).  
 
The presence of additional cardiovascular risk factors, such as hypertension, hypercholesterolaemia, 
dyslipidaemia and renal impairment, further contribute to the atherosclerotic disease burden in T2DM; 
however, the underlying mechanisms for accelerated atherosclerosis in T2DM are poorly understood. A 
number of abnormalities in molecular and cellular pathways are likely to be involved (187-189). 
 
As described in the introduction of Chapter 6, vascular substudies of the FIELD study were designed to 
investigate the mechanisms for potential arterial benefits of fenofibrate in patients with T2DM, as well as 
factors associated with impaired arterial vasodilatory function in this cohort. Given the age and diabetes 
status of subjects in the FIELD study, severely impaired arterial reactivity was considered a likely finding. 
The aim of this chapter to investigate factors associated with arterial endothelium-dependent and -
independent function in a subset of FIELD study subjects (N= 193), prior to treatment allocation.  
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7.2 Methods 
7.2.1  Subjects and study design 
A detailed description of FIELD study subjects is provided in Chapter 6 - Section 6.2.1 – Subjects. Eligibility 
into the FMD vascular substudy required a baseline ultrasound scan of suitable quality to accurately assess 
FMD and GTN responses. 198 underwent baseline ultrasound scans of the brachial (or radial) artery, and 
of these, 193 scans (97%) were considered of acceptable quality for inclusion. 185 subjects (96%) 
consented to sublingual GTN testing. A general description of the FIELD study design is provided in Chapter 
6 – Section 6.2.2 – Study design.  
 
7.2.2 Brachial artery ultrasound  
Methods used for the assessment of FMD and GTN responses are described in detail in Chapter 2 – Section 
2.3 – Flow-mediated dilatation (FMD). In brief, high-resolution ultrasound studies were performed on the 
right brachial (or radial) artery. Fasting subjects were asked to lie at rest for 5 min before commencement 
of the study. The brachial artery was scanned several centimetres above the elbow. If the resting brachial 
artery diameter was >5.0 mm, the radial artery was used instead. B-mode images were optimised by 
setting the best focal zone, image size and gain settings.  
 
Four sets of pictures were collected. A resting scan was recorded for 1 min to obtain a baseline vessel 
diameter. A rapid inflation cuff was then placed around the arm distal to the scanning site, and the 
regional blood flow was interrupted by inflating to 250 mmHg for 4.5 min. A second ultrasound scan was 
recorded continuously from 30 s before cuff release until 90 s afterwards. Vessel diameter 45–60 s after 
cuff deflation was used to determine the FMD. Increased blood flow (that is, ‘reactive hyperaemia’) 
resulting from cuff inflation and deflation stimulates the release of vasodilator substances from the 
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endothelium, such as NO, which causes arterial dilatation (45). A third ultrasound scan was recorded after 
10 min of rest to obtain another resting (baseline) vessel diameter. Sublingual GTN spray (400 µg; metered 
dose) was then administered, and a final ultrasound scan was performed 3–4 min later to determine the 
dilator response to GTN.  
 
Ultrasound studies were recorded for later off-line analysis. The ECG was recorded continuously and 
diameters were measured from 4 end-diastolic frames, for each of the 4 scans. All vascular studies were 
performed by experienced vascular technologists. To ensure consistency of techniques used across the 
study sites, technologists underwent on-site training conducted by experienced staff from the core 
reading laboratory in Sydney. Vessel diameters were measured by experienced staff, blinded to the 
identity of the subject, the sites at which the scans were performed, and the sequence of the images 
within each patient’s scan. 
 
7.2.3 Laboratory measures 
Details for the collection and analysis of venous blood and urine samples are described in Chapter 6 – 
Section 6.2.4 – Laboratory measures. 
 
7.2.4 Statistics 
Baseline characteristics were expressed as percentages for categorical variables and as mean and SD or 
median with IQR for continuous variables. Groups were compared by χ2 tests for categorical variables and 
using t tests for continuous variables, or if the data were not normally distributed, using the Wilcoxon 
rank–sum test. Key vascular parameters — FMD and GTN — were expressed as mean with SE. Multiple-
category variables were analysed using analysis of variance, and the Tukey test was used to compare the 
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difference between each pair of means, in order to adjust for multiple testing. To determine associations 
between continuous variables and FMD or GTN responses, urinary ACR, glucose and insulin were log-
transformed. GTN response was non-normally distributed and log-transformed after adding a constant, 
because of negative values. Continuous variables were divided by their SD before analyses; as such, β-
coefficients and 95%CIs in linear regressions represent the effect of 1 SD increment in these variables on 
FMD and GTN responses. Multivariable analysis was performed using backward linear regression. A two-
tailed P<0.05 was considered significant. All analyses were performed with SAS (version 9.2).  
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7.3 Results 
7.3.1 Characteristics of subjects 
The clinical characteristics of subjects in the FIELD vascular substudy (Table 7.1 and 7.2) were similar to 
those in the entire FIELD cohort. The median age was 64 years (IQR: 58–69 years) and 61% were male. 
The median duration of diabetes was 4 years (IQR: 2–9 years), fasting glucose was 8.5 mmol/L (6.8–10.0 
mmol/L) and HbA1c was 6.9% (6.0–7.6%), i.e. 52 mmol/mol (42–60 mmol/mol). 
 
7.3.2 Arterial responses in T2DM 
FMD was 3.06 ± 0.25% (mean ± SE) and GTN dilator response was 10.56 ± 0.52% (mean ± SE). FMD was 
not significantly associated with any of the traditional risk factors assessed, including sex, age, prior history 
of CVD, family history of CVD, lipoproteins, SBP or DBP, fasting glucose, HbA1c, cigarette smoking status, 
or measures of renal function (Table 7.3 and 7.5).  
 
In contrast, GTN dilator responses were significantly associated with prior history of CVD (β -0.110 (95%CI, 
-0.215 to -0.005); P=0.04) and cigarette smoking (present or past) (β -0.125 (95%CI, -0.219 to -0.031); 
P=0.009) (Table 7.4). There was some evidence for an inverse association of urine ACR with GTN dilator 
responses [β -0.046 (95%CI, -0.091 to 0.000); P=0.05) (Table 7.5). Age, sex, BMI, waist circumference and 
lipoprotein levels were not significantly associated with GTN responses (Tables 7.4 and 7.5).  
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Table 7.1 - Baseline characteristics for subjects in the vascular substudy compared with the entire FIELD 
cohort. 
Characteristic 
Vascular substudy 
(n= 193) 
FIELD cohort minus 
substudy 
(n= 9602) 
General Characteristics   
Sex (male) 117 (60.6%) 6021 (62.7%) 
Age at visit 1 (years) 64 (58-69) ¥ 62 (57-68) 
Age at diagnosis of diabetes (years) 58 (52-63) ¥ 55 (50-62) 
Diabetes duration (years) 4 (2-9) 5 (2-10) 
BMI (kg/m2) 29.8 (27.4-33.4) 29.8 (26.8-33.5) 
Waist-hip ratio 0.9 (0.9-1.0) † 0.9 (0.9-1.0) 
SBP (mmHg) 138 (15) 140 (15) 
DBP (mmHg) 81 (9) † 82 (9) 
Clinical History   
Prior cardiovascular disease 51 (26.4%) 2080 (21.7%) 
Smoking (past and present) 122 (63.2%) 5744 (59.8%) 
Never smoked 71 (36.8%) 3858 (40.2%) 
Present smokers 18 (9.3%) 904 (9.4%) 
Past smokers 104 (53.9%) 4840 (50.4%) 
Cigarettes per day, present smokers 20 (10-40) 15 (10-20) 
Patients treated for hypertension 108 (56.0%) 4813 (50.1%) 
Laboratory Data   
Total cholesterol (mmol/L) 4.9 (0.6) ¥ 5.0 (0.7) 
HDL-cholesterol (mmol/L) 1.1 (0.2) 1.1 (0.3) 
LDL-cholesterol (mmol/L) 2.9 (0.7) † 3.1 (0.7) 
Triglycerides (mmol/L) 1.7 (1.3-2.3) 1.7 (1.3-2.3) 
Glucose – fasting (mmol/L)  8.5 (6.8-10.0) 8.5 (7.0-10.3) 
Insulin (mU/L) 13.0 (9.0-19.0) 12.0 (8.0-18.3) 
HbA1c (%) 6.9 (6.0-7.6) 6.9 (6.1-7.8) 
HbA1c (mmol/mol) 52 (42-60) 52 (43-62) 
Plasma creatinine (umol/L) 76.4 (16.4) 77.6 (15.8) 
Urinary albumin (mg/L) 9.7 (5.2-26.9) 11.1 (5.7-28.9) 
Microalbuminuria ## 40 (20.7%) 2064 (21.5%) 
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Characteristic 
Vascular substudy 
(n= 193) 
FIELD cohort minus 
substudy 
(n= 9602) 
Macroalbuminuria ## 10 (5.2%) 394 (4.1%) 
 
Continuous data are presented as mean (SD) or median (IQR) and categorical data as a percentage of patients.  
† P < 0.05   ¥ P < 0.01 ‡ Microalbuminuria is defined as urine ACR ≥2.5 mg/mmol in men and ≥3.5 mg/mmol in women, and 
macroalbuminuria as ≥25 mg/mmol in men and ≥35 mg/mmol in women 
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Table 7.2 - Baseline medications for subjects in the vascular substudy compared with the entire FIELD 
cohort. 
 
 
Characteristic 
 
Vascular substudy 
(n= 193) 
FIELD cohort minus 
substudy 
(n= 9602) 
Baseline Cardiovascular Medications   
Any antithrombotic 65 (33.7%) 3003 (31.3%) 
Aspirin 63 (32.6%) 2766 (28.8%) 
Angiotensin II receptor antagonist 19 (9.8%) † 503 (5.2%) 
ACE inhibitor 72 (37.3%) 3209 (33.4%) 
Beta blocker 24 (12.4%) 1398 (14.6%) 
Calcium antagonist 41 (21.2%) 1851 (19.3%) 
Diuretic 36 (18.7%) 1449 (15.1%) 
Nitrate 10 (5.2%) 540 (5.6%) 
Blood-Glucose-Lowering Medications   
Diet only 46 (23.8%) 2562 (26.7%) 
Metformin alone 48 (24.9%) 1673 (17.4%) 
Sulfonylurea alone 37 (19.2%) 1574 (16.4%) 
Metformin + Sulfonylurea 57 (29.5%) ¥ 2263 (23.6%) 
Metformin and/or Sulfonylurea + other 2 (1.0%) 168 (1.7%) 
Insulin alone 2 (1.0%) 605 (6.3%) 
Insulin + oral agent 1 (0.5%) 738 (7.7%) 
 
 
Continuous data are presented as mean (SD) or median (IQR) and categorical data as a percentage of patients.  
† P < 0.05   ¥ P < 0.01 
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7.3.3 Univariate analysis 
Univariate analysis revealed significantly impaired GTN dilator responses in association with a prior history 
of CVD [β -0.110 (95%CI -0.215, -0.005); p<0.05] and cigarette smoking (present or past) [β - 0.125 (95%CI 
-0.219, -0.031); p<0.001; Figure 7.1]. No other parameters were found to be significantly associated with 
GTN responses. Results of univariate analysis are shown in Tables 7.3, 7.4 and 7.5. 
 
7.3.4 Multivariable analysis 
In our multivariable model adjusted for method of diabetes control, cigarette smoking [β -0.136 (95%CI, -
0.230 to -0.042); P=0.005] was independently associated with impaired GTN dilator responses (Figure 7.2). 
Urinary ACR (β -0.060 (95%CI, -0.107 to -0.014); P=0.01) was also independently associated with GTN 
responses. Prior history of CVD, shown to be significantly associated with impaired GTN dilator responses 
in univariate analysis, was not independently associated in the multivariable model. 
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Table 7.3 - Associations between patient characteristics (categorical variables) and FMD*. 
 
Categorical variables 
 
n 
FMD (%) 
Mean (SEM) 
% Difference  
(95% CI) 
Sex    
      Male (117) 117 2.85 (0.29) -0.54 (-1.54,0.47) 
      Female (76) 76 3.39 (0.44)  
Family history of heart disease    
      Yes (43) 43 2.67 (0.55) -0.50 (-1.68,0.68) 
      No (150) 150 3.17 (0.28)  
Prior CVD    
      Yes (51) 51 2.48 (0.50) -0.79 (-1.90,0.32) 
      No (142) 142 3.27 (0.29)  
Smoking (past and present)    
      Yes (122) 122 2.88 (0.31) -0.49 (-1.51,0.52) 
            Past smokers (104) 104 3.08 (0.34)  
            Present smokers (18) 18 1.71 (0.81)  
      No (71) 71 3.37 (0.41)  
Patients treated for hypertension    
      Yes (108) 108 2.74 (0.32) -0.74 (-1.73,0.25) 
      No (85) 85 3.48 (0.39)  
 
No associations were statistically significant. 
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Table 7.4 - Associations between patient characteristics (categorical variables) and dilator response to 
GTN. 
 
Categorical variables 
 
n 
GTN dilator 
response (%) 
  
 
% Difference  
(95% CI) 
Diabetes duration (years) *    
      <=2 49 8.67 (0.70)  
      3-4 45 11.16 (0.95)  
      5-9 50 11.72 (1.22)  
      >=10 39 10.95 (1.22)  
Family history of CVD    
      Yes 41 9.51 (0.93) -0.06 (-0.17,0.05) 
      No 144 10.85 (0.61)  
Prior CVD    
      Yes 47 9.03 (0.97) -0.11 (-0.22,-0.01) † 
      No 138 11.07 (0.61)  
Smoking (past and present)    
      Yes 116 9.61 (0.64) -0.13 (-0.22,-0.03) ‡ 
           Past smokers 100 9.57 (0.68)  
           Present smokers) 16 9.86 (1.83)  
      No 69 12.15 (0.86)  
Patients treated for hypertension    
      Yes 104 10.48 (0.68) -0.01 (-0.11,0.08) 
      No  10.65 (0.81)  
Albumin:creatinine ratio § (ACR) §    
      Normal 143 10.76 (0.58)  
      Microalbuminuria 40 10.64 (1.31)  
      Macroalbuminuria 10 6.67 (1.46)  
 
  * P=0.16 
  † P<0.05 
  ‡ P<0.01 
  § P=0.25 
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Table 7.5 - β coefficients for FMD or GTN dilator responses for 1 SD increment in patient characteristics 
or lipid variables at baseline. 
 
Continuous variables 
FMD  
 β (95% CI) 
GTN  
β (95% CI) 
Age -0.483 (-0.971-0.006) -0.035 (-0.081-0.011) 
Total cholesterol -0.331 (-0.821-0.160) 0.028 (-0.018-0.074) 
HDL cholesterol -0.189 (-0.682-0.303) -0.003 (-0.049-0.043) 
LDL cholesterol -0.308 (-0.799-0.183) 0.025 (-0.021-0.071) 
Triglycerides 0.047 (-0.446-0.541) -0.010 (-0.056-0.037) 
Creatinine -0.196 (-0.688-0.297) -0.009 (-0.055-0.037) 
HbA1c -0.272 (-0.763-0.220) -0.020 (-0.066-0.026) 
Homocysteine -0.312 (-0.807-0.183) -0.014 (-0.061-0.033) 
ACR (log) -0.308 (-0.799-0.184) -0.046 (-0.091-0.000) 
Apolipoprotein B -0.186 (-0.679-0.306) 0.040 (-0.005-0.086) 
SBP -0.357 (-0.847-0.134) -0.004 (-0.051-0.042) 
DBP -0.077 (-0.570-0.416) 0.020 (-0.026-0.066) 
Glucose (log) -0.120 (-0.613-0.373) 0.000 (-0.046-0.047) 
Insulin (log) -0.174 (-0.666-0.319) 0.014 (-0.032-0.060) 
Heart rate 0.191 (-0.301-0.683) -0.021 (-0.067-0.026) 
BMI 0.067 (-0.426-0.560) 0.004 (-0.042-0.051) 
Waist measurement -0.154 (-0.650-0.341) -0.004 (-0.051-0.042) 
Waist-hip ratio -0.269 (-0.763-0.225) -0.008 (-0.054-0.039) 
 
      No variables were statistically significant at p < 0.05 
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Figure 7.1 - Dilator response to GTN in patients with type-2 diabetes mellitus according to cigarette 
smoking status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Never smoked (n=69); ex-smokers (n=100); current smokers (n=16), adjusted for ACR and method of diabetes control. Groups 
were compared using the Tukey test (P=0.02). 
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Figure 7.2 - Dilator response to GTN in patients with type-2 diabetes mellitus according to albuminuria 
status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal (n =138), microalbuminuria (n=39) and macroalbuminuria (n=8). Data are expressed as mean (standard error), adjusted 
for smoking status and method of diabetes control. Groups were compared as a continuous variable using the Tukey test (P=0.01). 
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7.4 Discussion 
The aim of this study was to investigate factors associated with impaired arterial vascular reactivity in a 
cohort of middle-aged to elderly T2DM subjects participating in the FIELD study. Diabetes mellitus is 
associated with increased risk of CVD, and numerous traditional risk factors for CVD have been implicated. 
The effects of these and other risk factors on endothelium-dependent and endothelium-independent 
arterial function in a large subset of subjects with T2DM at risk of CVD are uncertain. We found that 
endothelial-independent (or SMC dilator) function was significantly impaired in association with cigarette 
smoking and albuminuria.  
 
As expected in this middle-aged to elderly group of adults with T2DM, endothelium-dependent function 
(as assessed by FMD) was significantly impaired, as compared with previously published normal values in 
people without diabetes (190). Impaired endothelium-dependent function is an early sign of vascular 
damage and correlates with the extent and severity of atherosclerosis. In this study, the severe level of 
impairment observed was to an extent that little else could be assessed with regard to other associations 
with FMD. This finding was not surprising given the age range of subjects enrolled (50–75 years) and the 
high prevalence of cigarette smoke exposure (past or present), in the presence of diabetes mellitus. 
 
Endothelium-independent function can be influenced by a number of traditional CVD risk factors. We and 
others have previously reported impaired SMC dilator responses to GTN in those at increased risk of 
atherosclerosis (191) and in adults with T2DM (184), independent of the endothelium (185). Impaired 
GTN responses have also been reported in the coronary circulation of patients with diabetes (186,192). 
Recently, we have shown that obesity is associated with impaired arterial SMC dilator function (193). 
 243 
 
Similarly, children with risk factors contributing to an increased risk of atherosclerosis also have impaired 
SMC dilator responses (194). These studies suggest that risk factors for CVD may exert damaging effects 
on arterial SMC function, in addition to promoting arterial endothelial dysfunction. The mechanisms by 
which such factors contribute to altered SMC function are poorly understood, as are the implications of 
such impairment. 
 
Cigarette smoking is a well-established independent risk factor for CVD (195-198). The severity of 
angiographically proven atherosclerosis is associated with the cumulative pack years of cigarette smoke 
exposure (199-201). Cigarette smoking is an independent risk factor for new coronary lesion formation 
(202), and further increases the risk of cardiovascular events in T2DM (146,203). The mechanisms for the 
additional risk attributed to cigarette smoking in diabetes are not well understood; however, cigarette 
smoking is known to worsen glycaemic control (204,205), contribute to hypertension (206,207) and 
exacerbate its complications, promote dyslipidaemia (208,209) and accelerate declining renal function in 
diabetes (210).  
 
The mechanisms for the impaired SMC dilator function are uncertain. Smoking stimulates SMC 
proliferation and survival. Both nicotine and cotinine (a byproduct of nicotine metabolism) exert a 
mitogenic effect on human SMCs in vitro (211). Further, nicotine inhibits SMC apoptosis (212). These 
effects enhance intimal hyperplasia and may contribute to stenosis in vivo. Smoking is also 
proinflammatory and increases the expression of inflammatory cytokines, C-reactive protein and markers 
of oxidative stress. Furthermore, cigarette smoke upregulates endothelin type-B receptors on arterial 
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SMCs (213). These pathophysiologic effects of smoking may be related to the vascular reactivity 
abnormalities found in our study. 
 
Albuminuria is also independently associated with an increased risk of cardiovascular events. CVD 
mortality in T2DM is further increased by the presence of microalbuminuria (214) and macroalbuminuria 
(160,215). Reports of increased cardiovascular events in T2DM associated with higher levels of urinary 
albumin still considered to be within the “normal range” (175,216-218) suggest earlier pathological 
changes and a need for revised definitions for those perceived at risk of CVD events. We previously 
described a relationship between urinary albumin excretion in the “normal-high” range and carotid artery 
wall thickness in patients with T2DM (174). 
 
Studies exploring the relationship between albuminuria and arterial function in T2DM have shown 
conflicting results. In one study, microalbuminuria was shown to be an independent predictor of both 
endothelium-dependent and endothelium–independent vasodilatation, and microalbuminuria correlated 
with higher CRP levels, suggesting a higher state of systemic inflammation (219). Another study showed 
an association between microalbuminuria and impaired FMD in elderly subjects with and without 
diabetes; however, there was no impairment in GTN-mediated vasodilatation (220). A study by Diercks et. 
al. found no relationship between urinary albumin excretion and FMD or GTN vasodilator responses in 
apparently healthy, nondiabetic subjects (221). A potential explanation for these differences could be the 
effect of other cardiovascular risk factors, such as hypertension and dyslipidaemia, on microalbuminuria. 
Similarly, the level of glycaemic control may have also played a role.  
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Our results are consistent with one study exploring functional changes in the intrarenal arteries of subjects 
with T2DM. Duplex ultrasound was used to determine GTN-elicited changes in renal interlobular arteries 
(222) and showed significantly impaired resistance indices in subjects with T2DM compared with controls. 
These impaired responses were associated with increasing age, cigarette smoking and proteinuria. Our 
findings suggest that similar derangement in SMC dilator function in conduit arteries is associated with 
cigarette smoking or albuminuria in adults with T2DM. 
 
There are a number of limitations to this study. Firstly, cigarette smoking was self-reported, which has the 
potential to introduce reporting or recall bias. Intensity of cigarette smoking was recorded in current 
smokers but not in ex-smokers. Thus, we were unable to determine whether smoking intensity or duration 
had a dose-related effect on impairment in smooth-muscle function in past cigarette smokers. Secondly, 
we examined a group of patients whose diabetes was fairly well controlled (HbA1c interquartile range: 6–
7.6%; 42–60 mmol/mol), so our results may not be applicable to those with poor glycaemic control. 
Similarly, subjects enrolled in the FIELD study had ‘normal’ cholesterol levels (range 3.0–6.5 mmol/L). A 
lack of association with other traditional cardiovascular risk factors, such as total and low-density 
lipoprotein cholesterol, blood glucose and blood pressure, may have been due to such selection criteria. 
Finally, our study was underpowered to examine the effect of several classes of commonly prescribed 
medications, such as the class of antihypertensive agent, or the use of aspirin or other antiplatelet agents, 
on vascular reactivity. 
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7.5 Conclusion 
Cigarette smoking and albuminuria were independently associated with impaired arterial SMC dilator 
function in adults with T2DM. These results suggest a potentially new mechanism contributing to arterial 
disease, as a direct result of exposure to key CVD risk factors. These findings may have implications for 
risk stratification in subjects with T2DM, and suggest the need for exploring the efficacy of GTN as a 
vasodilator in certain subsets of patients with T2DM and coronary artery disease.  
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CHAPTER 8:  
 
Fenofibrate Effects on Arterial Endothelial Function in Adults with Type-2 
Diabetes Mellitus: a FIELD Substudy. 
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8.1 Introduction 
Despite improvements in the targeted management of traditional cardiovascular risk factors in T2DM, for 
example, via the use of statins (for elevated LDL-C), antihypertensive agents, and oral hypoglycaemic 
agents, residual cardiovascular risk in T2DM remains high. Fenofibrate, a peroxisome proliferator-
activated receptor-α (PPAR-α) agonist, has been shown to improve lipoprotein and lipid profiles and a 
number of micro- and macro-vascular outcomes in T2DM. Although in the  FIELD study (145) the primary 
endpoint of all coronary events was not significantly reduced, several pre-specified endpoints, such as the 
progression of albuminuria (159,160), diabetic retinopathy (158), lower limb amputations (162), and the 
incidence of non-fatal myocardial infarction (223), were significantly better in those assigned to 
fenofibrate compared with placebo.  
 
FMD is a widely used measure of endothelium-dependent arterial NO release (44,45), and GTN dilator 
response measures SMC-dependent arterial function (independent of the endothelium). A few studies 
have previously reported short-term benefits of fenofibrate therapy on arterial endothelial function in 
T2DM patients with dyslipidaemia, alone (224), or in combination with coenzyme Q10 – a potent 
antioxidant (225). Enhanced arterial vasodilatory function in association with the addition of fenofibrate 
in statin-treated T2DM subjects (226) has also been reported. 
 
Endothelial dysfunction is a key early event in the development of atherosclerosis and correlates with the 
severity of coronary artery disease in adults (46,47). Numerous risk factors for CVD, including diabetes 
mellitus, dyslipidaemia, hypertension, cigarette smoking and obesity are associated with impaired FMD 
of the brachial artery, and interventions for reversibility may improve clinical outcomes. In this chapter, 
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we report the major findings of the FMD vascular substudy of the FIELD study, exploring the effects of 
fenofibrate versus placebo on arterial endothelial function in adults with T2DM. 
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8.2 Methods 
8.2.1 Subjects 
A detailed description of subjects in the FIELD study is provided in Chapter 6 – Section 6.2.1 – ‘Subjects’. 
As previously discussed, entry into the FMD vascular substudy required a baseline ultrasound scan of 
suitable quality to accurately assess FMD and GTN responses. 198 subjects underwent baseline ultrasound 
scans of the brachial (or radial) artery, and of these, 193 (97%) were considered of acceptable quality for 
inclusion into the FMD vascular substudy. 185 subjects (96%) underwent sublingual GTN testing. At 4 
months, 163 subjects (85%) returned for vascular ultrasound scans and were included in the FMD 
analyses. At 2 years, 168 subjects (87%) were studied and included in the FMD analyses. At 4 months, 153 
subjects (83%) underwent GTN testing and at 2 years 155 subjects (84%) had GTN testing. Subjects who 
were lost to follow-up or had declined participation at 4 months were again contacted, if possible, and 
invited to participate in the vascular substudy at 2 years. Subjects who had declined the use of GTN spray 
were still included in the FMD analyses. 
 
Comparing the 193 patients in this vascular substudy with the remaining 9,602 subjects in the entire FIELD 
cohort, there were no significant differences in sex, duration of diabetes, BMI, SBP, prior history of CVD, 
hypertension, cigarette smoking status, fasting glucose, HbA1c, HDL-C, TG, or urinary albumin. There were 
minor statistically significant differences in the age at diagnosis of diabetes (58 years in the vascular 
substudy versus 55 years for the entire FIELD cohort, p<0.01), age at visit 1 (64 years versus 62 years, 
p<0.01), TC (4.9 mmol/L versus 5.0 mmol/L, p<0.01), LDL (2.9 mmol/L versus 3.1 mmol/L, p<0.01),  DBP 
(80 mmHg versus 82 mmHg, p<0.01) and subjects reporting regular use of angiotensin II receptor 
antagonists (9.8% versus 5.2%, p<0.01) or metformin alone (25% versus 17%, p<0.01).  
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A detailed clinical history was obtained in all subjects. A prior history of CVD included any one of the 
following: MI, angina (stable or unstable), stroke, claudication or PVD, or arterial revascularisations 
(including CABG, PTCA or peripheral revascularisations). A family history of CVD was defined as CVD in a 
first degree relative before the age of 55 years. Smoking history was recorded as present (current smoker), 
past (ex-smoker) or never smoker, based on self-report. Cigarette smoking status was recorded as present 
(current), past (ex-smoker) or never smoker, based on self-report. History of hypertension, age at 
diagnosis of T2DM and the presence of diabetes complications were also obtained by self-report, 
supplemented by laboratory measurements of albuminuria and calculated eGFR, as well as monofilament 
testing for touch sensation. The method of diabetes control was documented as any one of the following: 
diet only, oral hypoglycaemic agents only (distinguishing those using metformin, a sulfonylurea, both 
metformin and a sulfonylurea, or another class of oral agent alone or in combination with other agents), 
diet and insulin, or diet and oral hypoglycaemic agents and insulin. This study was approved by the 
relevant Institutional ethics committees at each study site. All subjects gave written, informed consent, 
and participation was entirely voluntary. 
 
8.2.2 Study design 
A description of the FIELD study design is provided in Chapter 6 – Section 6.2.2 – ‘Study design’. The FMD 
vascular substudy was designed to end at 2 years after randomisation. Assuming a mean baseline FMD of 
4.0 ± 3.0 % (mean ± SD), a total study sample size of 150 subjects provided > 90% power (2p < 0.05) to 
detect a 50% improvement in the FMD in the fenofibrate group compared with placebo. The pre-specified 
primary vascular substudy endpoint was the FMD at 4 months, expressed as the percent change from 
baseline. Analyses included those who had dropped-in to statin therapy, or dropped-out from fenofibrate 
(or placebo), after randomisation. Subjects who had commenced statin therapy before 4 months were 
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removed from the analyses at 4 months and at 2 years, and patients who had dropped-in to statins 
between 4 months and 2 years were removed from the analyses at 2 years. 
 
8.2.3 Brachial artery ultrasound 
Methods used for the assessment of FMD and GTN responses are described in Chapter 2 – Section 2.3 – 
‘Flow-mediated dilatation; FMD’, and in Chapter 7 – Section 7.2.2 – ‘Brachial artery ultrasound’. 
Ultrasound studies were performed using a standardised protocol (227). 
 
8.2.4 Laboratory measures 
Details for the analysis of venous blood and urine samples are described in Chapter 6 – Section 6.2.4 – 
‘Laboratory measures’. 
 
8.2.5 Statistics 
Baseline characteristics were expressed as percentages for categorical variables and as mean (SD) or 
median (IQR) for normally distributed and non-normally distributed variables, respectively. Values for 
FMD and GTN were expressed as mean (SE). TG, creatinine, glucose, HbA1c, urine ACR and lipoprotein(a) 
levels were skewed and required log transformation for analysis. FMD and GTN responses were adjusted 
for baseline vessel diameter, at baseline. Groups were compared by independent-sample t tests or ANOVA 
for multiple-category analyses. The Tukey test was used to compare the difference between each pair of 
means, to adjust for multiple testing. Statistical evaluation of changes from baseline was performed by 
analysis of covariance (ANCOVA) models, with treatment group as a factor adjusted for baseline value. 
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Beta coefficients (β) and 95%CI are shown. A two-tailed p-value < 0.05 was considered significant. All 
analyses were performed according to the intention-to-treat principle, using SAS (version 9.2).  
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8.3 Results 
8.3.1 Baseline characteristics 
Subjects in the FIELD vascular substudy were aged 64 years (median; IQR: 58-69 years). 61 % were male 
and the duration of diagnosed diabetes was 4 years (median; IQR: 2-9 years). Fasting blood glucose was 
8.5 mmol/L (median; IQR: 6.8-10.0) and HbA1c was 6.9 % (IQR, 6.0-7.6). 144 (75 %) were on oral 
hypoglycaemic agents: metformin (33 %), sulfonylureas (26 %), both metformin and sulfonylureas (40 %), 
other oral agents in combination with metformin and/or sulfonylureas (1 %). 2 % of subjects received daily 
insulin. 125 subjects (65 %) were taking antihypertensive agents. 51 (26 %) had a prior history of CVD. 122 
(63 %) were past or present smokers and the number of cigarettes smoked per day was 20 (median; IQR: 
10-40 cigarettes). Urinary ACR was 0.95 (IQR, 0.50-3.00). 40 subjects (21 %) had microalbuminuria and 10 
subjects (5 %) had macroalbuminuria. 
 
Baseline clinical characteristics and laboratory parameters for subjects in the FIELD vascular substudy 
randomised to fenofibrate (N = 93) or placebo (N = 100) are shown in Table 8.1. There were no statistically 
significant differences in any of the baseline characteristics between the two treatment groups.  
 
8.3.2 Primary study endpoint 
There was a statistically significant improvement in FMD at 4 months on fenofibrate compared with 
placebo [absolute mean difference, +1.05 % (95%CI: 0.13, 1.97); p=0.03 by ANCOVA; adjusted for baseline 
differences in vessel diameter]. GTN responses were not significantly different at 4 months when 
comparing treatment groups [absolute mean difference, +0.22 % (95%CI: -1.27, 1.72); p=0.77]. Table 8.2 
provides absolute values obtained for FMD and GTN in each treatment group, at each study visit.   
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8.3.3 Other results at 4 months 
Allocation to fenofibrate resulted in statistically significant differences in several lipid parameters at 4 
months: TC [mean difference, -0.49 mmol/L (95%CI: -0.63, -0.35); p<0.001]; LDL-C [mean difference, -0.32 
mmol/L (95%CI: -0.44, -0.19); p<0.001]; TG log (mean difference, -0.33 mmol/L (95%CI: -0.41, -0.24; 
p<0.001]; and HDL-C [mean difference, +0.05 mmol/L (95%CI: 0.02, 0.09); p=0.005] (Table 8.3) (Figure 
8.1). Changes in lipid parameters were similar to those reported in the main FIELD study (145). None of 
the other parameters measured at 4 months were significantly different between treatment groups, with 
the exception of plasma creatinine. 
 
8.3.4 Results at 2 years 
FMD at 2 years on active treatment returned to levels observed at baseline [FMD on fenofibrate at 2 years: 
3.2 ± 0.4 %, c.f. FMD at baseline: 3.2 ± 0.3 % (mean ± SEM); p=NS]. The observed improvement in FMD on 
fenofibrate at 4 months was thus not sustained at 2 years [absolute mean difference, -0.40 % (95%CI: -
1.45, 0.65); p=0.46]. GTN responses were again similar at 2 years when comparing treatment groups 
[absolute mean difference, +0.57 % (95%CI: -1.32, 2.47); p=0.55] (Table 8.2) (Figure 8.1).  
 
The lipid parameters found to be significantly reduced at 4 months showed sustained improvement on 
fenofibrate at 2 years. TC remained significantly reduced [-0.43 mmol/L (95%CI: -0.66, -0.20); p<0.001], as 
did LDL-C [-0.23 mmol/L (95%CI: -0.42, -0.04); p=0.02] and TG log [-0.33 (95%CI: -0.43, -0.23); p<0.001]. 
In contrast, the improvement in HDL-C at 4 months on fenofibrate was no longer apparent at 2 years 
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[+0.005 (95%CI: -0.04, 0.05); p=0.84) (Table 8.3) (Figure 8.1). These results were also similar to those 
published in the main FIELD study (145). 
 
Laboratory measures of glycaemic control (fasting blood glucose and HbA1c) and renal function (urinary 
ACR) were taken at baseline and 2 years. None of these measures were found to be influenced by 
treatment with fenofibrate (or placebo) (Table 8.3) (Figures 8.2 and 8.3). Plasma creatinine was 
significantly increased on fenofibrate at 4 months and 2 years, however, this was likely due to increased 
muscle turn-over from fenofibrate rather than a true decline in renal function (145,163).  
 
8.3.5 Exploratory analyses  
Further analyses were undertaken to investigate any potential effect on FMD changes, from ‘dropping-in’ 
to statins or ‘dropping-out’ of fenofibrate (or placebo) after randomisation. In the placebo group, 3 
subjects commenced statin therapy within 4 months, and 11 subjects commenced statins between 4 
months and 2 years. In the fenofibrate group, 2 subjects were taking statins within 4 months, and 5 
subjects between 4 months and 2 years. 2 subjects had dropped out of fenofibrate within 4 months and 
1 subject had dropped out of fenofibrate between 4 months and 2 years.  
  
Excluding subjects who had ‘dropped-in’ to statins had no effect on the overall vascular substudy results: 
the mean difference in FMD at 4 months was +1.03% (95%CI: 0.08, 1.98); p=0.03]; and at 2 years, -0.39% 
(95%CI: -1.48, 0.70); p=0.48 (Table 8.4). Similarly, excluding subjects who had ‘dropped-out’ of fenofibrate 
(or placebo) prior to completion of the study had no effect on the overall substudy results (Table 8.5).  
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Additional subgroup analyses were conducted to explore the effect of fenofibrate (versus placebo) on 
FMD in patients with dyslipidaema (defined as the presence of low HDL-C (males: <1.03 mmol/L, females: 
<1.29 mmol/L) with high TG (≥1.7 mmol/L] compared to those without dyslipidaemia. There was no 
statistically significant improvement in FMD on fenofibrate in those with dyslipidaemia at 4 months [+0.55 
(95% CI: -1.19, 2.29), p=0.53]; however, there was a statistically significant difference in FMD at 4 months 
in those without dyslipidaemia [+1.42 (95%CI: 0.34, 2.49), p=0.01]; [p=0.35, for a test of interaction 
between treatment and dyslipidaemia status]. By contrast, at 2 years there was no statistically significant 
difference in FMD on fenofibrate in those with or without dyslipidaemia (Table 8.6). Additional analyses 
were conducted in patients with dyslipidaemia with very high TG levels (> 2.3 mmol/L). There was no 
statistically significant improvement in FMD on fenofibrate in those with dyslipidaemia (with very high 
TG) or without dyslipidaemia, at 4 months or 2 years (Table 8.7). 
 
8.3.6 Predictors of improvement in FMD at 4 months  
To investigate potential factors associated with improvement in FMD at 4 months on fenofibrate, we 
constructed a multivariable model of change in FMD between baseline and 4 months (incorporating TC, 
HDL-C, LDL-C, TG, DBP and HbA1c), using backward elimination. None of the potential predictors explored 
in our model were significantly associated with change in FMD at 4 months. Further, there was no 
correlation between change in FMD between 4 months and 2 years and change in HDL-C (r=0.04, p=0.67), 
however, there was a correlation between change in FMD and change in LDL-C (r = -0.22, p=0.01), over 
the same time period.  
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Table 8.1 - Baseline clinical characteristics of FIELD vascular substudy subjects assigned to placebo or to 
fenofibrate. 
Characteristic 
Placebo 
(n= 100) 
Fenofibrate 
(n= 93) 
General Characteristics   
Sex - Male 55 (55.0%) 62 (66.7%) 
Age at visit 1 (years, median[IQR]) 65 (59-70) 63 (58-68) 
Diabetes duration (years, median[IQR]) 4 (2-7) 4 (2-10) 
BMI (kg/m2, median[IQR]) 30.4 (27.6-32.9) 29.1 (26.8-34.8) 
Waist-to-hip ratio (median[IQR]) 0.94 (0.89-0.99) 0.96 (0.90-1.00) 
Waist measurement (cm) 103 (12) 105 (14) 
SBP (mmHg) 140 (15) 138 (15) 
DBP (mmHg) 80 (9) 80 (9) 
Heart rate (bpm) 74 (9) 74 (9) 
Clinical history   
Prior CVD 29 (29.0%) 22 (23.7%) 
Prior myocardial infarction 6 (6.0%) 9 (9.7%) 
Prior stroke 4 (4.0%) 4 (4.3%) 
Prior angina 8 (8.0%) 16 (17.2%) 
History of hypertension 59 (59.0%) 58 (62.4%) 
Patients treated for hypertension 56 (56.0%) 52 (55.9%) 
Smoking (past and present) 61 (61.0%)  61 (65.6%) 
Never smoked 39 (39.0%) 32 (34.4%) 
Current smokers 10 (10.0%) 8 (8.6%) 
Ex-smokers 51 (51.0%) 53 (57.0%) 
Microalbuminuria ## 17 (17.0%) 23 (24.7%) 
Macroalbuminuria ## 5 (5.0%) 5 (5.4%) 
Laboratory data   
Total cholesterol (mmol/L) 4.8 (0.7) 4.9 (0.6) 
LDL-cholesterol (mmol/L) 2.9 (0.7) 3.0 (0.6) 
HDL-cholesterol (mmol/L) 1.1 (0.2) 1.1 (0.2) 
Triglycerides (mmol/L, median[IQR]) 1.7 (1.3-2.3) 1.7 (1.4-2.2) 
Lipoprotein a (mg/L, median[IQR]) 91.0 (34.5-240.0) 94.0 (52.0-260.0) 
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Characteristic 
Placebo 
(n= 100) 
Fenofibrate 
(n= 93) 
Glucose (mmol/L, fasting, median[IQR]) 8.2 (6.6-9.8) 8.8 (7.3-10.1) 
HbA1c (%, median[IQR]) 6.6 (5.8-7.5) 7.1 (6.2-7.7) 
Insulin (mU/L, median[IQR]) 13.0 (8.5-19.0) 13.0 (9.0-18.0) 
Plasma creatinine (umol/L) 74.2 (16.6) 78.7 (16.0) 
Homocysteine (umol/L, median[IQR]) 9.5 (8.2-11.5) 9.5 (7.7-11.5) 
ACR (mg/mmol, median[IQR]) 0.80 (0.48-2.18) 1.05 (0.55-3.70) 
Baseline cardiovascular medications   
Any antithrombotic 36 (36.0%) 29 (31.2%) 
Aspirin 35 (35.0%) 28 (30.1%) 
Angiotensin II receptor antagonist 10 (10.0%) 9 (9.7%) 
ACE inhibitor 33 (33.0%) 39 (41.9%) 
Beta blockers 14 (14.0%) 10 (10.8%) 
Calcium antagonist 20 (20.0%) 21 (22.6%) 
Diuretic 20 (20.0%) 16 (17.2%) 
Nitrate 3 (3.0%) 7 (7.5%) 
Blood-Glucose-Lowering Medications   
Diet 23 (23.0%) 23 (24.7%) 
Metformin alone 28 (28.0%) 20 (21.5%) 
Sulfonylurea alone 20 (20.0%) 17 (18.3%) 
Metformin + Sulfonylurea 28 (28.0%) 29 (31.2%) 
Metformin and/or Sulfonylurea and other 1 (1.0%) 1 (1.1%) 
Insulin alone 0 (0.0%) 2 (2.2%) 
Insulin + oral agent 0 (0.0%) 1 (1.1%) 
 
Continuous data are expressed as mean (SD) or median (IQR) and categorical data as the number of subjects (valid %). 
No characteristics were statistically significant at p <0.05. 
## Microalbuminuria is defined as urine ACR ≥2.5 mg/mmol in men and ≥3.5 mg/mmol in women and 
macroalbuminuria as ≥25 mg/mmol in men and ≥35 mg/mmol in women.
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Table 8.2 - Effect of fenofibrate versus placebo on FMD and GTN response at 4 months and 2 years. 
 
 Placebo Fenofibrate Unadjusted Adjusted** 
Variable Visit n Mean SEM n Mean SEM 
Mean 
Diff* 95% CI P-value  Estimate 95% CI  P-value  
FMD Baseline 100 2.90 0.36 93 3.23 0.34 0.328 (-0.66, 1.31) 0.51    
 4 Months 90 3.20 0.31 73 4.39 0.40 1.186 ( 0.21, 2.16) 0.02 1.051 (0.13, 1.97) 0.03 
 2 Years 88 3.56 0.39 80 3.19 0.38 -0.364 (-1.43, 0.71) 0.50 -0.398 (-1.45, 0.65) 0.46 
GTN Baseline 96 10.32 0.60 89 10.81 0.87 0.483 (-1.60, 2.56) 0.65    
 4 Months 86 11.74 0.53 67 12.18 0.76 0.447 (-1.39, 2.28) 0.63 0.221 (-1.27, 1.72) 0.77 
 2 Years 84 11.37 0.67 71 12.27 0.81 0.900 (-1.16, 2.96) 0.39 0.574 (-1.32, 2.47) 0.55 
 
 
*    Fenofibrate minus Placebo. Groups were compared with independent-sample t-tests. **   ANCOVA model adjusted for baseline (FMD or GTN) and vessel size at baseline. 
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Table 8.3 - Effect of fenofibrate versus placebo on laboratory measures and blood pressure at 4 months and 2 years. 
 Placebo Fenofibrate Unadjusted Adjusted** 
Variable Visit n Mean SD n Mean SD 
Mean 
Diff* 95% CI 
P-
value Estimate 95% CI  P-value  
TC Baseline 100 4.84 0.69 93 4.88 0.60 0.042 ( -0.14,  0.22) 0.66    
 4 Months 100 4.71 0.69 93 4.25 0.73 -0.458 ( -0.66, -0.26) <0.001 -0.491 (-0.63,-0.35) <0.001 
 2 Years 92 4.69 0.88 83 4.32 0.89 -0.364 ( -0.63, -0.10) 0.01 -0.428 (-0.66,-0.20) <0.001 
HDL-C Baseline 100 1.07 0.22 93 1.06 0.24 -0.003 ( -0.07,  0.06) 0.93    
 4 Months 100 1.08 0.24 93 1.12 0.26 0.048 ( -0.02,  0.12) 0.18 0.050 (0.02,0.09) 0.01 
 2 Years 92 1.07 0.25 83 1.08 0.26 0.009 ( -0.07,  0.09) 0.81 0.005 (-0.04,0.05) 0.84 
LDL-C Baseline 100 2.92 0.68 93 2.95 0.63 0.036 ( -0.15,  0.22) 0.70    
 4 Months 99 2.82 0.65 93 2.52 0.67 -0.297 ( -0.48, -0.11) 0.01 -0.319 (-0.44,-0.19) <0.001 
 2 Years 91 2.79 0.75 82 2.63 0.75 -0.163 ( -0.39,  0.06) 0.16 -0.233 (-0.42,-0.04) 0.02 
TG #(log) Baseline 100 1.97 1.41 93 1.91 0.78 0.006 ( -0.11,  0.12) 0.91    
 4 Months 100 1.82 0.80 93 1.34 0.65 -0.321 ( -0.44, -0.20) <0.001 -0.326 (-0.41,-0.24) <0.001 
 2 Years 92 1.86 0.91 83 1.36 0.93 -0.341 ( -0.47, -0.22) <0.001 -0.332 (-0.43,-0.23) <0.001 
SBP Baseline 100 139.6 15.0 93 137.9 14.9 -1.704 ( -5.94,  2.54) 0.43    
 4 Months 100 134.7 15.2 93 131.7 16.1 -2.982 ( -7.43,  1.47) 0.19 -1.984 (-5.69,1.73) 0.29 
 2 Years 95 137.4 16.3 88 135.3 17. 0 -2.083 ( -6.94,  2.77) 0.40 -0.890 (-5.03,3.25) 0.67 
DBP Baseline 100 80.1 8.5 93 80.0 8.5 -0.111 ( -2.53,  2.31) 0.93    
 4 Months 100 79.2 9.7 93 77.1 10.0 -2.030 ( -4.84,  0.78) 0.16 -1.946 (-4.07,0.18) 0.07 
 2 Years 95 77.1 10.1 88 76.5 8.2 -0.519 ( -3.18,  2.15) 0.70 -0.263 (-2.51,1.98) 0.82 
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 Placebo Fenofibrate Unadjusted Adjusted** 
Variable Visit n Mean SD n Mean SD 
Mean 
Diff* 95% CI 
P-
value Estimate 95% CI  P-value  
Glucose # (log) Baseline 100 8.40 2.35 93 8.77 1.91 0.056 ( -0.01,  0.13) 0.12    
 2 Years 91 9.04 2.57 84 8.76 2.83 -0.042 ( -0.13,  0.04) 0.34 -0.063 (-0.14,0.01) 0.10 
HbA1c # (log) Baseline 100 6.80 1.27 93 6.99 1.15 0.031 ( -0.02,  0.08) 0.21    
 2 Years 92 6.94 1.43 84 7.33 1.46 0.054 ( -0.00,  0.11) 0.06 0.031 (-0.01,0.07) 0.13 
ACR # (log) Baseline 100 5.10 17.87 93 5.40 14.10 0.177 ( -0.21,  0.57) 0.37    
 2 Years 88 3.36 9.52 81 5.57 16.88 0.011 ( -0.41,  0.43) 0.96 -0.155 (-0.43,0.12) 0.26 
Creatinine #(log) Baseline 100 74.2 16.6 93 78.7 16.0 0.063 (  0.00,  0.12) 0.04    
 4 Months 100 72.7 17.6 93 94.0 25.0 0.254 (  0.18,  0.32) <0.001 0.189 (0.16,0.22) <0.001 
 2 Years 92 73.7 19.1 83 89.9 24.6 0.193 (  0.12,  0.27) <0.001 0.141 (0.10,0.18) <0.001 
 
*   Fenofibrate minus Placebo. Groups were compared with independent-sample t-tests. **ANCOVA Model adjusted for laboratory measure at baseline.  #Log transformed for 
unadjusted and adjusted analysis. TC = total cholesterol; HDL-C = high-density lipoprotein; LDL-C = low-density lipoprotein; TG = triglyceride; SBP = systolic blood pressure; DBP = 
diastolic blood pressure; ACR = albumin:creatinine ratio. 
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Figure 8.1 – Effect of fenofibrate versus placebo on: a) FMD, b) GTN response, C) HDL-C and LDL-C, d) TG. Data expressed as mean difference 
between fenofibrate and placebo groups ± 95%CI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) FMD  
c) HDL-C, LDL-C  d) TG  
b) GTN response 
Values at baseline are the unadjusted mean difference (fenofibrate minus placebo). Estimates at 4 months and 2 years are adjusted for the parameter at baseline. 
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Figure 8.2 – Effect of fenofibrate versus placebo on: a) SBP, b) DBP, c) Creatinine (log), d) ACR (log). Data expressed as mean difference between fenofibrate 
and placebo groups ± 95%CI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
   
c) Creatinine (log) d) ACR (log)  
a) SBP b) DBP 
Values at baseline are the unadjusted mean difference (fenofibrate minus placebo). Estimates at 4 months and 2 years are adjusted for the parameter at baseline. 
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Figure 8.3 – Effect of fenofibrate versus placebo on: a) Glucose (log), b) HbA1c (log).  Data expressed as mean difference between fenofibrate and placebo 
groups ± 95%CI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
   
a) Glucose (log)  b) HbA1c (log)  
Values at baseline are the unadjusted mean difference (fenofibrate minus placebo). Estimates at 2 years are adjusted for the parameter at baseline. 
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Table 8.4 - Effect of fenofibrate versus placebo on FMD and GTN response at 4 months and 2 years (excluding patients that had dropped-in to statin 
therapy). 
 
 Placebo Fenofibrate Unadjusted Adjusted** 
Variable Visit n Mean SEM n Mean SEM 
Mean 
Diff* 95% CI P-value Estimate 95% CI  P -value 
FMD Baseline 100 2.90 0.36 93 3.23 0.34 0.328 (-0.66, 1.31) 0.51    
 4 Months 87 3.23 0.32 71 4.34 0.40 1.112 ( 0.12, 2.11) 0.03 1.034 (0.08, 1.98) 0.03 
 2 Years 75 3.53 0.43 73 3.06 0.35 -0.476 (-1.57, 0.62) 0.39 -0.389 (-1.48, 0.70) 0.48 
GTN Baseline 96 10.32 0.60 89 10.81 0.87 0.483 (-1.60, 2.56) 0.65    
 4 Months 83 11.58 0.54 65 12.12 0.79 0.538 (-1.35, 2.42) 0.57 0.356 (-1.18, 1.89) 0.65 
 2 Years 72 11.58 0.72 65 11.71 0.76 0.127 (-1.95, 2.21) 0.90 0.158 (-1.84, 2.16) 0.88 
 
 
 
*    Fenofibrate minus Placebo. Groups were compared with independent-sample t-tests. **   ANCOVA model adjusted for baseline (FMD or GTN) and vessel size at baseline. Patients who 
started on statins before 4 months are removed from the analyses at 4 months and at 2 years, and patients who dropped into statins between 4 months and 2 years are removed from the 
analyses at 2 years only. 
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Table 8.5 - Effect of fenofibrate versus placebo on FMD and GTN response at 4 months and 2 years (excluding patients that had dropped-out of fenofibrate 
therapy). 
 
 Placebo Fenofibrate Unadjusted Adjusted** 
Variable Visit n Mean SEM n Mean SEM 
Mean 
Diff* 95% CI P-value Estimate 95% CI  P -value 
FMD Baseline 100 2.90 0.36 93 3.23 0.34 0.328 (-0.66, 1.31) 0.51    
 4 Months 90 3.20 0.31 71 4.19 0.38 0.982 ( 0.03, 1.93) 0.04 0.897 (-0.01, 1.81) 0.05 
 2 Years 88 3.56 0.39 78 3.08 0.36 -0.474 (-1.52, 0.57) 0.37 -0.467 (-1.50, 0.57) 0.38 
GTN Baseline 96 10.32 0.60 89 10.81 0.87 0.483 (-1.60, 2.56) 0.65    
 4 Months 86 11.74 0.53 66 12.11 0.77 0.376 (-1.47, 2.23) 0.69 0.114 (-1.38, 1.61) 0.88 
 2 Years 84 11.37 0.67 69 12.10 0.82 0.728 (-1.35, 2.81) 0.49 0.475 (-1.43, 2.38) 0.62 
 
 
 
*    Fenofibrate minus Placebo. Groups were compared with independent-sample t-tests. **   ANCOVA model adjusted for baseline (FMD or GTN) and vessel size at baseline. Patients who 
dropped out of Fenofibrate before 4 months are removed from the analyses at 4 months and at 2 years and patients who dropped out of Fenofibrate between 4 months and 2 years are removed 
from the analyses at 2 years only. 
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Table 8.6 - Effect of fenofibrate versus placebo on FMD according to dyslipidaemia group with high TG (> 1.7 mmol/L). 
 
No Dyslipidaemia  
(n=117) 
Dyslipidaemia#  
(n=76) 
Test for interaction 
Trt*Dyslipidaemia 
  Estimate* 95%CI p-value Estimate* 95%CI p-value p-value 
FMD 4 Months 1.419 (0.34,2.49) 0.0102 0.547 (-1.19, 2.29) 0.53 0.35 
 2 Years -1.189 (-2.59, 0.22) 0.0964 0.884 (-0.73, 2.50) 0.28 0.06 
 
*     Fenofibrate minus Placebo 
**  ANCOVA Model adjusted for baseline FMD and vessel size at baseline. 
#       Dyslipidaemia = Low HDL-C (Males: <1.03 mmol/L, Females: <1.29 mmol/L) with high TG (≥1.7 mmol/L). 
 
 
 
Table 8.7 - Effect of fenofibrate versus placebo on FMD according to dyslipidaemia group with very high TG (> 2.3 mmol/L). 
 
No Dyslipidaemia  
(n=117) 
Dyslipidaemia#  
(n=76) 
Test for interaction 
Trt*Dyslipidaemia 
  Estimate* 95%CI p-value Estimate* 95%CI p-value p-value 
FMD 4 Months 0.948 (-0.12, 2.01) 0.0800 1.412 (-0.60, 3.42) 0.16 0.70 
 2 Years -0.538 (-1.72, 0.64) 0.3681 -0.072 (-2.58, 2.44) 0.95 0.72 
 
*     Fenofibrate minus Placebo 
**  ANCOVA Model adjusted for baseline FMD and vessel size at baseline. 
#       Dyslipidaemia = Low HDL-C (Males: <1.03 mmol/L, Females: <1.29 mmol/L) with high TG (≥2.3 mmol/L). 
 269 
 
8.4 Discussion 
We investigated the effects of fenofibrate compared with placebo on arterial endothelial function at 
4 months and 2 years, in a subset of representative adults with T2DM from the FIELD study. Regarding 
the pre-specified primary vascular sub-study endpoint, fenofibrate was associated with significantly 
improved FMD at 4 months compared with placebo. This was associated with significant 
improvements in TC, LDL-C, HDL-C and TG at 4 months, on fenofibrate. After 2 years of fenofibrate 
therapy, however, FMD was no longer significantly different from the placebo group. Improvements 
in TC, LDL-C and TG on fenofibrate at 4 months were sustained at 2 years. However, the observed 
improvement in HDL-C at 4 months on fenofibrate was no longer apparent after 2 years of active 
treatment. Despite favourable changes in several lipoproteins on fenofibrate compared with placebo, 
our multivariable model did not reveal any traditional cardiovascular risk factors to be independently 
associated with the short-term fenofibrate-related improvement in FMD.  
 
Impaired arterial endothelial function is an early sign of vascular damage and correlates with the 
extent and severity of atherosclerosis in adults (46,47). FMD is a reliable, non-invasive method for the 
assessment of arterial endothelial vasodilatory function, and correlates with local NO bioavailability. 
NO is a key modulator of arterial function and plays an important role in vascular protection by 
regulating inflammation, haemostasis, thrombotic potential, oxidation, and vasodilatory activity. 
Strategies that improve NO-mediated arterial function in high-risk groups have generally been shown 
to reduce the risk of atherosclerosis-related outcomes (228,229). Given the high rates of CVD-related 
mortality in diabetes mellitus, strategies to reduce the risk of atherosclerosis-related events would be 
of potentially great benefit.  
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The primary study endpoint here suggested an early significant benefit of fenofibrate on arterial 
endothelial function, due to lipid and lipoprotein-related or other beneficial changes, such as the 
putative anti-inflammatory effects of PPAR-α agonists. A previous study of short-term fenofibrate 
therapy in dyslipidaemic T2DM subjects reported improved FMD (224).  This effect was not observed 
in a group of age-and sex-matched normoglycaemic control subjects. By contrast, short-term 
fenofibrate therapy did not improve forearm microvascular vasodilatory function in dyslipidaemic 
T2DM subjects; however, a combination of fenofibrate and coenzyme Q10 (antioxidant) therapy 
significantly improved forearm blood flow in response to acetylcholine, bradykinin and sodium 
nitroprusside (225), suggesting improved endothelium-dependent and –independent 
microcirculatory function by targeting PPAR-α-dependent and antioxidant pathways, simultaneously. 
Interestingly, the observed changes in forearm vasodilation in this study were also independent of 
changes in plasma lipids and lipoproteins, and blood pressure.  
 
A small study of statin-treated T2DM subjects randomised to fenofibrate or placebo, showed 
improved endothelium-dependent vasodilatory function in the brachial (conduit) artery and forearm 
resistance arterioles (microcirculation) in response to fenofibrate (226), implying potential 
enhancement of arterial vasodilatory function in high-risk patients with T2DM by combining a statin 
with fenofibrate. One study exploring the effects of fenofibrate and coenzyme Q10 on haemodynamic 
parameters, in T2DM subjects with left ventricular diastolic dysfunction, reported lower 24-hour 
ambulatory SBP in response to combination therapy, with no change in echocardiographic indices of 
diastolic function (230). Fenofibrate alone lowered 24-hour DBP and 24-hour heart rate, whereas 
coenzyme Q10 alone lowered 24-hour DBP, without any effect on heart rate. Improved 24-hour BP 
may have resulted from increased endothelial NO bioavailability, decreased oxidative stress, and 
improved NOS activity, by combining the effects of fenofibrate and coenzyme Q10. In the main FIELD 
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study, there were modest improvements in clinic measured SBP and DBP, of 2 mmHg and 1 mmHg on 
fenofibrate, respectively (145).  
 
These smaller studies of fenofibrate effects differed from the FIELD vascular substudy, as they selected 
T2DM subjects with known dyspilidaemia or abnormal arterial endothelial function. The finding of an 
early but not sustained improvement in FMD on fenofibrate may have been due to a combination of 
factors, which could not be fully adjusted for in statistical models in this intention-to-treat analysis. 
Such factors could include the effect of statin drop-ins and fenofibrate drop-outs over this time 
interval. The beneficial effects of fenofibrate on HDL-C were also attenuated significantly, between 4 
months and 2 years.  
 
Nevertheless, it remains plausible that the short term benefit on FMD of fenofibrate on endothelial 
function became less marked over time due to other biological factors which were not measured in 
this study. For example, one possible explanation for a lack of sustained benefit in FMD on fenofibrate, 
between 4 months and 2 years, might be due to alteration in the acetylcholine-cyclooxygenase 
pathway for arterial relaxation, mediated by decreased prostacyclin and increased prostaglandin-E2 
release from long-term fenofibrate therapy, as observed in animal models (231).  In any event, the 
lack of effect of fenofibrate at 2 years, in a study where there was long term benefit on a variety of 
clinical cardiovascular endpoints, suggests that the mechanism of the observed clinical benefit is 
unlikely to be due to improvement in large arterial endothelial function.  
 
The highest benefit of fibrates has consistently been shown in patients with dyslipidaemia. In the main 
FIELD study, the largest effect of fenofibrate in reducing CVD risk was observed in subjects with 
marked dyslipidaemia (i.e. low HDL-C and TG > 2.3 mmol/L) [hazards ratio, 0.73 (95% CI: 0.58, 0.91) 
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p=0.005]; however, this relationship was also observed using more conservative TG levels (i.e. > 1.7 
mmol/L) to define dyslipidaemia [hazards ratio, 0.84 (95%CI: 0.71, 1.00), p=0.04] (232). Other studies, 
including the Bezafibrate Infarct Prevention (BIP) study (156), the Helsinki Heart Study (HHS) (233), 
and Veterans Administration High-Density Lipoprotein Intervention Trial (VA-HIT) (155), have shown 
greater benefit in those with metabolic syndrome or lower HDL-C levels. Subgroup analyses performed 
in this vascular substudy failed to show any additional benefit of fenofibrate on FMD in those with 
dyslipidaemia compared to those without, at 4 months or 2 years. 
 
In this study, there was no significant difference in GTN responses when comparing fenofibrate and 
placebo, at either 4 months or 2 years, consistent with previous studies reporting fenofibrate-related 
increases in endothelial NO bioavailability and reduced endothelin-1 (ET-1) production (152,234). We 
have previously reported impaired SMC function (as assessed by GTN responses) in association with 
cigarette smoking and albuminuria in this cohort of subjects with T2DM (235). The lack of any 
significant beneficial effect of fenofibrate on GTN responses in this study implies that the short-term 
improvement in FMD was likely due to increased endogenous NO bioavailability, as opposed to an 
alteration in molecular mechanisms within arterial SMC. 
 
Fenofibrate has been shown to increase eNOS protein levels by increasing messenger RNA 
stabilisation and eNOS phosphorylation (150-152), leading to an increase in NO production. 
Fenofibrate has been shown to decrease ADMA (an endogenous NOS inhibitor) and DDAH (which 
metabolises ADMA) induced by oxidised-LDL in cultured endothelial cells (153). L-arginine, the 
precursor for NO, was increased by 6 weeks of fenofibrate therapy in a group of hypertriglyceridaemic 
men, without any apparent increase in ADMA (236):  the net effect was in favour of NO synthesis, due 
to a relative increase in the L-arginine:ADMA ratio. ET-1, a potent endogenous vasoconstrictor, has 
been shown to be reduced by fenofibrate in an immortalised human microvascular cell line (234), 
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independent of PPAR-α receptor agonism. Elevated levels of ADMA and ET-1 have been reported in 
diabetes mellitus, and may contribute to impaired vasodilatory function. Fenofibrate has also been 
shown to reduce endothelial cell apoptosis and MCP-1 production, induced by high-glucose 
concentrations (237,238), and inhibit cytokine-induced NF-ΚB activation, which suppresses adhesion 
molecule gene expression (152). Many of these studies were of short duration (24 hours to ≤ 6 weeks) 
and, subsequently, did not explore whether favourable responses might possibly be attenuated over 
time.  
 
A number of smaller, short-term intervention studies in T2DM subjects have shown that combined 
fibrate and statin therapy achieved greater reductions in lipoprotein parameters compared with 
fibrate or statin therapy alone (239-242). The Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) study is the first large-scale clinical study of combined fibrate and statin therapy exploring 
major CVD endpoints. This study reported no significant difference overall in primary (i.e. major CVD 
events) or secondary endpoints between the two treatment groups (243). Endothelial function 
substudies were not incorporated into the ACCORD study design.  
 
Limitations 
There were a number of limitations to this study. Firstly, a small number of subjects had dropped-out 
of fenofibrate therapy after commencement of the study, with the potential to reduce the power to 
detect statistically significant differences in FMD, at 4 months and 2 years. Furthermore, a number of 
subjects had also dropped-in to statin therapy after randomisation - notably, fewer subjects had 
dropped-in to statins in the fenofibrate group, compared with placebo. Exploratory analyses revealed 
no major effect of dropping-out of fenofibrate or dropping-in to statin therapy on the pre-specified, 
primary (or secondary) endpoints in this study. Secondly, this representative group of adults with 
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T2DM had fairly well controlled diabetes (HbA1c: IQR, 6-7.6%), with no clear indication for the 
commencement of lipid-lowering therapy, according to guidelines for the management of 
cardiovascular risk factors, at the time of study enrolment. Thirdly, this was a study of large (conduit) 
artery function, and at the time of study design it was not known that the main significant benefits of 
fenofibrate found in the FIELD study would be reported in the microvasculature. Furthermore, FMD 
only explores one aspect of endothelial function. The effects of fenofibrate on microvascular reactivity 
are not known, and would be of interest for further study. As FMD only explores one aspect of 
endothelial function, the use of different techniques to investigate multiple arterial beds would have 
enhanced testing of the vascular substudy hypothesis. The aim of this substudy was to investigate the 
effect of fenofibrate on arterial vasodilator function; consequently, the potential benefits of 
fenofibrate on other aspects of endothelial function – e.g. thromboresistance, antioxidant and 
inflammatory potential, adhesion molecule expression, inhibition of SMC proliferation, and regulation 
of vascular permeability – remain uncertain. Finally, a number of characteristics relating to clinical 
history were obtained by self-report, including age at diagnosis of diabetes, the presence or absence 
of some diabetes-related complications, a prior history of CVD, hypertension, and cigarette smoking 
status. These characteristics were potentially open to reporting or recall bias; however, it is unlikely 
that these characteristics had any significant effect on the study results, due to the “randomised, 
double-blinded” design of this study. 
 
8.5 Conclusion 
Fenofibrate was associated with a short-term improvement in large artery endothelial function in 
adults with T2DM. This improvement was not sustained after 2 years of treatment. Statistically 
significant improvements in TC, LDL-C and TG at 2 years, and a short-term improvement in HDL-C at 4 
months, on active treatment, did not account for the observed improvement in FMD. These results 
suggest that the long-term, beneficial effects of fenofibrate reported in the main FIELD study were 
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likely mediated via mechanisms other than an improvement in arterial endothelial function. Further 
studies are required to understand the mechanisms responsible for such clinical benefit, and the 
effects of additional therapies such as antioxidant (e.g. coenzyme Q10) or statin therapy, for further 
enhancing arterial endothelial function in high-risk patients. 
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CHAPTER 9:  
 
Conclusions and Future Directions 
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9.1 Comparison of Carotid Intima-Media Thickness Measurements Between a Mainframe and a 
Portable Ultrasound Machine: a Validation Study 
 
In this study, we reported acceptable agreement in carotid IMT measurements when assessing inter- 
and intra-observer variability for the two ultrasound machine types under investigation – except when 
assessing maximum carotid IMT, with the Philips ATL 5000 (clinic-based ultrasound machine). In the 
inter-machine comparison, we also reported acceptable agreement for carotid IMT measurements. 
Thus, the portable, laptop-based ultrasound machine (i.e. the Teratek Terason 3000) was proven to 
be a suitable alternative to the traditional, clinic-based, mainframe ultrasound machine (i.e. the ‘gold 
standard’), for use in clinical studies assessing carotid IMT. The Teratek Terason 3000 is suitable for 
studying rural and remote populations, and may be applied to gain greater insights into associations 
between traditional CVD risk factor levels and the extent of subclinical vascular disease, in ‘high-risk’ 
populations that would otherwise not be accessible to this type of study.  
 
9.2  The Determinants of Carotid Intima-Media Thickness in Migrant Australian-Indians 
Compared with Rural Indians in Andhra Pradesh 
 
This study found no difference in carotid IMT when comparing migrant Australian Indians to rural 
Indians living in Andhra Pradesh, suggesting “westernisation” had no impact on the extent of 
subclinical vascular disease in South-Asian Indians in Australia. A number of important associations 
between carotid IMT were identified. Age, male sex and smoking history were independent predictors 
of carotid IMT in both populations. Waist:hip ratio, diabetes and plasma creatinine were independent 
predictors of carotid IMT only in rural Indians, whereas, BMI and hypertension were independent 
predictors of carotid IMT in migrant Australian-Indians.   
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In contrast to the lack of effects of “westernisation” on carotid IMT, there were statistically significant 
differences in levels of many traditional cardiovascular risk factors between populations. Notably, 
migrant Australian-Indians had higher SBP, fasting blood glucose, BMI, waist circumference, and a 
higher prevalence of diabetes, suggesting potentially adverse effects of “westernisation” on 
traditional cardiovascular risk factor levels. Rural Indians had higher LDL-C, lower HDL-C and a higher 
prevalence of cigarette smoking (past or present).  
 
Differences in traditional CVD risk factor levels and the relative strength of associations with subclinical 
vascular disease in South-Asian Indians suggest the importance of different therapeutic targets, for 
the primary and secondary prevention of CVD. Future studies should aim to confirm these findings, 
given the implications – especial in the migrant Australian population, as methods for population 
sampling were non-randomised and therefore open to selection bias.  Furthermore, correlation with 
mortality and morbidity data in migrant Australian-Indians and in rural Andhra Pradesh would be of 
interest, as region-specific data on the impact of the traditional risk factors on CVD events is also 
lacking. Studies would also need to be conducted on the effectiveness of strategies targeting risk 
factor management, in distinct geographic regions – in particular, in India, due to limitations in the 
availability of health resources, and the cost of diagnostic tests and treatments. 
 
9.3  The Determinants of Novel Measures of Arterial Structure and Function in Children Aged 8 
Years: CardioCAPS 
 
We found that birth length, TC, TG, ADMA, and HDL-C were independent predictors of carotid IMT 
heterogeneity; and that sex, height, BMI, heart rate and ADMA, were independent predictors of 
measures of arterial stiffness, in apparently healthy children aged 8-years. These findings suggest an 
important role for these risk factors in early structural and functional changes in the arterial wall, 
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which may contribute to the onset of premature atherosclerosis in adulthood and an increased risk of 
future CVD events. Future studies may explore the mechanisms for increased arterial wall thickness 
in response to these risk factors, and the potential for reversibility and arterial remodelling. Effective 
primary prevention strategies targeting risk factors such as obesity, sedentary lifestyle, and exposure 
to environmental tobacco smoke or maternal smoking in pregnancy are required. Furthermore, 
studies on the impact of traditional cardiovascular risk factors on subclinical vascular disease in 
children from different ethnic backgrounds has not been studied, nor has the effects of 
“westernisation” on children from different countries of origin. Given our findings in chapter 5, this 
may be of clinical interest. 
 
9.4 Fenofibrate Effects on Carotid Intima-Media Thickness in Adults with Type-2 Diabetes 
Mellitus: a FIELD Substudy 
 
In this study, we found that fenofibrate was not associated with improved carotid IMT in adults with 
T2DM when compared with placebo, despite statistically significant improvements in TC, LDL-C and 
TG at 2 and 4 years, and improved HDL-C at 4 months and 2 years. Future studies targeting the 
mechanisms for the observed clinical benefit in microvascular and macrovascular endpoints in the 
main FIELD study are required, in particular, exploring the effects of additional therapies alone or in 
combination with fenofibrate (such as statins) for reducing the risk of atherosclerosis-related events 
in T2DM in those with dyslipidaemia. Furthermore, the effects of fenofibrate on atherosclerotic 
plaque stability in humans may be of importance, given findings in animal models (described in 
chapter 6).  
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9.5 Baseline Determinants of Arterial Function in Adults with Type-2 Diabetes Mellitus: a FIELD 
Substudy 
 
This study found that cigarette smoking and albuminuria were independent factors associated with 
impaired arterial SMC dilator function in adults with T2DM. These results suggest a potentially new 
mechanism contributing to arterial disease, at the level of the SMC. Future studies could investigate 
whether these findings correspond to equivalent arterial abnormalities in the coronary circulation, or 
in more peripheral arterial beds – e.g. in the kidney, heart, brain and eyes – with implications for 
autoregulation of vascular tone. Studies could also explore whether there is a dose-dependent effect 
of cigarette smoking exposure and the degree of SMC vasodilator dysfunction, and similarly with 
albuminuria. Furthermore, studies investigating the rate of progression of renal dysfunction 
(comparing albuminuria and creatinine clearance) in T2DM and effects on progression of SMC 
vasodilator function would be useful, to understand whether slowing renal disease progression could 
preserve arterial function, and reduce CVD events. 
 
9.6 Fenofibrate Effects on Arterial Endothelial Function in Adults with Type-2 Diabetes Mellitus: 
a FIELD Substudy 
 
In this study, fenofibrate was associated with a short-term improvement in large artery endothelial 
function at 4 months in adults with T2DM. This improvement, however, was not sustained after 2 
years of active treatment compared with placebo. Statistically significant improvements in TC, LDL-C 
and TG at 2 years, and a short-term improvement in HDL-C at 4 months, on active treatment, did not 
account for the observed improvement in FMD. The long-term beneficial effects of fenofibrate 
observed in the main FIELD study were likely mediated via mechanisms other than an improvement 
in arterial endothelial function. Future studies could be designed to investigate the mechanisms 
responsible for improvement in clinical endpoints on fenofibrate. The effects of additional therapies 
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such as antioxidant (e.g. coenzyme Q10) or statin therapy in combination with fibrates, in high-risk 
patients with T2DM or dyslipidaemia, would be of some interest.   
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